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Physiological importance of various NFκB family members in 
regulating intestinal responses to injury 
Abdalla Farj Hanedi 
Abstract 
As key regulators of cell survival, proliferation and immune responses, the NFκB 
family of transcription factors, which signal via the classical and alternative 
activation pathways, play important roles in intestinal physiology. The pro-
inflammatory function of the classical NFκB activation pathway has previously been 
demonstrated in various animal models of intestinal inflammation. Persistent 
activation of this pathway has also been detected in the colonic mucosa of patients 
with inflammatory bowel diseases (IBD). Conversely, several studies in transgenic 
mice have shown that disruption of the classical NFκB activation pathway 
specifically in intestinal epithelial cells renders these cells more susceptible to 
undergoing apoptosis and also results in increased susceptibility to developing 
colitis. However, the specific roles of individual members of the NFκB family and in 
particular the role of the alternative NFκB activation pathway in regulating the 
susceptibility of the intestine to apoptosis, inflammation and colitis associated colon 
cancer have not been well defined. We therefore hypothesised that individual 
members of the NFκB family of proteins which signal via the classical and 
alternative activation pathways specifically regulate intestinal epithelial cell 
proliferation, apoptosis and colonic inflammation, consequently modulating 
susceptibility to developing inflammation associated colon cancer.  
Most of these aims were addressed using transgenic mice with germline deletions 
of c-Rel, NFκB1, and NFκB2, along with their wild-type counterparts. Intestinal 
20 
 
epithelial apoptosis was induced using either γ-irradiation or irinotecan 
administration. Colitis was induced using dextran sulphate sodium (DSS) and colitis 
associated cancer by a combination of azoxymethane (AOM) and DSS. In vitro 
studies were performed in HCT116 colon carcinoma cells. 
Disruption of classical NFκB signalling by deletion of NFκB1 but not c-Rel sensitised 
intestinal epithelial cells to undergo apoptosis following γ-irradiation and irinotecan 
administration. Deleting either c-Rel or NFκB1 also exacerbated the severity of 
experimental acute and chronic DSS-induced colitis in mice. However, only c-Rel-
null mice showed an increase in AOM/DSS induced colonic tumours. This was 
associated with c-Rel, but not NFκB1 deletion resulting in persistent colonic 
epithelial mitosis and increased crypt regeneration following DNA damage.  
Disruption of the alternative NFκB activation pathway by either deleting NFκB2 (in 
vivo) or suppressing its expression (in vitro) also increased the susceptibility of 
intestinal epithelial cells to undergo apoptosis following DNA damaging stimuli. 
Conversely and intriguingly however, deleting NFκB2 also protected mice from 
developing colitis and colitis associated colon cancer.  
Specific members of the NFκB family therefore play different roles in regulating the 
intestinal responses to various types of cellular injury. NFκB2 in particular appears 
to be essential for developing colitis and its associated cancer. Pharmacological 
inhibition of NFκB2 may therefore be a promising novel therapeutic strategy for 
IBD, whereas inhibition of c-Rel signalling may increase susceptibility to developing 
colitis and its associated colon cancer. 
21 
 
1 Introduction 
The intestinal tract forms a mucosal barrier which separates the host’s cells from 
the outside world. Although this intestinal mucosal barrier allows the absorption of 
various nutrients, it also prevents water loss and protects the body from 
environmental toxins, harmful luminal contents and microbial insults. The 
outermost element of this barrier is a single layer of epithelial cells. In order to 
sense intestinal microbes and mount appropriate responses to maintain 
homeostasis, epithelial cells express pattern recognition receptors (PRRs) such as 
Toll-like receptors (TLRs) and NOD-like receptors (NLRs). Once bacteria have been 
detected, the TLRs and NLRs are ligated and this eventually leads to the activation 
of NFκB signalling as one of their main downstream effectors. NFκB activation 
induces the expression of various inflammatory mediators (such as pro-
inflammatory cytokines and chemokines) and anti-microbial factors, which are 
required for the elimination of invading bacteria (1).  
As a key regulator of cell survival and proliferation, and of the immune responses 
which are mediated by PRRs, NFκB signalling plays important roles in regulating 
intestinal epithelial homeostasis and pathophysiology. As a consequence, 
dysregulated NFκB signalling has been detected in several intestinal disorders such 
as chronic inflammatory intestinal diseases (2, 3). However, NFκB signalling has 
various functions depending on cell context and it can also modulate other key 
pathways involved in cancer development such as apoptosis and proliferation. This 
therefore complicates the prediction of the outcomes of dysregulated NFκB 
signalling on development of intestinal diseases. Hence, dissecting the roles of NFκB 
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signalling pathways in the intestine is essential to improve our understanding of the 
pathogenesis of many intestinal diseases. 
Several lines of evidence have suggested that the classical NFκB activation pathway 
is involved in the pathogenesis of inflammatory bowel disease and its associated 
colorectal cancer. However, most previous investigations have involved generic 
disruption of this pathway (by disrupting upstream components of the classical 
signalling pathway such as IKKβ). The NFκB family however consists of 5 
transcription factors. Therefore, it is important to investigate and define the 
importance of these individual members of the NFκB family of proteins in regulating 
intestinal homeostasis, intestinal responses to injury and the development of 
inflammatory and neoplastic intestinal disorders.  
In this thesis the consequences of deleting three individual members of the NFκB 
family on intestinal responses to injury and development of colonic inflammation 
and colitis associated cancer have been assessed using murine models. In order to 
understand the studies described later in this thesis, I will begin by briefly outlining 
the major elements involved. These include: structure and functions of the 
intestine; cell apoptosis and proliferation, particularly in intestinal epithelia; 
inflammatory bowel disease and its associated colorectal cancer and NFκB signalling 
pathways. 
1.1 Structure and function of the intestinal tract 
Anatomically, the intestinal tract is composed of two parts, the small and large 
intestines. Each part plays a particular role in the digestion and absorption of food. 
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Ultimately energy and nutrients are extracted from ingested food and the 
remaining waste is expelled. Additionally, the intestinal tract constitutes a 
prominent part of the immune system. It is the first line of defence against harmful 
microbes and toxins. This function is achieved through many factors such as mucus 
containing secreted IgA antibodies and the gut associated lymphoid tissue (GALT). 
These vital processes within the intestinal tract are tightly controlled and their 
disturbance contributes to the development of many local and systemic diseases. 
All parts of the intestinal tract share a similar general structure, but there are some 
differences which reflect the specialisation of each section. Histologically, the 
intestinal tract generally consists of four concentric layers which are as follows from 
the inside (lumen) of the tract to the outside: mucosa, submucosa, muscularis 
externa and serosa. 
The mucosa is a mucous membrane that lines the inner surface of the intestinal 
tract and consists of three layers. The innermost is a simple columnar epithelium. 
The second layer of mucosa is the lamina propria which is composed of loose 
connective tissue including blood and lymphatic vessels. The muscularis mucosae is 
the outermost layer of the mucosa and is a thin layer of smooth muscle. The folds in 
the small intestine are formed by contractions and movements of this smooth 
muscle layer.  
1.1.1 Small intestine 
The small intestine which extends from the gastric pylorus to the ileocaecal junction 
is divided into three segments from proximal to distal; duodenum, jejunum and 
ileum. The duodenum is about 25 cm in length in humans and this is the place 
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where the stomach contents are emptied and where pancreatic juice and bile enter 
from the pancreas and liver respectively. The second segment is the jejunum, which 
is about 2.5 m long in man. The last section (ileum) is about 3.5 m long and extends 
until the ileocecal valve. The boundaries of these three segments are not 
observable either by the naked eye or microscopically. Nevertheless, there are 
histological differences between them. In some animals including mouse and rat, 
discrimination between small intestinal segments is less important and the 
anatomical description is based on the percentage of length. The entire small 
intestinal mucosa forms finger-like projections called villi which are approximately 
1mm in length in man and consist of a core composed of lamina propria. Villi are 
covered by a layer of simple columnar epithelium (absorptive enterocytes) that 
have at their luminal side a brushlike surface formed by micro-villi. These villi and 
micro-villi hugely increase the absorptive surface area. The enterocytes are 
interspersed with goblet cells that secrete mucus and protect the epithelial cells 
from digestion. In the space between the bases of villi, there are deep tubular 
cavities called intestinal crypts (crypts of Lieberkühn) that extend to the muscularis 
mucosae through the lamina propria (Figure 1.1). These crypts are lined 
predominantly by less differentiated epithelial cells. At the base of crypts is a zone 
that is believed to contain the tissue’s stem cells, which continually divide to 
eventually produce all the types of differentiated epithelial cells in the crypts and on 
the villi. Enteroendocrine cells are scattered individually among the absorptive cells, 
most commonly in the lower parts of the crypts. These cells secrete various 
hormones that stimulate intestinal motility and secretion. Additionally, there are 
secretory epithelial cells located at the bottom of intestinal crypts called Paneth 
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Figure 1.1: Small intestinal cross section and illustration of the structure of villi 
and crypts of Lieberkühn (adapted from 
http://www.daviddarling.info/encyclopedia/S/small_intestine.html). 
 
 
 
cells. These are thought to provide protection for stem cells by releasing anti-
microbial substances into the gut lumen. 
 
 
 
 
 
 
 
 
 
 
 
1.1.2 Large intestine  
The distal part of the digestive system includes the caecum, appendix, colon, 
rectum and anal canal. The colon of humans is subdivided into the ascending, 
transverse, descending and sigmoid colon. However, in mouse these divisions are 
not well defined and subdivisions have simply been designated as proximal and 
distal colon in this thesis. The main function of the large intestine is the 
reabsorption of ions and water from the food that has already passed through the 
small intestine.  
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All parts of the large intestine share a common histological structure with the 
exception of the anal canal. The mucosa consists of a layer of simple columnar 
epithelium that is configured into deep invaginations called crypts. In contrast to 
the small intestine, the luminal surface is flat and does not contain villi. The region 
between the crypts is called the inter-crypt table. The cellular composition of the 
mucosa is similar to that of the small intestine with the exception that there are no 
Paneth cells. Additionally, the crypts of the colon contain more cells than those of 
the small intestine and the proportion of goblet cells is higher. 
1.2 Intestinal epithelial stem cells 
Cell generation and replacement in intestinal crypts is regulated by stem cells that 
divide constantly. Intestinal stem cells are morphologically indistinguishable from 
intestinal epithelial cells. Generally, there are two characteristic features of stem 
cells. The first is longevity such that they are able to maintain the tissue for long 
periods of time. The second feature is multipotency which refers to the ability of 
tissue stem cells to generate all types of differentiated cells within that tissue. In 
addition to these characteristic properties, stem cells are believed to be quiescent 
and divide very infrequently. A stem cell divides into one daughter stem cell and a 
rapidly cycling daughter cell which provides a large number of proliferating cells 
which subsequently undergo differentiation (4). Several experimental approaches 
have been used to try to identify candidate intestinal stem cells. These include long 
term label retention, transplantation and in vivo lineage tracing studies. However, 
there are a number of limitations for each of these methods.  
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Intestinal stem cells are now thought to be localised near the crypt base. The 
precise location of small intestinal stem cells however remains uncertain and two 
schools of thought have been proposed, the "+4 position" model and the "stem cell 
zone" model (Figure 1.2). The "+4 position" model suggests that stem cells reside at 
cell position +4 in the crypt axis starting from the bottom with the lower three 
positions being occupied by differentiated Paneth cells. This model has been 
supported by several studies conducted by Potten and colleagues. For example they 
showed that label retaining cells specifically exist at the +4 cell position (5). In 
addition, they also demonstrated that the cells which reside at the +4 cell position 
are highly radio-sensitive, an essential function acquired by stem cells to protect 
them from genetic damage (6). However, the multipotency of these +4 cells has not 
yet been proven in the literature. By contrast the "stem cell zone" model proposes 
that the small undifferentiated Crypt Base Columnar (CBC) cells that are located 
between the Paneth cells are actually the small intestinal epithelial stem cells (7-9). 
This model relied originally on morphological considerations, but has recently been 
supported by clonal marking techniques (10). 
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Figure 1.2: Location of the small intestinal stem cells as proposed by two 
models, "+4 position" model and "stem cell zone" model (CBC cell means Crypt 
Base Columnar cell). Modified from Barker et al, 2008 (4). 
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Several studies have investigated the number of epithelial stem cells that are 
present within each crypt. Mathematical models have suggested that there are 4-6 
stem cells per crypt in the murine small intestine (11). However, there is currently 
considerable debate about this. Some studies have proposed that all proliferative 
cells in the crypt are stem cells, whereas other researchers have suggested that 
there is only one stem cell present in each crypt. These differences in stem cell 
number have been attributed to the fact that stem cell number varies in response 
to crypt injury (12). It is unlikely that there is only one stem cell per crypt, as this 
might lead to crypt asymmetry and might result in crypt extermination if that stem 
cell were to die (13). In the colon, stem cells are thought to be located at the very 
bottom of colonic crypts (at cell positions 1-2) (12, 14). There are no Paneth cells in 
the colon in the normal state (15), but in chronically inflamed colon such as 
ulcerative colitis, Paneth cells can be found (11, 16, 17).  
Although long term retention, transplantation and in vivo lineage tracing methods 
have demonstrated important aspects of intestinal stem cells, the lack of a unique 
marker of stem cells hindered the exact identification of intestinal stem cells for 
many years (18). Recent studies have however identified various potential intestinal 
epithelial stem cell markers and several of these are summarised in Table 1.1. 
LGr5/GPR49 has been recently identified as a novel potential marker for intestinal 
stem cells. It is the first marker to have identified cells that are situated between 
the Paneth cells. LGr5 positive cells were also observed at the base of colonic crypts. 
These cells actively divide approximately once every 24 hours and are capable of 
producing all types of differentiated intestinal epithelial cells (19, 20). Additionally, 
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it has been shown that Bmi-1 is expressed in a few cells which are located 
predominantly at cell position 4 in small intestinal crypts, but this protein is also 
occasionally expressed in the cells that are located between Paneth cells. Bmi-1 
positive cells have been shown to proliferate and can generate all differentiated cell 
lineages within the small intestinal epithelium. However, the observation of Bmi-1 
positive cells only in proximal small intestinal crypts suggests the existence of Bmi-1 
negative intestinal stem cells in other parts of the intestine (13, 21). Mushashi-1 
(Msi-1) has also been suggested as a marker of intestinal stem cells. It is expressed 
in cells which are distributed at cell positions 4-5 and also in a few cells at the base 
of the crypt in the adult small intestine and colon respectively (11, 13, 22). Other 
potential intestinal stem cell markers include doublecortin and CaM kinase-like-1 
(Dcamkl1) and SOX9. Dcamkl1 has been found to colocalize with Msi-1 staining and 
is expressed mainly in the upper stem cell zone (20).To date, it has not yet been 
confirmed whether the stemness of these cells is intrinsically acquired or is due to 
the influence of the microenvironment in which they reside. 
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Table 1.1: Some potential markers for intestinal stem cells. Adapted from Lin et al, 
2011 (18). 
 
Marker Method of 
discovery
Expression Evidence for stem cell 
properties
Evidence against stem 
cell properties
Lgr5 In vivo lineage 
tracing
Only in CBC cells Lgr5+ cells are proven to 
be multipotent cells in 
vivo and in vitro
None to date
Bmi1 In vivo lineage 
tracing
Predominantly in 
+4 cells
Bmi1+ cells are 
multipotent and targeted 
deletion of Bmi1+ cells 
results in crypt 
extermination
Bmi1 is expressed 
only in crypts of the 
proximal small 
intestine
Ascl2 Microarray 
profiling of Lgr5+ 
cells
Only in CBC
cells
In addition to restricted
expression of Ascl2 in the 
CBC compartment, Ascl2 
is required for survival of 
Lgr5+ stem cells
Not supported by in 
vivo lineage tracing
Sox9 In vivo lineage 
tracing
Crypt base and
sporadically in 
villus.
High expression 
at +4 to +6, low
expression in 
CBC and Paneth
cells
In addition to restricted
expression of Sox9 in CBC 
cells, Sox9+ cells are
multipotent in vitro
Sox9 is expressed in 
Paneth cells
Musashi1 Positional 
information
based on 
expression
analysis
In +4 and CBC 
cells
Msi1 activates some 
known active pathways in 
stem cells and colocalises
with Dcamkl1
Msi1 is expressed in 
non stem cells at the 
crypt base
Dcamkl1 Positional 
information
based on laser 
capture
microdissection
of +4 cells
Sporadic 
expression
along crypt-villus
axis
Dcamkl1 labels +4 cells Sporadic expression 
along crypt-villus axis
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1.3 Proliferation and differentiation of the intestinal epithelium and 
the crypt/villus hierarchy 
By the process of proliferation, the murine intestinal epithelium renews itself 
approximately every 5 days. Intestinal epithelial cell proliferation is confined to the 
crypt compartment and is initiated by asymmetric stem cell division which results in 
the production of an identical stem cell (retaining the original DNA strand as a 
protective mechanism against replication errors) and a differentiated progenitor 
cell (a committed transit-amplifying cell). The transit-amplifying cell cycles very 
quickly compared to the original stem cell. As the transit-amplifying cell undergoes 
several divisions, it migrates upwards along the crypt-villus axis in the small 
intestine and along the crypt axis in the colon, before undergoing differentiation 
(23). The first few of about 6 cell generations in the small intestine and 8 cell 
generations in the colon cells retain some stemness and are capable of replacing 
the ultimate stem cells when they die. These cells are referred to as clonogenic cells 
and constitute a reserve force to supply additional stem cells to preserve crypt 
survival. The clonogenic cell population is about 30-40 cells per crypt while about 
124 dividing transit committed cells completely lose their stemness (24). As these 
committed precursor cells migrate upwards, they gradually differentiate when they 
reach the crypt-villus junction in the small intestine and the upper part of the large 
intestinal crypt. They differentiate predominantly into absorptive enterocytes and 
secretory lineages, particularly goblet cells and enteroendocrine cells (4, 12, 24-26). 
Paneth cells represent the fourth cell lineage in the small intestine and result from 
the downward migration of committed precursor cells. Paneth cells reside in the 
crypt base for around 20 days (27). The upwardly migrating epithelial cells are 
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organised in coherent lines from the upper third of the crypt until they reach the 
villus tip in the small intestine and inter-crypt table in the colon where they are 
eventually removed by apoptosis (26). 
Regulation of proliferation and differentiation is very important for maintaining 
homeostasis within intestinal epithelia. This equilibrium is dynamic and depends 
upon tissue conditions. For instance, tissue injury triggers more proliferation 
through rapid division of precursor cells and an increase in clonogenic cell number 
(28). Two vital signalling pathways that appear to control intestinal proliferation and 
differentiation are the Wnt/β-catenin and Notch pathways.  
1.3.1 Wnt/β-catenin signalling pathway 
Wnt/β-catenin(canonical Wnt) signals influence cell proliferation by regulating 
progression through the cell cycle. Active Wnt/β-catenin signalling at the bottom of 
crypts maintains transit amplifying progenitors in a proliferative state. Inactivating 
Wnt signalling by over expression of the inhibitor DΚΚ1 results in loss of crypt 
proliferation (29, 30). Conversely, a constitutively active Wnt/β-catenin/TCF 
pathway keeps intestinal epithelial cells in a proliferative state and suppresses 
differentiation (31). A cytoplasmic protein β-catenin is a key element of the 
canonical Wnt signalling pathway. It translocates into the nucleus and stimulates 
the subsequent transcriptional regulation of Wnt target genes such as the c-myc 
oncogene. Therefore, nuclear accumulation of β-catenin is considered to be a 
hallmark of an activated canonical Wnt signalling. When the trigger of Wnt 
disappears, β-catenin is removed from the nucleus and is degraded by the tumour 
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suppressor gene product Adenomatous Polyposis Coli (APC). APC therefore acts as a 
suppressor of Wnt/β-catenin signalling (26).  
The role of Wnt signalling in influencing cell proliferation is probably mediated by 
suppressing the expression of p21CIP1/WAF1. Additionally, it has been shown that 
Wnt-dependent down regulation of p21CIP1/WAF1 is mediated by c-Myc. Therefore, it 
has been suggested that Wnt signalling regulates cell cycle progression through up-
regulation of c-Myc, which subsequently leads to down-regulation of p21CIP1/WAF1 
(31, 32). 
1.3.2 Notch signalling pathway 
Whereas both Wnt and Notch signals are important for maintaining a proliferative 
state in the lower crypt, many studies have suggested that the key determinant of 
cell fate and differentiation in the intestinal epithelium is the Notch signalling 
pathway. This pathway is stimulated by the interaction between Notch receptors 
and their ligands. This leads to cleavage of an intracellular domain (ICD) from the 
transmembrane domain of the receptor and the subsequent translocation of ICD 
into the nucleus, where it binds to the DNA binding protein RBP-J. Subsequently this 
complex activates the transcription of Notch target genes such as Hes1 (33, 34). 
These Notch signalling pathway elements, ligands, receptors and the target gene 
Hes1, are expressed in the proliferative cell compartment of the intestinal crypt 
(35). Inhibiting Notch signalling through intestinal-specific deletion of RBP-J resulted 
in increased expression of Math1 (which is usually repressed by active Notch 
signalling), and the replacement of the transit amplifying (proliferative) 
compartment by goblet cells. This was associated with repression of all epithelial 
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cell division while Wnt signalling stayed active (36, 37). Interrupting the Notch 
signalling pathway in Zebrafish by mutating DeltaD (which is a Notch ligand) and 
mind bomb (in which all Delta-Notch signalling is blocked) also resulted in an 
increase in goblet cell number in the gut epithelium (35, 38). Murine intestinal 
epithelium deficient in Hes1 displayed an increase in the number of secretory cell 
types (goblet cells, entero-endocrine cells and Paneth cells) and a decrease in 
enterocytes. This suggests that Hes1 functions as a negative regulator of secretory 
cell type differentiation (39). Additionally, Hes1 inhibits Math1 which is a positive 
regulator of secretory cell lineage differentiation. Math1 deletion in mice caused a 
reduction in intestinal epithelial goblet cells, entero-endocrine cells and Paneth cells 
without affecting enterocytes (40). Therefore, the commitment choice of progenitor 
cells to differentiate into either absorptive or secretory cell types depends to a 
certain extent on the balance between Hes1 and Math1 expression (Figure 1.3). 
However, further downstream regulation of Math1-specified secretory cell lineages 
is necessary for the differentiation of individual secretory cell lineages. This 
downstream choice involves the zinc-finger transcriptional repressor Gfi1 which is 
shown to be lost in Math1-null embryonic intestines. Deleting Gfi1 in mice was 
shown to cause loss of Paneth cells and a reduction in the number of goblet cells 
and an increase in the number of enteroendocrine cells. This suggests that Gfi1 is 
essential for the differentiation of Paneth and goblet cells and that it is a negative 
regulator of the differentiation of enteroendocrine cells (41). Deleting neurogenin 3 
(Ngn3) in mice resulted in complete loss of enteroendocrine cells, while the other 
three cell types (enterocytes, goblet cells and Paneth cells) developed normally. This 
suggests that Ngn3 is specifically essential for the enteroendocrine cell fate decision 
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Figure 1.3: Schematic diagram showing the contribution of several 
regulators to fate decision from intestinal epithelial stem cells. 
 
in intestinal multipotent stem cells (42). Homozygous Kruppel-like factor 4 (Klf4)-
null mice die within 15 hours of birth. The colon of these Klf4-null mice showed a 
90% decrease in goblet cell numbers. Therfore Klf4 is likely to be a goblet cell-
specific differentiation factor (43). Sox9 has been shown to be crucial for the 
differentiation of Paneth cells (44) (Figure 1.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
1.4 Apoptosis 
Currently there are thought to be four main distinct modalities of cell death, 
apoptosis, autophagy, cornification and necrosis. Cornification is a morphologically 
and biochemically distinct form of programmed cell death that occurs in the 
epidermis and results in the formation of corneocytes. Autophagic cell death is a 
self-degradative process which is thought to be required during critical times of 
insufficient energy availability during development and nutritional stress. 
Autophagy is morphologically characterised by massive accumulation of two-
membrane autophagic vacuoles in the cytoplasm and the absence of chromatin 
condensation (45). Unlike other forms of cell death, necrosis is morphologically 
characterised by cell swelling, dilatation of cytoplasmic organelles, plasma 
membrane rupture and the release of cellular contents which can subsequently 
evoke an inflammatory response. Apoptosis is a morphologically and biochemically 
distinct form of physiological cell deletion. It is the process whereby unwanted 
healthy, damaged and deleterious cells are removed from tissues (46). Apoptosis 
also plays a central role in tissue morphogenesis during development and in tissue 
homeostasis in adult animals. Many pathophysiological conditions have been 
attributed to a disturbance in the regulation of apoptosis. In the intestinal 
epithelium, homeostasis is ultimately determined by a balance between cell 
proliferation and cell death. The cells that are lost from the small intestine villus tip 
or from the inter-crypt colonic table into the gut lumen are replaced by equal 
number of cells through cell proliferation in the crypt. In pathological conditions 
such as colon cancer, impaired apoptosis may result in failure to delete mutated 
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cells, which subsequently may accumulate and result in progression to colon cancer 
and resistance to chemotherapeutic drugs (47).  
1.4.1 Molecular mechanisms that regulate apoptosis 
Apoptosis is mediated mainly by two pathways, extrinsic and intrinsic. The extrinsic 
pathway is activated through the binding of pro-apoptotic ligands to pro-apoptotic 
receptors, such as Tnfsf10/Apo2L/TRAIL to DR4 and DR5 receptors or FasL to the Fas 
receptor. As a result, two intracellular protease enzymes termed caspase-8 and 
caspase-10 are released in their active forms. This signal leads to activation of 
caspases-3, 6 and 7, which are the enzymes responsible for apoptosis (48, 49). This 
pathway is independent of p53 expression (50). The intrinsic pathway is initiated 
within the cell in response to cellular stress. It basically depends on the equilibrium 
between pro-apoptotic and anti-apoptotic proteins of the BCL2 superfamily (51). 
The cell senses stress through p53 and activates the pro-apoptotic BH3-only 
proteins PUMA and NOXA, which augment the stimulation of multi-domain pro-
apoptotic proteins such as BAX or BAK. As a result, these proteins proceed to the 
mitochondrial membrane where they counteract the function of the anti-apoptotic 
BCL2 proteins which suppress the permeability of the mitochondrial membrane. As 
a consequence, mitochondrial permeability is increased and cytochrome c and the 
pro-apoptotic protein SMAC/DIABLO escape from the mitochondria into the 
cytosolic space. Through this process, cytochrome c activates caspase 9, which in 
turn activates caspases-3, 6 and 7 that carry out apoptosis. The SMAC/DIABLO 
protein has a pro-apoptotic role by interacting with inhibitor of apoptosis proteins 
(IAPs) and preventing their ability to inhibit caspases (52, 53) (Figure 1.4).  
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Figure 1.4: Extrinsic and intrinsic pathways of apoptosis. Modified from 
Ashkenazi, 2002 (48). 
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1.4.2 Detecting apoptosis in intestinal epithelium 
Apoptosis is characterised by well-defined morphological and biochemical changes. 
These include shrinking of the cell, disappearance of microvilli and condensation of 
chromatin at the nuclear margins. Eventually, the cell fragments into separate 
membrane-bound bodies termed apoptotic bodies which are ultimately 
phagocytosed by adjacent epithelial cells and phagocytic cells (54). Most of these 
features can be seen in adequately fixed, processed, embedded and well oriented 
hematoxylin and eosin (H/E) stained paraffin embedded tissue sections (55). 
However, there are some problems associated with interpreting apoptotic indices 
obtained in this way as discussed by Potten (56). The number of apoptotic cells in 
the normal intestinal epithelium is relatively small, hence most biochemical 
methods for detecting apoptosis are insensitive in this setting. 
1.4.3 Spontaneous apoptosis in the normal intestinal epithelium 
1.4.3.1 Small intestine 
The small intestinal epithelium has a high turnover rate. In healthy murine intestinal 
epithelium, the number of apoptotic cells is very small (<1%) relative to the total 
epithelial cell number. This spontaneous apoptosis is predominately located at crypt 
cell positions 4 to 5 just above the Paneth cells, where the stem cells have been 
proposed to reside in one hypothesis (57). The apoptotic cell number, expressed as 
a percentage of all cells at cell position 4, reaches about 10% (55). Comparable 
amounts of spontaneous apoptosis levels are observed in mutant mice in which the 
p53 gene has been deleted. This p53-independent process may therefore function 
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as a regulatory mechanism to delete excess stem cells and maintain stem cell 
number (57-60).  
1.4.3.2 Large intestine 
The large intestine shows significantly lower rates of spontaneous apoptosis than 
the small intestine. Furthermore, the apoptotic cells observed in murine colonic 
crypts do not predominate in the proposed stem cell zone (cell position 1-2), but 
are located throughout the proliferative compartment of the crypt. Therefore, 
spontaneous apoptosis may not be the sole mechanism for the regulation of stem 
cell number in the large bowel. Unlike the small intestine, the antiapoptotic gene 
BCL2 is expressed at the base of murine and human colonic crypts. This may 
contribute to the relative lack of spontaneous apoptosis in the stem cell zone of 
colonic crypts (55, 59, 61, 62).  
1.4.3.3 Genetic determinants of spontaneous intestinal apoptosis 
The trigger that induces spontaneous intestinal epithelial apoptosis has not yet 
been identified. However, its genetic regulation has been assessed using knockout 
mice. As mentioned above, spontaneous apoptosis does not depend on p53 
expression. In addition, homozygous BCL2-null mice do not show any differences in 
the amounts of spontaneous apoptosis in the small intestine relative to control 
mice (46, 63). However, BCL2 knockout mice do demonstrate higher rates of 
spontaneous colonic apoptosis, located predominantly at cell positions 1-2 at the 
bottom of the crypt (61). These findings suggest that BCL2 is involved in regulating 
the homeostasis of normal colonic epithelium. Bax-null mice showed similar levels 
of spontaneous apoptosis to their wild-type counterparts in both the small intestine 
42 
 
and midcolon. This is consistent with the known distribution of Bax expression 
which is confined to differentiated Paneth cells and villus enterocytes that are not 
responsible for cell renewal (46, 64, 65). Additionally, Bcl-w does not appear to be 
involved in the regulation of spontaneous intestinal apoptosis (66). However, it has 
been demonstrated that BAK regulates spontaneous apoptosis at the colonic 
intercrypt table region, but it is not involved in regulating spontaneous apoptosis in 
the small intestine (67). 
1.4.4 Damage–induced intestinal apoptosis 
Several studies have investigated the apoptosis that is induced in gastrointestinal 
epithelia by cytotoxic agents such as irradiation and cytotoxic drugs. As a result of 
double strand breaks in DNA due to γ-irradiation, p53-dependent apoptosis is 
initiated (60, 68). The mechanism of apoptosis induction in intestinal epithelium 
following DNA damage has not however been completely clarified. The DNA 
glycosylase MBD4 has been implicated in the cellular response to DNA damage and 
the subsequent initiation of cell apoptosis in APCMin/+ mice (69). Radiation-induced 
apoptosis occurs mainly in cells above the Paneth cell zone in small intestinal crypts. 
This suggests that cells within this potential stem cell zone and thus probably the 
actual stem cells are highly sensitive to apoptosis. Intestinal apoptosis induced by γ-
irradiation increases as the dose increases until it reaches a plateau at doses greater 
than 1Gy in the small intestine and 6-8Gy in the mid-colon (59). This early wave of 
apoptosis reaches peak levels within 3-6h of radiation exposure. p53 appears to be 
the main regulator of this early wave of intestinal apoptosis following γ-irradiation 
as p53-null mice demonstrate complete absence of this response (68). However, 
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p53-null mice demonstrate a significant increase in small intestinal apoptotic cells 
24h following 8Gy, but not 1Gy γ-irradiation. Therefore, a p53-independent 
mechanism appears to function to delete damaged cells following exposure to high 
doses of radiation several hours after the p53-dependent wave of apoptosis (60). 
Other studies have also demonstrated that induction of apoptosis by doses of γ-
irradiation less than 10Gy is mediated by p53 and BAK, but inhibited by BCL2 and 
BCL-w (60, 61, 64, 66, 67). 
The cell positional distributions of apoptosis induced in the intestinal epithelium by 
18 cytotoxic agents, 5 sources of radiation (70, 71) and 4 mutagens was 
systematically assessed by Ijiri and Potten (72, 73). Each agent tends to induce 
apoptosis within a particular region of the crypt, however apoptosis could be 
induced in any region (59). Irinotecan (CPT-11) is a relatively a new 
chemothereuptic drug used to treat various tumours particularly colon cancer. Its 
mechanism of action is by inhibiting DNA topoisomerase I (74, 75), which prevents 
DNA from unwinding. Chemically, it is a semisynthetic analogue of the natural 
alkaloid camptothecin. In several studies, irinotecan has been shown to display 
distinctive concentration-dependent effects such as apoptosis and differentiation 
induction, in addition to its cytotoxic activity (76, 77). An increase in apoptosis has 
been observed throughout the intestinal epithelium in mice following 
intraperitoneal administration of irinotecan (77). Irinotecan-induced apoptosis has 
however not previously been well defined on a cell positional basis in the murine 
small intestine and colon. 
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1.5 Inflammatory bowel diseases 
The inflammatory bowel diseases (IBD) are characterised by chronic inflammation 
of the intestinal tract. Ulcerative colitis (UC) and Crohn’s disease (CD) are the two 
main disorders that constitute IBD. Clinically, patients with IBD present with 
symptoms such as loss of body weight, diarrhoea and rectal bleeding. The 
histological hallmark of IBD is chronic and uncontrolled inflammation of the 
intestinal mucosa characterised by distortion of the normal crypt architecture and 
the presence of a mixed inflammatory cell infiltrates. This architectural distortion 
distinguishes IBD from the chronic inflammation that occurs in the gut of healthy 
individuals or patients with bacterial colitis (78).  
1.5.1 Aetiology and pathogenesis of IBD  
The aetiological factors that are involved in the pathogenesis of IBD have not yet 
been fully determined. However, accumulating evidence suggests that both genetic 
and environmental factors contribute to the pathogenesis of IBD (79, 80). The 
current hypothesis for the pathogenesis of IBD suggests that it results from the 
interaction of environmental factors, mainly the intestinal microbiota, and 
inappropriate immune responses in genetically predisposed individuals (81). Recent 
genome-wide association studies have identified approximately 100 genomic loci 
that confer susceptibility to IBD. These susceptibility loci contain candidate genes 
that encode proteins that are required for various crucial cellular functions such as 
microbial recognition, cytokine signalling and epithelial barrier function. Among 
these genes is Rel that encodes the NFκB family member c-Rel (82, 83). Several of 
the identified candidate genes have been shown to be specifically associated with 
Crohn’s Disease such as NOD2 (84), ATG16L1 (85) and IRGM (86). These genes 
45 
 
encode key proteins involved in microbial recognition (eg NOD2) and autophagy (eg 
NOD2, ATG16 and IRGM). NOD2 is expressed in immune and epithelial cells of the 
intestine and it is important for microbial sensing and subsequent NFκB activation 
to initiate an adequate innate immune response which required for bacterial 
clearance (87). Moreover, autophagy (intracellular bacterial processing) is also 
required for the clearance of invading bacteria (88) and polymorphisms of NOD2, 
ATG16 and IRGM which are key regulators of this process (86, 89, 90) have been 
strongly associated with Crohn’s Disease.  
In addition to defective bacterial sensing and autophagy, impairment of the 
intestinal mucosal barrier is also a key pathophysiological process that leads to 
intestinal inflammation and has been linked to the pathogenesis of IBD (91, 92). The 
mucosal barrier consists of several layers of protection, including outer mucosal 
barrier elements (such as commensal microbiota, the mucus layer and 
immunoglobulin A), intestinal epithelial cells and subepithelial immune cells. These 
elements communicate with and affect each other. The normal commensal 
microbiota contribute to maintaining a functional intestinal mucosal barrier. This 
results from inhibition of the colonisation of pathogenic bacteria and by influencing 
the development of both the intestinal epithelium and the gut associated lymphoid 
tissues (81, 93, 94). However, this beneficial relationship between the microbiota 
and host can break down and this may result in chronic intestinal inflammation. This 
abnormal reaction may occur as a consequence of dysbiosis and an altered gut 
microbial ecosystem which are common findings in IBD. Several studies have shown 
that the gut microbiota represent a crucial factor in inducing inflammation in IBD 
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(95, 96). Several environmental factors have also been shown to be associated with 
IBD such as diet and life style (eg smoking). These factors also influence the 
composition of the gut microbiota (96, 97). Defects in the intestinal epithelial cell 
barrier have been shown to be essential for the abnormal response of the mucosal 
immune system to microbiota that leads to chronic intestinal inflammation (98). 
Disruption of the intestinal epithelium is a hallmark of IBD and is associated with 
increased intestinal epithelial cell apoptosis (81). As a consequence, subepithelial 
immune cells are exposed to luminal bacteria resulting in an uncontrolled 
inflammatory response (98). Indeed, a large body of evidence from human studies 
has indicated the importance of these factors in the pathogenesis of IBD. However, 
animal models have also provided insights into the pathogenesis of IBD. 
In order for an animal to act as a model of IBD, several characteristic features of 
human IBD should be demonstrated such as characteristic histopathology and 
accompanying clinical features. Although none of the available animal models is 
exactly identical to human IBD, they do represent several aspects of the human 
disease. They can therefore provide valuable information about the pathogenesis of 
the disease and are useful tools for evaluating the therapeutic potential of new 
therapies for IBD before they are tested in human clinical trials. In the last two 
decades, a large number of animal models of IBD have been developed. These can 
be classified into four categories: spontaneous models, genetically engineered 
models, inducible models and adoptive transfer models in immunocompromised 
hosts (99-101). Colitis develops spontaneously in certain strains of mice. For 
instance, C3H/HejBir mice spontaneously develop colitis by the age of 3 - 4 weeks 
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and this disappears by the time they reach 10 - 12 weeks old (102). A spontaneous 
IBD animal model has been also demonstrated in SAMP1/Yit mice, which develop 
chronic terminal ileitis, resembling Crohn’s disease (103). The genetically 
engineered models include two subgroups, knockout and transgenic. IL-7 transgenic 
mice develop chronic colitis when they are 4-11 weeks old and this resembles 
ulcerative colitis in humans (104). Genetic deletion of IL-10 has also been shown to 
induce spontaneous chronic colitis in mice (105). In adaptive transfer models, 
intestinal inflammation occurs as a result of selective transfer of certain cell types to 
immunodeficient host animals such as the adoptive transfer of CD45 RBhigh T-helper 
cells into SCID mice (severe combined immunodeficient mice) (106). Inducible colitis 
models are however probably the most widely used by researchers for studying IBD 
pathogenesis and the effects of new therapeutic agents. Therefore, we have 
focused on inducible models in this thesis as described below.  
1.5.2 Inducible colitis models 
Acute and chronic inflammation of an animal’s intestine can be induced by 
mechanical or chemical disruption of the mucosal barrier. Induction of colitis in this 
model is thought to be due to the activation of the mucosal immune system on 
exposure to luminal contents particularly the microbiota (107). Induced models, 
particularly chemically induced forms of colitis are therefore widely used. 
1.5.2.1 Dextran sulphate sodium induced colitis 
 Chemically induced colitis in mice, particularly dextran sulphate sodium (DSS) 
induced colitis is one of the most frequently used animal models of IBD. This is 
because it has low cost, is simple to use and the severity of the resultant colonic 
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inflammation can be easily controlled (107). It has also been shown that 
administration of azoxymethane (AOM) prior to DSS treatment results in the 
development of several colorectal tumours in areas which have developed colonic 
inflammation. This suggests that experimental DSS induced colitis can also be used 
as a model for studying the potential molecular mechanisms that may link 
inflammation to inflammation associated carcinogenesis in the colon (108) and thus 
the pathogenesis of IBD and IBD associated colon cancer. The murine model of DSS-
induced colitis is thus a valid model to translate mouse data to human diseases 
(109). In contrast to other models, acute, chronic and relapsing colitis can be 
induced easily by changing the DSS concentration and the number of DSS cycles. 
Therefore, the DSS induced colitis model was chosen in this thesis for studying the 
individual contribution of individual NFκB family members to the pathogenesis of 
colitis and colitis associated colonic cancer. 
1.5.2.1.1 Induction of colitis using DSS 
Colitis is induced in animals by adding DSS to their drinking water. Animals can 
develop acute or chronic colitis. This depends on the concentration, duration and 
frequency of administered DSS (110). It has been shown that mice exposed to one 
DSS cycle of 5 days develop acute colitis which resolves after approximately 2 weeks 
following DSS removal, with the exception C57BL/6 mice in which colitis may 
progress to chronicity. Chronic colitis can be induced by subjecting the mice to 
three to five DSS cycles and this is manifested by monocyte and lymphocyte 
infiltration and architectural distortion of crypts (111).  
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1.5.2.1.2 Clinical and histological features of DSS induced colitis 
DSS induced colitis has similar clinical and histological manifestations to IBD 
(particularly UC) in humans. These include body weight loss, diarrhoea, bloody stool 
and compromised general health. Severe DSS induced colitis may eventually lead to 
death. As a result of administrating 3-5% DSS for a few days, C57BL/6 mice develop 
acute colitis which is characterised by epithelial and crypt loss, infiltration of 
neutrophils into the mucosa and submucosa and shortening of the colon. 
Consistent with IBD in humans, cryptitis and crypt abscesses may also be observed 
in DSS induced colitis, particularly in C57BL/6 mice (112). 
1.5.2.1.3 Important factors that influence DSS induced colitis 
Various factors have been shown to influence the susceptibility, onset and severity 
of DSS induced colitis and these factors can be divided into three categories. The 
first category is related to the nature of DSS itself and its mode of administration. 
These include the molecular weight, concentration, duration, manufacturer and 
batch of administered DSS. It has been shown that the severity of colitis and colitis 
associated carcinogenesis varies following administration of different molecular 
weights of DSS ranging from 5 to 500 kDa. It appears that DSS with a molecular 
weight around 50 kDa is optimal for inducing severe colitis and enhancing the 
carcinogenic activity of AOM in the colon (113, 114). The second category is related 
to the animal species, strain and gender and reflects the importance of genetic 
factors in the pathogenesis of DSS induced colitis, similar to the contribution of 
genetic factors during the development of IBD in humans (111, 115). The third 
category involves environmental factors such as housing conditions and the 
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intestinal microbiota. The importance of the intestinal microbiota in the 
pathogenesis of DSS induced colitis is supported by the observation that mice did 
not develop colitis when maintained in germ free conditions, but colitis appeared 
immediately after mice had been reconstituted with commensal bacteria (116). 
Thus, similar to IBD in humans, both genetic and environmental factors contribute 
to the pathogenesis of DSS-induced colitis.  
Despite evidence for the involvement of all the above mentioned factors in the 
pathogenesis of DSS induced colitis, the exact mechanism by which DSS induces 
colitis remains unknown. It is believed that the toxic effect of DSS on colonic 
epithelial cells results in impairment of the epithelial barrier. This is evident in the 
acute stage of DSS induced colitis, where crypt loss, increased epithelial apoptosis, 
decreased epithelial proliferation and altered expression of tight junction proteins 
are observed in the colon along with inflammation following DSS administration 
(117, 118). Hence, defects in the epithelial layer, which functions as a physical and 
immunological barrier, permit the uncontrolled entry of commensal bacteria and 
toxins into the mucosa. Consequently, this leads to an overwhelming inflammatory 
response (115). Given the importance of inflammatory mediators such as cytokines, 
chemokines and nitric oxide in the pathogenesis of colitis, it has been shown that 
DSS induced colitis is associated with up-regulation of these mediators. The acute 
phase of DSS induced colitis is dominated by a Th1 response, whereas during the 
chronic phase both Th1 and Th2 responses are observed (119).  
In summary, the simplicity of induction of colitis and colitis associated 
carcinogenesis, the low cost and the similarities between DSS induced colitis and 
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human IBD suggest that the murine model of DSS induced colitis is suitable for 
studying the specific roles of individual members of the NFκB family of transcription 
factors in the pathogenesis of both colitis and colitis associated cancer. However, as 
mentioned above, several factors may affect the susceptibility to DSS; it is therefore 
important to report details of all the conditions that may alter the susceptibility to 
DSS such as mouse strain, gender, animal housing conditions, and the molecular 
weight, manufacturer, concentration and duration of DSS treatment. 
1.5.2.2 Other inducible models of colitis 
Several other models of induced colitis have also been established such as acetic 
acid induced colitis, indomethacin induced enterocolitis, 2,4,6-trinitrobenzene 
sulphonic acid (TNBS) induced colitis and oxazolone induced colitis. Rectal 
administration of a diluted acetic acid results in epithelial damage and mucosal and 
submucosal inflammation in the colon (120). It has been suggested that this model 
is suitable for studying the early phase of colonic inflammation and wound healing 
(121, 122). Indomethacin induced enterocolitis is based on subcutaneous injection 
or addition of dissolved indomethacin to the diet, and results in inflammation in the 
small intestine and colon of rodents (120, 123). Acute colitis can be induced in mice 
by luminal intracolonic instillation of TNBS or oxazolone in ethanol. Repeated 
enema administration of TNBS or skin sensitisation by subcutaneous injection of 
oxazolone before administration of oxazolone enema can result in chronic colitis 
(124, 125). In contrast to the DSS model however, these models do not show such 
high reproducibility (126). 
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1.5.3 Risk of colorectal cancer in IBD  
The risk of colorectal cancer (CRC) development is increased in patients with IBD 
compared to the general population. Although a multitude of epidemiological 
studies have been conducted, the exact magnitude of this risk remains difficult to 
determine. This has been attributed to several biases and methodological errors 
(127, 128). Due to geographical and study variations, the risk of developing CRC in 
patients with UC and CD ranges between a 2 to 8.2-fold increase compared to the 
general population (129). Eaden et al extracted data from 116 published studies 
which involving around 55,000 patients with UC. CRC was diagnosed in 1,700 
patients. Using meta-analysis, Eaden et al estimated the risk of developing CRC in 
patients with UC and found it to be 2% at 10 years, 8% at 20 at years and 18% at 30 
years (irrespective of disease extent) (130). In another more recent meta-analysis of 
the results of 34 published studies involving 60,122 patients with CD, the estimated 
risk of developing CRC was 2.59 times and the risk of developing small intestinal 
carcinoma was 28.4 times compared to the normal population (131). In general, 
several risk factors have been found to be associated with an increased risk of 
developing CRC in UC such as the severity of inflammation, duration, extent of the 
disease, family history of CRC, presence of pseudopolyposis and smoking (132, 133). 
Chronic colonic inflammation has been strongly linked to an increased susceptibility 
to developing colorectal cancer. This has been supported by several lines of 
evidence. For example, a positive association has been found between the 
increased susceptibility to CRC and the duration and extent of colitis. This is further 
supported by the fact that the use of several anti-inflammatory drugs that reduce 
the severity of inflammation is associated with reduced risk the development of CRC 
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(133, 134). Additionally, the production of cytokines (which are regulated by NFκB) 
and oxidative stress, which are both enhanced in UC, are considered to be 
important risk factors that contribute to colorectal carcinogenesis (135, 136). 
1.6 Colorectal cancer 
1.6.1 Epidemiology of colorectal cancer 
Colorectal cancer (CRC) is the one of most common malignancies worldwide and 
has a high mortality and morbidity. CRC is more prevalent in Europe, North America, 
Australia and Japan (137). The incidence of CRC is still increasing and it represents 
the most common cancer and the second leading cause of cancer deaths in Europe, 
where 436,000 new cases of CRC were diagnosed and 212,000 deaths were 
reported in 2008 (138). The majority of cases of CRC present with advanced disease 
at diagnosis (139).  
Genetic and environmental risk factors have been identified and linked to the 
development of CRC. The lifetime risk of developing CRC is 5% in the general 
population and this risk increases with age (140). Family history of CRC in one first 
degree relative imposes a 2-fold increase in risk of developing CRC and this risk 
increases to 4-fold when three or more of first degree relatives have been affected 
compared to individuals with no family history (141). Individuals with inherited 
conditions such as familial adenomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC) have 100% and 80% lifetime risks of developing 
CRC respectively (142). Personal and environmental factors have been also 
implicated in the development of CRC. Obesity, high consumption of red and 
processed meats, and low dietary fibre increase the risk of developing CRC (143). In 
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contrast, negative associations have been shown between physical activity, calcium 
intake, vitamin D intake, aspirin use and the development of CRC (144).  
1.6.2 Types of colorectal cancer 
CRC can be categorised by aetiology into three types: sporadic, hereditary and 
inflammation associated.  
1.6.2.1 Sporadic CRC 
Sporadic CRC is the most predominant type and accounts for more than 80% of all 
cases. Sporadic colorectal cancers show a variety of genetic mutations which have 
been identified as underlying causes. Inactivating somatic mutations in the 
adenomatous polyposis coli (APC) gene have been detected in approximately 70-
80% of sporadic colorectal cancers. Subsequent mutations of the oncogene K-ras 
and tumour suppressor gene p53 are often observed in the later stages of cancer 
development (142, 145, 146). Other mutations have also been reported in sporadic 
colorectal cancers particularly mutations of the mismatch repair (MMR) genes, but 
these occur in only 10-15% of sporadic colorectal cancers (147, 148). The 
contributions of mutated APC and MMR genes in the pathogenesis of 
carcinogenesis will be discussed below. 
1.6.2.2 Hereditary CRC  
There are several forms of hereditary CRC. However, familial adenomatous 
polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) (also termed 
the Lynch syndrome) are the most frequent forms. Both of these hereditary 
syndromes are inherited as autosomal dominant diseases. FAP accounts for less 
than 1% of all CRC cases (149). The major cause of FAP has been attributed to 
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germline mutation of the APC gene. Individuals with FAP present with multiple 
adenomatous polyps in the colon and rectum during childhood and the number 
increases to hundreds or thousands of polyps by the age of 30-40 years. These 
adenomatous polyps eventually transform into CRC if they not treated (150, 151). 
HNPCC is caused by germline mutations in one of the MMR genes and the tumours 
which develop in these patients are characterised by the presence of microsatellite 
instability (152). 80% of patients with HNPCC develop colorectal cancer and this can 
occur by the age of 45 years (142). 
1.6.2.3 Colitis associated colorectal cancer 
Colitis-associated colorectal cancer describes a subtype of CRC that arises as a 
complication of the chronic colonic inflammation that occurs in inflammatory bowel 
disease. Chronic inflammation has been implicated in the development of colitis 
associated colorectal cancer as described above in section 1.5.3. Although this type 
of cancer accounts for only 1-2% of CRC, it is aggressive in nature and has a high 
mortality. A milestone meta-analysis study performed by Eaden et al showed that 
the cumulative risk of developing colitis associated cancer in ulcerative colitis 
patients is approximately 2% at 10 years, 8% at 20 years, and 18% at 30 years and 
50% of those patients die from their cancer (130). However, more recent 
population based studies have showed this risk to be decreased by time (153-155). 
Various genetic alterations which contribute to the pathogenesis of sporadic CRC 
are also observed in colitis associated cancer. These include the two forms of 
genomic instability chromosomal instability (CIN) and microsatellite instability 
(MSI), inactivating mutations in tumour suppressor genes such as APC (resulting in 
56 
 
overactivation of Wnt/β-catenin signalling pathway) and p53, activating mutations 
in oncogenes such as K-ras and defects in MMR genes.  
1.6.3 Molecular pathogenesis of colorectal cancer 
CRC occurs as a result of the accumulation of genetic and epigenetic alterations that 
eventually cause the transformation of normal colonic epithelial cells into colonic 
adenocarcinoma cells. The loss of genomic stability is recognised as an early event 
in colorectal carcinogenesis. Genomic instability in turn provides the mechanism for 
the occurrence and accumulation of genetic mutations. These are the early key 
molecular pathogenic processes that occur during carcinogenesis. A sufficient 
accumulation of genetic alterations involving tumour suppressor genes, oncogenes 
and DNA repair genes permits cells to escape from growth and regulatory control 
mechanisms. This promotes cell transformation and tumour progression. However, 
the exact timing of genomic instability during the carcinogenesis process remains 
elusive. Inactivating mutations of the tumour suppressor gene APC, resulting in 
overactivation of the Wnt/β-catenin signalling pathway have been proposed as the 
early initiating event in most cases of sporadic colorectal cancer. In addition to 
activation of the Wnt/β-catenin signalling pathway, the resultant truncated APC 
protein has been shown to cause genomic instability during the early phase of 
colonic carcinogenesis (156). The finding of genomic instability in adenomas has 
provided supportive evidence for the proposed important role of genomic 
instability in tumour formation (157, 158).  
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1.6.3.1 Genomic instability 
In colon cancer, two genomic instability pathways have been identified, 
chromosomal instability (CIN) and microsatellite instability (MSI). CIN is the 
predominant form of genomic instability. It occurs in 80% of all colorectal cancers 
and is particularly more frequent in sporadic and colitis associated cancers (159). 
CIN is characterised by an increased rate of chromosome missegregation in mitosis 
and results in the gain or loss of whole chromosomes (aneuploidy) or fractions of 
chromosomes, a characteristic feature of solid cancers. This pathway is manifested 
by inactivating mutations of tumour suppressor genes such as APC and p53, or 
activation of oncogenes such as Kirsten rate sarcoma viral oncogene homolog (K-
ras) (160). The second form of genomic instability is MSI which is manifested by 
alterations in the length of microsatellites in genomic DNA. This pathway is caused 
by dysfunction of the mismatch repair (MMR) system which fails to correct errors 
that may occur in short repeat sequences during DNA replication (161). This 
promotes mutations in the downstream target genes of MSI that are important in 
tumour progression such as TGFβRII (which encodes TGF-β receptor type II) and 
BAX (146, 162). MSI is observed in most cases of HNPCC (which have germline 
mutations in a particular MMR gene) (163), in 15-20% of sporadic colorectal cancer 
cases (147) and at a variable frequency in colitis associated cancer (164). A multi-
step model of colorectal carcinogenesis was firstly proposed by Vogelstein et al 
(165) who described the genetic changes associated with colorectal oncogenesis. 
This is referred to as the adenoma-carcinoma sequence as described below. 
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1.6.3.2 Adenoma-carcinoma sequence 
This describes a sequences of progressive genetic mutations that results in the 
histopathological changes from normal epithelium to colonic adenoma to 
carcinoma. These genetic mutations involve tumour suppressor genes and 
oncogenes. Among the earliest genetic events that trigger the progression towards 
these pathogenic changes are inactivating mutations of the APC gene. Mutated APC 
gene is a characteristic feature in FAP and is also observed in most cases of sporadic 
colorectal cancer. The APC protein is an important regulator of the Wnt signalling 
pathway and loss of APC function leads to activation of this pathway and 
subsequent nuclear accumulation of β-catenin. This leads to transcriptional 
activation of several Wnt target genes that regulate cell cycle progression and 
apoptosis such as c-Myc and Cyclin D1 (166). In addition, APC mutation has been 
shown to result in chromosomal instability (140). These early genetic alterations 
facilitate activating mutations of oncogenic K-ras and inactivating mutations of the 
tumour suppressor genes deleted in colorectal carcinoma (DCC) and TP53 leading to 
cancer development (167, 168). These key stages of genetic and histopathological 
events during malignant transformation are similar between colitis associated 
colorectal cancer and non-inflammatory colorectal cancer. However, several 
differences in the sequence of molecular events have been demonstrated in colitis 
associated cancer as illustrated in Figure 1.5. This involves progression from 
inflammation induced dysplasia to carcinoma without the development of well-
defined adenomas (169, 170). Although colitis associated cancer shows similar 
genetic mutations to those observed in sporadic and hereditary CRC, there are 
some differences in the sequence of these genetic events. For example, in sporadic 
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colorectal carcinogenesis, inactivating mutations of the APC gene are considered to 
be early genetic events. By contrast, in colitis associated colorectal carcinogenesis 
these mutations occur at a later stage (170). 
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Figure 1.5: Comparison of the molecular alterations that occur in sporadic colon 
cancer and colitis associated colon cancer development. Modified from Terzic et 
al, 2010 (169). 
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1.6.4 Colitis associated colorectal carcinogenesis 
Various epidemiological, pharmacological and genetic studies have linked 
inflammation to carcinogenesis. This is evident in IBD where patients have an 
increased risk of developing colorectal cancer as discussed in section 1.5.3. As 
mentioned above, several of the molecular alterations that are responsible for the 
development of sporadic colon cancer have also been implicated in pathogenesis of 
colitis associated cancer, including the two major forms of genomic instability (CIN 
and MSI) and functional alterations in key proteins that regulate cell proliferation 
and apoptosis (APC, K-ras and p53). Additionally, increased activation of NFκB (as a 
crucial element of the inflammatory pathway), immune cell infiltration and 
increased expression of proinflammatory cytokines have also been observed in 
sporadic colorectal tumours (171-173). These findings suggest a large overlap in the 
mechanisms responsible for the development of colitis associated colon cancer and 
sporadic colon cancer (169). Chronic colonic inflammation contributes to colorectal 
carcinogenesis by multiple mechanisms such as induction of genomic instability and 
alteration of DNA methylation patterns, oxidative DNA damage, enhancement of 
proliferation of initiated preneoplastic cells and suppression of apoptosis of those 
cells with DNA damage or mutation (174). NFκB is a crucial mediator of all these 
inflammation induced processes that drive normal cells toward malignant 
transformation and finally cancer development. NFκB, which is constitutively active 
in inflamed tissues and frequently detected in tumours, has been recognised as a 
key molecular factor that links inflammation to cancer (175). For instance, various 
proinflammatory cytokines (e.g. IL-1β, IL-6 and TNF-α), chemokines, inducible nitric 
oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and adhesion molecules are 
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transcriptionally regulated by NFκB. Data from numerous studies support the notion 
that all these inflammatory mediators can promote colitis associated colorectal 
carcinogenesis via several mechanisms. These mechanisms include induction of 
oxidative DNA damage, genomic instability and functional and genetic alterations of 
key regulatory genes which are implicated in the process of carcinogenesis (174, 
176-180). Oxidative DNA damage that occurs as a result of overproduction of 
reactive oxygen species (ROS) during colonic inflammation is considered to be a 
major contributor to the development of colitis associated cancer in patients with 
IBD. Various inflammatory mediators enhance ROS production by infiltrating 
inflammatory cells and also induce ROS generation within epithelial cells. ROS 
induced DNA damage leads to genomic instability and inactivation of tumour 
suppressor genes and/or activation of oncogenes, which are considered to be 
important initial genetic events for tumourigenesis (180-182). Apoptotic and DNA 
repair responses to oxidative damage-induced telomere shortening might not be 
initiated and senescence associated secretory phenotypes may be acquired by 
epithelial cells (183). These cells have been shown to secrete more proinflammatory 
cytokines and ROS, which further promotes malignant transformation (182, 184).  
1.6.5 Animal models of colitis associated colorectal cancer  
Numerous animal models of inflammation associated colorectal cancer have been 
established. Studies using these animal models have provided insights into the 
pathogenesis and risk factors for colitis associated colorectal cancer and have 
estabilished the chemopreventive potential of various drugs for this condition. 
These animal models can again be classified into genetically modified and 
chemically induced types. Several knockout animal models of colitis have been 
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shown to develop colitis associated colorectal cancer. Deleting certain genes that 
are involved in the immune response has been shown to result in the development 
of a disease in animals similar to IBD in humans. Development of adenocarcinoma 
in these animal models has however been documented with variable frequency. 
These knockout animal models that have also been demonstrated to be models of 
colitis associated colorectal cancer include IL10-null (185), IL2-β2-M-null (186) and 
RAG2-null mice (187). Abrogation of genes that encode important proteins involved 
in maintaining the physiological intestinal barrier have also been shown to 
represent another type of animal models that develop colitis and colonic 
adenocarcinomas such as Muc2-null mice (188) .  
Chemically induced animal models of colitis associated colorectal cancer are also 
widely employed. DSS is the most commonly used substance to induce colitis 
particularly in mice and this murine model of colitis has been discussed in detail in 
section 1.5.2 (110). To promote colorectal carcinogenesis as seen in chronic 
ulcerative colitis in humans, several cycles of DSS administration which are 
separated by periods of free water are required. The number of DSS cycles ranges 
from 4 to 15 cycles depending on DSS dose and duration, and mouse strain. 
However, the incidence and multiplicity of tumours are low in the DSS induced 
colitis model (189). A novel murine model of colitis associated colorectal cancer 
(AOM/DSS model) has therefore recently been established and validated by Tanaka 
et al (190) as described below.  
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1.6.5.1 AOM/DSS model  
This model involves an initial single low dose intraperitoneal administration of the 
genotoxic colon carcinogen azoxymethane (AOM) followed by oral administration of 
DSS using different protocols. For example in the original study conducted by 
Okayasu et al (108), a dose of 7.4mg/kg AOM was injected intraperitoneally 2 weeks 
prior to DSS administration. This was followed by exposure to three cycles of 
alternating administration of 3% DSS in the drinking water for 7 days, followed by 
14 days of ordinary water intake. 11 weeks following AOM pre-treatment, mice 
developed multiple tumours seen as polypoid or flat elevated lesions in the distal 
colon. Most of these tumours were adenomas with high-grade dysplasia, but a few 
invasive adenocarcinomas were also observed. The location of these tumours 
corresponded to the areas of the colon that showed the greatest inflammation and 
damage. This provided evidence for inflammation driven colorectal carcinogenesis 
in this model (108).  
Similar to the standard UC model (DSS-induced colitis), the AOM/DSS model 
depends on DSS administration to produce chronic colitis as the main promoter of 
carcinogenesis. Pre-treatment with the carcinogen AOM may recapitulate the 
chronic exposure to low doses of environmental mutagens and carcinogens that 
initiates colorectal cancer development in humans (191). Data from several studies 
support the notion that the AOM/DSS model is relevant for investigating various 
aspects of colitis associated cancer in humans. For example, the clinical and 
histopathological features of the colitis induced in the AOM/DSS model are similar 
to those observed in patients with ulcerative colitis. These features include body 
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weight loss, diarrhoea, rectal bleeding, distortion of colonic crypts, colonic mucosal 
ulceration and diffuse inflammatory cell infiltrate. These changes can be observed 
from the third week of the AOM/DSS regimen.  
In addition to the presence of inflammation as a predisposing factor for cancer 
development, the early molecular and genetic alterations that occur in colitis 
associated colorectal cancer are also observed in the AOM/DSS model. For example 
increased expression and mutation of the β-catenin gene, which occurs in 
inflammation related colorectal cancer in humans, are also detected in tumours 
induced by AOM/DSS treatment in mice (190). This was also shown to be associated 
with increased expression of target genes of the Wnt/β-catenin pathway such as c-
Myc both in humans and in AOM/DSS treated mice (192). Similar to humans, 
activating mutations in the oncogene K-ras have been identified and shown to 
contribute to the early phases of colorectal carcinogenesis in the AOM/DSS model 
(193). In contrast to colitis associated colorectal carcinogenesis in humans, 
however, no immunoreactivity to p53 is observed in the neoplastic lesions that 
develop in the AOM/DSS model (190). Other key molecular changes that are 
involved in the development of inflammation related colorectal carcinogenesis in 
humans such as up-regulations of Cox-2, iNOS and several pro-inflammatory 
cytokines have been also observed in the dysplastic and neoplastic colonic lesions 
that develop in the AOM/DSS model. Due to these close similarities between colitis 
associated colorectal cancer in humans and AOM/DSS induced tumours in rodents, 
the AOM/DSS model has been described as a valuable and practical tool for 
investigating the pathogenesis of colitis associated colon cancer (194). Therefore, 
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the AOM/DSS murine model was employed to study inflammation associated 
colorectal carcinogenesis in this thesis.  
1.7 Nuclear Factor κB (NFκB) 
The mammalian nuclear factor κB (NFκB) complex consists of a family of five related 
transcriptional factors, RelA (also called p65), c-Rel, RelB, NFκB1 (p50 and its 
precursor p105), and NFκB2 (p52 and its precursor p100). These proteins share the 
ability to bind DNA in a specific manner and to regulate the expression of a diverse 
range of NFκB-dependent genes. These NFκB-dependent genes are involved in 
regulating various physiological processes and functions including cell division, 
differentiation, cell survival and immunity, and have therefore been implicated in 
the development of several diseases (195).  
1.7.1 Structure and forms 
Structurally, all the NFκB transcription factors are characterised by the presence of 
an N-terminal Rel homology domain (RHD), which is responsible for DNA binding 
and homo- and heterodimerisation through a conserved dimerisation interface in 
the RHD. Dimerisation of NFκB subunits is a fundamental characteristic and is 
essential for DNA binding (196). However, only RelA, c-Rel and RelB contain a C-
terminal transcription activation domain (TAD) that is required for the positive 
regulation of gene expression. p50 and p52 are synthesised as large precursor 
proteins named p105 and p100 respectively and proteolytic cleavage of ankyrin 
repeats at their C terminus leads to the release p50 and p52. Therefore, the p52 
and p50 subunits which lack TAD, depend on interactions with other family 
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members to positively regulate gene transcription, otherwise they may function to 
repress transcription (197).  
RelA and c-Rel heterodimerise mainly with p50 (197-199) while RelB preferentially 
heterodimerises with p100 and its processed form p52 (197, 200). Additionally, RelB 
has a unique property owing to the presence of a leucine zipper (LZ) motif in its N 
terminus which has a transcriptional regulatory function (201). All the mammalian 
NFκB subunits can form homodimers or heterodimers in vivo, with the exception of 
RelB which can only heterodimerise with other proteins in vivo. These various 
combinations and forms are thought to be responsible for regulating the expression 
of distinct and overlapping sets of genes (202).  
1.7.2 NFκB signalling 
A diverse range of stimuli that include endogenous and exogenous ligands, and 
different physical and chemical stresses can trigger NFκB signalling. In unstimulated 
cells, NFκB dimers are sequestered in a latent form by the attachment of their RHD 
to NFκB inhibitory proteins termed IκBs. However, the unprocessed NFκB1 and 
NFκB2 precursor proteins p105 and p100 act as IκBs which upon processing produce 
the active proteins p50 and p52 respectively (203-205). NFκB activation is mediated 
by two pathways, classical (canonical) and alternative (noncanonical). The dominant 
and most extensively investigated of these is the canonical pathway. It involves 
RelA, c-Rel and NFκB1 proteins that are found mainly as RelA:p50 and c-Rel:p50 
heterodimers. The main initiating event in this pathway is the activation of the IκB 
kinase (IKK) complex which is composed of two catalytic subunits (IKKα and IKKβ) 
and a regulatory subunit (IKKγ, also called NEMO) (197, 206, 207). Activated IKK 
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phosphorylates IκBα (this is mainly by IKKβ although a role for IKKα has also been 
proposed in this process)(203) and results in IκBα polyubiquitination. This in turn 
leads to its proteasomal degradation and the subsequent release of associated 
NFκB subunits, which translocate into the nucleus where they regulate the 
transcription of target genes (Figure 1.6). 
The alternative NFκB activation pathway is activated by only certain members of the 
TNF receptor superfamily including lymphotoxin-β receptor, CD40L, BAFF (B cell 
activating factor), RANKL (receptor activator of NFκB ligand) and TWEAK (TNF-
related weak inducer of apoptosis) (197-199, 203, 208, 209). Once any of these 
receptors engages with its corresponding ligand it activates NFκB-inducing kinase 
(NIK), which then phosphorylates and activates IKKα homodimers (not associated 
with the NEMO subunit) (202, 210). The latter NIK-activated IKKα dimers 
phosphorylate two serine residues adjacent to the ankyrin repeat at the C-terminal 
IκB domain of p100 (211). As a result of this phosphorylation, the SCFIκBE3 ligase 
complex detects p100 and leads to its polyubiquitination and subsequent partial 
proteolysis. The partial proteolysis is due to the presence of a STOP signal located 
between the p100 C-terminal ankyrin repeat domain and the p52 N-terminal part. 
Subsequently, the p52:RelB dimer liberates and translocates into the nucleus (197, 
212) (Figure 1.6).  
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Figure 1.6: NFκB activation pathways: two pathways (classical and alternative) 
lead to activation of NFκB. Activation of the classical pathway is triggered by a 
wide range of stimuli such as pro-inflammatory cytokines and DNA damaging 
stimuli. These stimuli result in IKK-β and IKK-γ-dependent phosphorylation of IκB 
and its subsequent proteasomal degradation and liberation of NFκB subunits 
(which are commonly p50:RelA or p50:c-Rel dimers) that translocate into the 
nucleus where they regulate the transcription of a wide array of target genes. 
The alternative pathway is activated by certain TNF family members such as 
CD40 and BAFF. This triggers IKK-β and IKK-γ-independent, but IKK-α dependent 
phosphorylation of p100 that is bound to RelB. This results in the partial 
proteasomal degradation of p100 to p52. As a consequence, p52 and RelB dimers 
liberate and translocate into the nucleus for target gene transcription.          
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Approximately 500 different target genes for NFκB signalling have been gathered 
from the literature by the Gilmore Laboratory at Boston University (213). Based on 
biological functions, these genes that are under NFκB transactional regulation can 
be generally divided into four groups: (1) Apoptosis regulating genes that encode 
both pro-apoptotic proteins such as BAK, FAS and FAS-L (214), and anti-apoptotic 
genes such as BCL-2 (215) and BCL-XL (216). (2) Cell cycle progression regulating 
genes which encode proteins that control cell cycle progression. Some of these 
proteins facilitate cell cycle progression such as cyclin dependent kinases (217) and 
others suppress or arrest cell cycle progression such as the cyclin dependent kinase 
inhibitor p21 and p53 (218). (3) Inflammation mediating genes which include 
cytokines such as TNF-α (219), IL-1β (220) and IL-6 (221) which can further enhance 
NFκB activity and result in a positive feedback loop, various adhesion molecules and 
inducible nitric oxide synthase iNOS (222). (4) NFκB inhibitory genes which encode 
various proteins (such as IκB) that inhibit NFκB activity and hence provide a negative 
feedback regulatory mechanism that balances the pro-inflammatory function of 
NFκB (223). 
1.7.3 Functions of individual NFκB family proteins 
The apparent functions of the transcriptional factors RelA, c-Rel, NFκB1, NFκB2 and 
RelB have been demonstrated using knockout mouse models. Investigating these 
mice that have been rendered homozygously null for individual NFκB family 
members has demonstrated several functions of these transcription factors in 
various tissues. The phenotypes of these knockout mouse models are summarised 
in Table 1.2 
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Genotype Phenotype Reference 
RelA-null 
mice 
Embryonic lethal as a result of extensive TNFα-mediated fetal 
hepatocyte apoptosis. 
Defects in secondary lymphoid organ development when this 
strain of mice was crossed with TNFR1 deficient mice. 
 
(224) 
 
(225) 
c-Rel-null 
mice 
Mice are fertile and have a normal lifespan under standard 
housing conditions. 
Defects in the proliferation and responses of B and T cells. 
Impaired neuronal survival. 
 
 
(226) 
(227) 
NFκB1-null 
mice 
Mice are fertile and have a normal lifespan under standard 
housing conditions. 
Impaired innate and adaptive immune functions. 
More susceptible to irradiation induced intestinal apoptosis.  
Enhanced colonic epithelial proliferation. 
Resistant to unloading-induced muscle atrophy. 
 
 
(228) 
(229) 
(230) 
(231) 
NFκB2-null 
mice 
Mice are fertile and have a normal lifespan under standard 
housing conditions. 
Defects in secondary lymphoid structures. 
Impaired B cell maturation; abnormal T and dendritic cell 
functions. 
 
 
(232) 
(212) 
RelB-null 
mice 
Survive to maturity with T cell mediated inflammation in multiple 
organs and impaired cell-mediated immunity. 
Defects in secondary lymphoid structures. 
Absence of certain dendritic cell populations. 
 
(233) 
(234) 
(235) 
Table 1.2: Phenotype of knockout mouse strains for individual members of the 
NFκB family of proteins. 
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1.7.4 NFκB and apoptosis 
NFκB is an inhibitor of the two main types of cell death (apoptosis and necrosis). 
This physiological role of NFκB is important during development and for the 
homeostasis of several systems (236, 237). The anti-apoptotic function of NFκB is 
highlighted by the observation that deletion of RelA in mice leads to embryonic 
death as a result of extensive tumor necrosis factor α (TNFα)-mediated fetal 
hepatocyte apoptosis (195, 224). NFκB has also been shown to suppress apoptosis 
and necrosis in various adult mouse models of liver damage. This pro-survival role 
of NFκB has now been demonstrated in various tissues and cell types (238-240). 
However, NFκB can also promote apoptosis in other cell types under certain 
conditions. For example NFκB is usually a cell protective factor in the nervous 
system, but in microglia it has the opposite effect. Therefore, the effect of NFκB 
appears to be dependent on the cell type and the nature of the death-triggering 
stimulus (241, 242). The antiapoptotic functions of NFκB apply to apoptosis induced 
via both extrinsic and intrinsic pathways (238, 243, 244). 
Various transgenic mouse models have clarified the importance of NFκB family 
members in regulating apoptosis and proliferation. As mentioned above, RelA 
knockout mice die at embryonic day 15 as a result of extensive hepatocyte 
apoptosis (224). This apoptotic liver damage is rescued by deleting the TNF-R1 gene, 
suggesting that hepatocyte apoptosis is induced by TNFα in the absence of RelA 
(245). Similar findings have been demonstrated in IKKβ and IKKγ (NEMO) deficient 
mice (246-248). In order to avoid embryonic lethality, researchers have 
conditionally deleted IKKβ in the intestine and have demonstrated that IKKβ 
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activation (classical pathway) protects the intestinal epithelium from apoptosis as 
well as systemic inflammation following ischemia-reperfusion injury (249). 
Moreover, absence of intestinal epithelial IKKβ was associated with increased 
intestinal apoptosis and reduced tumour incidence following induction of colitis-
associated cancer, whereas IKKβ deletion in myeloid cells caused a significant 
decrease in tumour size which was attributed to decreased levels of pro-
inflammatory cytokines (250). Additionally, blocking the classical pathway of NFκB 
activation selectively in intestinal epithelial cells in vivo by the deletion of IKKβ 
resulted in a significant increase in small intestinal epithelial apoptosis after 
irradiation. This was associated with an increase in p53 and a decrease in anti-
apoptotic BCL2 family member expression (251). Azoxymethane (AOM) did not 
cause an increase in epithelial cell apoptosis in the colon of IKKβ-deleted mice (250). 
Specific intestinal epithelial cell inhibition of NFκB via conditional knockout of IKKγ 
or both IKKα and IKKβ subunits, spontaneously resulted in severe chronic intestinal 
inflammation in mice as a result of increased epithelial colonic apoptosis, impaired 
expression of antimicrobial peptides and translocation of bacteria into the mucosa 
(252). 
p50-/- mice also showed a significant increase in intestinal epithelial cell apoptosis 
following exposure to total body irradiation compared to wild-type mice. This 
indicates that selective NFκB activation can protect the small intestine from 
radiation-induced damage (229). However, the effects of deleting other individual 
members of NFκB family or of disrupting the alternative pathway of NFκB signalling 
upon intestinal apoptosis have not yet been well defined. 
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1.7.5 Regulation of mechanisms of apoptosis by NFκB  
1.7.5.1 Inhibition of apoptosis by NFκB 
1.7.5.1.1 Activation of transcription of antiapoptotic genes 
NFκB regulates the transcriptional activation of a number of apoptosis-regulating 
genes resulting in the subsequent up-regulation of their protein products. These 
include the inhibitors of apoptosis proteins (IAPs) such as c-IAP1, c-IAP2, XIAP which 
prevent the activation of procaspase-9 and suppress caspase-3 and -7 activities 
(241, 253, 254). In addition, IAPs exert an antiapoptotic role by inducing the 
degradation of Smac/Diablo (255, 256). XIAP also has an inhibitory effect on the 
persistent activation of JNK (241, 257). 
The second group of proteins that is upregulated by NFκB includes the antiapoptotic 
BCL2 family members BCL-XL, BCL2, Bfl-1/A1 and NR13. These proteins compete 
with pro-apoptotic BCL2 family proteins to prevent the release of cytochrome c and 
Smac/Diablo from mitochondria, thus preventing the activation of effector caspases 
and apoptosis (215, 241, 258, 259). Other NFκB target genes which encode proteins 
that promote cell survival include c-FLIP, TRAF1, TRAF2, TRAIL decoy receptor 1 
(DcR1) and GADD45β. c-FLIP suppresses apoptosis through inhibition of caspase-8 
activation (260). The adaptor molecules TRAF1 and TRAF2 inhibit TNF-induced 
apoptosis through augmenting NFκB activation and therefore represent a positive 
feedback mechanism. DcR1 is involved in the inhibition of TRAIL-induced apoptosis 
(261) whereas GADD45β suppresses JNK signalling and hence inhibits cell death 
(241, 262). 
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1.7.5.1.2 Repression of transcription of proapoptotic genes 
The second mechanism by which NFκB can promote cell survival is by 
downregulation of apoptosis inducing proteins and receptors such as caspase-8, 
TRAIL receptors DR4 and DR5, and hypoxia-inducible protein BNIP3. Additionally, 
NFκB can promote cell survival by inducing p53 degradation through the 
upregulation of Mdm2 (E3 ligase for p53) (241, 263). 
1.7.6 NFκB’s role in intestinal inflammation 
Although inflammation is a key physiological process that protects the host against 
microbial challenges, it can also cause tissue damage and other complications if 
activated inappropriately or excessively. Altered NFκB signalling has been linked to 
the development of cancer, inflammatory and autoimmune diseases. NFκB plays a 
fundamental role in regulating the inflammation response. NFκB expression is up-
regulated in several inflammatory conditions such as the inflammatory bowel 
diseases (IBD) ulcerative colitis and Crohn’s disease, hence NFκB is thought to be 
involved in the pathogenesis of these conditions. This has been attributed to its pro-
inflammatory role via transcriptional regulation of several genes which encode 
proteins that are involved in inflammation, including pro-inflammatory cytokines 
(such as TNFα, IL-1β, IL-6), chemokines, cyclooxygenase 2 (COX2), inducible nitric 
oxide synthase (iNOS), surface receptors and adhesion molecules (2). Additionally, 
these NFκB regulated cytokines enhance NFκB activity, leading to further 
production of inflammatory mediators (264). A recent study which used topological 
proteomic analysis identified NFκB as one of the key proteins that regulates the 
formation of various molecular networks responsible for different cellular functions 
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linked to IBD (265). This pro-inflammatory function of NFκB has also been 
previously documented in various experimental models of intestinal inflammation. 
For example, inhibition of the classical NFκB activation pathway by an antisense 
oligonucleotide for RelA (P65) (266) or by a small-molecule inhibitor of IKKβ (267) 
has been shown to attenuate inflammation in a murine model of colitis. 
Although several lines of evidence have linked NFκB activity to intestinal 
inflammation, several recent studies that have addressed the cell specific functions 
of NFκB have unexpectedly demonstrated a protective function for intestinal 
epithelial cell derived NFκB activity in the intestine. For instance, mice with specific 
deletions of IKKγ (NEMO) or both IKKα and IKKβ subunits in intestinal epithelial cells 
develop spontaneous colitis (252) and selective deletion of IKKβ from intestinal 
epithelial cells resulted in increased inflammation in the DSS-induced colitis model 
(250, 268). In humans, mutations in NEMO are associated with several disorders 
such as immunodeficiency, osteopetrosis and colitis. Those patients with mutations 
in NEMO who underwent allogeneic haematopoietic stem cell transplantation were 
shown to recover from immunodeficiency and osteopetrosis disorders, but colitis 
persisted and actually worsened. These findings suggest that dysregulated NFκB 
signalling in non-immune intestinal epithelial cells is crucial for colitis development 
(269, 270). In the normal intestine, the intraluminal microbiota are separated from 
the mucosal immune system by a single layer of epithelial cells. This physical barrier 
and antimicrobial factors produced by intestinal epithelial cells prevent the invasion 
of commensal bacteria into the mucosa, where they can be recognised by immune 
cells and induce inflammation. It has been shown that enterocyte derived NFκB 
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activity contributes to maintenance of the integrity of this barrier by promoting 
intestinal epithelial cell survival and proliferation (243). For example, IKK-β deficient 
enterocytes have been shown to be more susceptible to irradiation induced (251) 
and DSS induced apoptosis, thus sensitising mice to DSS induced colitis (268). Most 
of the studies that have elucidated the dual functions of NFκB were based on 
defects in upstream components particularly of the classical NFκB activation 
pathway. There is only one study that has evaluated the consequences of specific 
intestinal epithelial cell deletion of one of the classical NFκB proteins RelA on DSS 
induced colitis. Similarly to mice with IKK-β deficient enterocytes, these mice 
showed increased intestinal epithelial apoptosis, a disrupted intestinal barrier and 
increased susceptibility to DSS induced colitis (271). Another study has investigated 
the consequences of deleting other NFκB family members on parasite infection. 
Infestation with helminth parasites such as Trichuris muris (a natural parasite which 
inhabits the caecum and large intestine of mice) is associated with intestinal 
inflammation and crypt hyperplasia. Unlike c-Rel-null mice, NFκB1 and NFκB2 
deficient mice failed to clear infection with this parasite, but only chronically 
infected NFκB1-null mice developed destructive colitis-like pathology. Therefore, a 
direct role of NFκB1 and an indirect role of NFκB2 in Th2 responses have been 
suggested. This has provided evidence of nonoverlapping functions of NFκB family 
members in the development of Th2 cytokine-mediated resistance to T. muris and 
the regulation of infection-induced intestinal inflammation (272). Apart from 
parasite infection and RelA, the specific roles of NFκB family proteins and the role of 
the alternative NFκB activation pathway in intestinal inflammation have not been 
well defined to date. 
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1.7.7 The impacts of NFκB’s role in apoptosis and inflammation regulation on 
inflammation related colorectal carcinogenesis 
The contribution NFκB signalling to the process of carcinogenesis has now been 
documented in many studies. NFκB is considered to be a key factor in the 
pathogenesis of many human tumours and their resistance to chemotherapeutic 
agents. NFκB plays an important role in inflammation related colorectal 
carcinogenesis via different mechanisms. The first mechanism appears to be via 
promoting cell survival of tumour or cells targeted by carcinogens through the 
transcriptional activation of anti-apoptotic genes. For example, in a mouse model of 
colitis associated cancer, specific ablation of IKKβ in intestinal epithelial cells 
resulted in a marked decrease in tumour incidence without a reduction in tumour 
size or composition. An increase in epithelial apoptosis was observed during tumour 
promotion and no difference in inflammation was noticed between animal groups 
(250). Thus, NFκB’s ability to promote cancer in the intestine does not appear to be 
related to its pro-inflammatory properties, but rather to its role in inhibiting 
apoptosis (273). 
In addition to the central role of NFκB in promoting cancer cell survival, it also 
functions in a paracrine manner to enhance cancer cell growth. Recently, NFκB has 
been shown to act as a molecular link between inflammation and cancer (175). 
NFκB activity in tumour or pre-neoplastic cells and in inflammatory cells up-
regulates the expression of genes encoding pro-inflammatory cytokines, 
chemokines, adhesion molecules, COX2 and iNOS. The cytokines further induce 
NFκB activation in tumour or pre-neoplastic cells and in tumour associated 
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inflammatory cells, thus a sustained chronic inflammatory microenvironment is 
formed (274). This chronic inflammatory state promotes colorectal cancer 
development as described in section 1.6.4. This is illustrated by several mouse 
models of inflammation-associated cancer (241, 250). The mouse model of colitis 
associated colorectal cancer provides direct evidence that NFκB (particularly IKKβ-
dependent NFκB activation) links inflammation and cancer. In this model, deleting 
IKKβ only in myeloid cells reduced tumour number and size without affecting 
apoptosis. This decrease in tumour size resulted from reduced expression of the 
pro-inflammtory cytokines which are required for tumour growth (250). The 
expression of major inflammatory factors such as TNFα, IL-1, IL-6, IL-8 is regulated 
by NFκB and these cytokines in turn activate NFκB expression. This therefore 
represents a positive feedback loop whereby cellular and DNA damage promote cell 
proliferation and transformation, ultimately leading to the initiation, promotion and 
progression of cancer (175, 273, 275). The previous findings suggest that IKKβ-
driven NFκB activation participates in the development of colitis associated cancer 
via distinct cell-type-specific mechanisms. Thus, in enterocytes, it activates 
antiapoptotic genes which in turn inhibit the process of apoptotic elimination of 
pre-neoplastic cells, whereas in myeloid cells, it enhances the production pro-
inflammatory cytokines that act as growth factors for transformed enterocytes 
(276). These NFκB-dependent mechanisms that are involved in inflammation 
associated colorectal carcinogenesis are summarised and illustrated in Figure 1.7. 
However, in certain contexts NFκB can also play a major anti-inflammatory role in 
the intestine. This opposite effect may lead to suppression of inflammation driven 
colorectal carcinogenesis rather than promoting this type of carcinogenesis. 
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Together these previous studies have provided evidence that the classical NFκB 
activation pathway plays a role in regulating susceptibility towards developing 
intestinal inflammation and inflammation associated colorectal cancer. However, 
the specific roles of individual members of the NFκB family of proteins or of the 
alternative signalling pathway in regulating the development of colonic 
inflammation and colitis associated colorectal cancer have not previously been 
addressed. 
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Figure 1.7: NFκB-dependent mechanisms that are involved in inflammation 
associated colorectal carcinogenesis. NFκB is a key factor in mediating 
inflammation by inducing the production of various inflammatory mediators 
such as pro-inflammatory cytokines which in turn further enhance NFκB 
activity. ROS and other reactive species derived from inflammation stress 
cause oxidative DNA damage, genomic instability and mutations in various 
genes such as tumour suppressor genes and oncogenes and this leads to 
tumour initiation. This event is also facilitated by the anti-apoptotic function 
of NFκB. The pro-inflammatory cytokines, growth and survival factors induced 
by NFκB are also involved in tumour promotion and progression stages by 
enhancing the survival and proliferation of pre-cancer cells leading to cancer 
development. (+) symbol means promotion effect and (–) symbol means 
inhibition effect.  
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1.8 Hypothesis 
In several previous studies, the classical NFκB activation pathway has been shown 
to regulate intestinal epithelial cell proliferation, apoptosis and colonic 
inflammation. This regulation of cell proliferation, apoptosis and intestinal 
inflammation by the classical NFκB activation pathway has also been implicated in 
the development of inflammation associated colorectal cancer. Previous studies 
have predominantly involved disrupting the upstream components of the classical 
NFκB activation pathway such as IKK-β and IKK-γ. However, the specific roles of 
individual NFκB family proteins (as downstream components of both the classical 
and alternative NFκB activation pathways) and the roles of the alternative NFκB 
activation pathway itself in intestinal epithelial cell proliferation and apoptosis, 
intestinal inflammation and inflammation related intestinal carcinogenesis have not 
been well defined to date. We therefore hypothesise that: 
Individual members of the NFκB family which signal via the classical and alternative 
activation pathways specifically regulate intestinal epithelial cell proliferation, 
apoptosis and colonic inflammation, consequently modulating susceptibility to 
developing inflammation associated colon cancer.  
1.9 Aims 
1. To investigate whether individual members of the NFκB family of 
transcription factors specifically regulate murine intestinal epithelial cell 
turnover during physiological conditions.  
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2. To assess the specific roles of individual members of the NFκB family of 
transcription factors in regulating the susceptibility of intestinal epithelial 
cells to undergo apoptosis following induction of cellular injury.  
3. To investigate the consequences of in vitro suppression of the expression of 
the NFκB family members NFκB2 or RelB (which signal via the alternative 
activation pathway) upon proliferation and apoptosis in human colon cancer 
(HCT116) cells. 
4. To determine how individual members of the NFκB family of transcription 
factors regulate susceptibility to developing colonic inflammation and 
inflammation associated colorectal cancer in vivo. 
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2 Materials and methods 
Unless otherwise stated, reagents were provided by Sigma-Aldrich (Gillingham, UK). 
2.1  Animals 
All animals were adult 10-12 weeks old male mice which were housed under 
conventional conditions with food and water ad libitum. Animals were kept on a 
12:12 hour light-dark cycle. Groups of 5 to 10 male mice were used for each 
experiment. 
2.1.1  Wild-type C57BL/6 mice  
In-bred, wild-type C57BL/6 mice were purchased from Charles River Laboratories 
(Margate, UK), and were acclimatised under standard animal house conditions for a 
minimum of 1 week prior to being used in experimental procedures. 
2.1.2 c-Rel-null mice 
This strain of mice was generated on the C57BL/6 genetic background and provided 
by Dr Jorge Caamano of the University of Birmingham. Exons 4-9 of the c-Rel gene 
encoding amino acid residues 145-588 have been targeted with a PGKNeo cassette. 
This disruption truncates the c-rel protein, removing sequences required for DNA 
binding, Rel/NFκB dimerisation, nuclear transport, and transcriptional trans-
activation (226). The c-Rel-null mice were fertile and had a normal lifespan when 
maintained under standard conditions. The correct genotype of these mice was 
confirmed in our laboratory by Dr Mike Burkitt using conventional PCR.  
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2.1.3 NFκB1-null mice 
This strain of mice was generated on the C57BL/6 genetic background and donated 
to our laboratory by Dr Jorge Caamano of the University of Birmingham. This null 
colony was originally generated by Sha et al in 1995 (228). Targeted disruption of 
the NFκB1 gene was achieved by insertion of a PGK-neo cassette into exon 6 of the 
NFκB1 gene. Exon 6 encodes residues 134-187 that lie within the Rel homology 
domain that extends from residues 30-330. This disruption was shown to produce a 
functionally inactive protein that is unable to dimerise with other NFκB proteins or 
bind to DNA. This genetic alteration efficiently inhibits the synthesis of NFκB1 p105 
and p50 and does not affect the transcription of IKK-γ which is encoded also by the 
same gene through an alternative promoter site (228). NFκB1-null mice survive to 
maturity and are fertile. This null colony was maintained under standard animal 
house conditions. The genotype of this null colony was verified in our laboratory by 
Dr Mike Burkitt using conventional PCR. 
2.1.4  NFκB2-null mice   
This strain of mice was generated on a C57BL/6 genetic background and provided 
by Dr Jorge Caamano, University of Birmingham, UK. Exon 4 of the NFκB2 gene has 
been targeted with a PGKNeo cassette, effectively interrupting the production of 
both p100 and p52 (232). The generated NFκB2-null mice were fertile and were 
maintained under conventional conditions. Confirmation of the genotype of these 
mice was again performed in our laboratory by Dr Mike Burkitt using conventional 
PCR.  
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2.2  Animal procedures 
Experiments were conducted with UK Home Office approval under a project licence 
as specified by the Animals (Scientific Procedures) Act 1986. All experiments were 
performed by the author as a UK Home Office personal licensee and conducted 
within the University of Liverpool in specified rooms for animal procedures. All 
experiments were conducted during the daytime starting between 9-11am. 
2.2.1  Induction of apoptosis 
2.2.1.1 γ-irradiation 
Protocols for investigating apoptosis induction and mitosis suppression by γ-
radiation including dosages and time points have previously been established by 
Potten and Grant, 1998 (277). These protocols have determined the doses and time 
points that induce maximal differences in apoptosis between different groups of 
mice. A dose of 8Gy γ-radiation at a rate of 2.6Gy/min from a 137Cs closed source 
was therefore used in these studies and the irradiated mice were sacrificed 4.5 
hours after exposure using a schedule 1 approved method. 
2.2.1.2 Irinotecan 
In previous studies, a marked increase in the number of apoptotic crypt cells and a 
marked decrease in the total number of crypt cells were observed in murine small 
intestine and colon, 24 hours following intraperitoneal (i.p.) administration of 
280mg/kg irinotecan. Administration of a second dose of irinotecan 24 hours later 
was associated with approximately 25% mortality of mice along with extensive 
damage of intestinal mucosa 24 hours following this second dose (278). Therefore, 
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the consequences of a single dose of 250mg/kg of irinotecan (irinotecan solution 
20mg/ml, RLBUH NHS Trust, Pharmacy Dept., Liverpool, UK) were assessed in 
C57BL/6 wild-type mice (5 mice per group). Intestinal apoptosis and mitosis and 
intestinal damage were assessed during a time course. Mice received a 
subcutaneous (s.c) injection of 0.01mg/kg Atropine (Atropine 600mg/ml, RLBUH 
NHS Trust, Pharmacy Dept., Liverpool, UK) 2 minutes prior to administration of the 
single i.p. dose of irinotecan to reduce any cholinergic reactions (279, 280). Mice 
were sacrificed after 6, 12, 24, 48, 72 and 96 hours. 6 hours was considered as an 
early time point that showed a significant increase in epithelial apoptosis 
particularly in the small intestine and 48 hours was considered as a late time point 
that showed maximal intestinal damage. These time points were therefore chosen 
for subsequent experiments involving c-Rel-null, NFκB1-null mice and NFκB2-null 
mice.  
2.2.1.3  Azoxymethane (AOM) 
It has been shown in previous studies that maximal induction of intestinal apoptosis 
and maximal suppression of mitosis were observed 8 hours and 24 hours 
respectively after a dose of 10mg/kg azoxymethane (AOM) (281, 282). Mice were 
therefore administrated interaperitoneally with a dose of 10mg/kg AOM 
(Cat#A5486, Sigma-Aldrich, UK).and mice were culled either 8 or 24 hours later. 
2.2.2 Crypt regeneration assay 
Mice were exposed to a dose of 12Gy γ-radiation at a rate of 2.6Gy/min from a 137Cs 
closed source and culled 96 hours later to allow for detection of regenerating 
crypts. 
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2.2.3 Colitis induction 
Mice were administrated 2% dextran sulphate sodium (DSS) (M.W= 36,000 – 
50,000; Catalogue number: 160110; Lot number: 6683K; MP Biomedicals, LLC, UK) 
in their drinking water for 5 days to induce colitis. This was followed by one day of 
DSS-free water and mice were sacrificed on day 6 from the start of the experiment. 
2.2.4 Induction of Colitis associated colonic cancer using AOM/DSS 
According to the findings observed in DSS induced colitis experiments (see section 
2.2.3), some strains of mice particularly the c-Rel-null and NFκB1 null mice were 
highly susceptible to 2% DSS and mice were not able to recover and were severely 
ill at day 6 from the start of the experiment. Therefore, the experiment was 
terminated at day 6. In order to choose a suitable DSS concentration that induced 
colitis with less than 20% mortality rate, lower DSS concentrations were given 
(1.5%, 1%, 0.75% and 0.5% DSS) to 5-6 mice per group of the susceptible strains and 
mice were monitored for 12 days. 0.5% and 0.75% DSS effectively induced colitis 
and most mice were able to recover (only one c-Rel-null mouse failed to recover 
following 0.75% DSS). However, 1.5% and 1% DSS resulted in higher mortality rates. 
Therefore, 0.5% and 0.75% DSS concentrations were used in the subsequent 
experiments using a murine model of colitis associated cancer (CAC). Mice were 
injected (i.p) with 12.5mg/kg AOM (Cat#A5486, Sigma-Aldrich, UK). After 5 days, 
DSS (0.5%) was given in the drinking water for 5 days followed by 16 days of 
ordinary water. This cycle was repeated twice with 0.75% DSS and mice were 
sacrificed 12 days after the last DSS cycle as described by Greten et al (250) (Figure 
2.1). 
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Figure 2.1: Schematic overview of murine model of colitis associated cancer. 5 
days following the initial AOM (i.p) injection (12.5mg/kg), DSS was provided in 
drinking water (yellow areas) followed by ordinary tap water (blue areas) as 
indicated above. 
 
AOM  i.p (12.5mg/kg)
Days
0                5               10                                                    26               31                   47               52                                    64 
Mice sacrificed
0.75% DSSH2O0.75% DSSH2O0.5% DSSH2O H2O
 
 
 
 
 
2.3 Tissue dissection and preparation  
Following sacrifice, standard dissection techniques were used to excise the small 
intestine and colon. Faecal matter was removed by flushing with PBS and the 
excised intestines were immersed in 4% formalin solution overnight. Tissues were 
then stored in 70% ethanol prior to gut bundling. 
2.3.1 Gut bundling 
The entire fixed small intestine was bundled, however the colon was first divided 
into halves designated proximal and distal colon. The small intestine and colon were 
placed into loops of 3M micropore surgical tape. Following bundling by squeezing 
the tape around the tissue, they were cut into about 0.6cm lengths and excess tape 
and tissue was cut off using a Swann-Morton size 22 scalpel blade (VWR 
international Ltd, Lutterworth, UK). Bundles were placed in histology cassettes and 
stored in 70% ethanol prior to processing and embedding in paraffin wax. During 
the embedding step, bundles were oriented vertically in order to obtain transverse 
sections during tissue cutting. 
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2.3.2 Haematoxylin and eosin staining 
Transverse tissue sections of 4μm thickness were attached to glass microscope 
slides. Following drying at 37°C, slides were dewaxed in xylene for 10 minutes and 
rehydrated by passing through a series of decreasing ethanol concentrations to 
distilled water. Nuclei were stained by immersing in haematoxylin (Sigma-Aldrich 
Co, Dorset, UK) for 3 minutes and then washed in running tap water for 10 minutes. 
To stain the cytoplasm, sections were placed in eosin (Sigma-Aldrich Co, Dorset, UK) 
for 4 minutes. The excess eosin was removed and sections were dehydrated by 
dipping the slides briefly (twice, 4 seconds each) in 95% ethanol and (twice, 4 
seconds each) in 100% ethanol. After clearing in xylene for 10 minutes, the slides 
were mounted with DPX, coverslipped and examined under a light microscope.  
2.3.3 Immunohistochemical staining 
2.3.3.1 Primary antibody incubation 
Several treatments were applied to the samples prior to primary antibody 
incubation. Tissue sections were placed on APES coated slides and left to dry at 
37°C in a fan assisted drying oven overnight. Following de-waxing in 2 changes of 
xylene, sections were dehydrated by passing them through different concentrations 
of ethanol from 100% to 70%. After that, endogenous peroxidase activity was 
abolished by immersing the slides in 3% H2O2 diluted in methanol for 4 minutes. 
Following washing in distilled water, sections were subjected to antigen retrieval 
process by placing them in citric acid buffer (10mM, pH6) and microwaved for 20 
minutes at 800W. Slides were allowed to cool for 10 minutes at room temperature 
and were rinsed in slow running tap water for 10 minutes before being washed in 
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Table 2.1: Primary antibody which was used in immunohistochemistry. 
 
50mM Tris buffered saline (150mM NaCl) with 0.1% Tween20 (TBS-tween) solution. 
Sections were blocked by 5% rabbit serum in TBS-tween for Ki67 staining for 40 
minutes before being incubated with primary antibody overnight at 4°C (primary 
antibody concentration is shown in Table 2.1. Following 2 washes in TBS-tween for 
5 minutes each, sections were incubated with a suitable secondary antibody.  
 
 
 
 
 
 
2.3.3.2 Secondary antibody and chromagen application using streptavidin / 
biotin based assay 
The Envision+ detection kit was not appropriate for sections which were stained 
with the anti-Ki67 primary antibody. Hence, a biotinylated anti-Rat secondary 
antibody raised in rabbit was used (E0468, Dako, Ely, UK) at a dilution of 1:200 in 
blocking solution for 30 minutes. Sections were washed twice in TBS for 5 minutes 
each before being incubated with Vectastain ABC Kit (Vector Laboratories, 
Peterborough, UK) solution for 30 minutes. The ABC solution conjugates multiple 
horseradish peroxidase molecules to each biotinylated secondary antibody moiety, 
thereby amplifying the primary antibody signal for chromagen detection. Sections 
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were incubated in 0.07% DAB in TBS with 5µl 30% hydrogen peroxide for 5 minutes 
in the dark and following a wash step they were counterstained with Gill’s 
haematoxylin for 3.5 minutes before being dehydrated and mounted with DPX. 
2.4 Cytological and histological scoring methods 
Various techniques were applied to quantify physiological and pathophysiological 
responses following different treatments. All scoring procedures were performed by 
the author who was blinded to the treatment and genotype of the samples being 
scored. In order to validate the scoring procedure and the accuracy of scoring, inter- 
and intra-scorer variability were both assessed during the training process for 
scoring and this is demonstrated in the examples shown in Figure 2.2 and Figure 2.3 
respectively. Also, the degree of variability between individual animals within a 
treatment group is shown in Figure 2.4. 
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Figure 2.2: Inter-scorer variability shown in the small intestine. C57BL/6 wild-type 
male mice were assessed for apoptotic index following 8Gy γ-irradiation (a) and 
basal mitotic index (b) by scorer 1 (black) (an individual previously trained in this 
technique) and scorer 2 (light blue) (author). Mean apoptotic index from 4 mice 
following 8Gy γ-irradiation and mean basal mitotic index from 4 mice were also 
assessed by scorer 2 (black dotted line) (author). No statistical differences were 
found by modified median test. 
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Figure 2.3: Intra-scorer variability in the small intestine. C57BL/6 wild-type male 
mice were assessed for apoptotic index following 8Gy γ-irradiation (a, c and e) 
and basal mitotic index (b, d and f). 2 examples of apoptotic index (a and c) and 
basal mitotic index (b and d) from individual mice are demonstrated after 
assessment and reassessment of the same H and E stained small intestinal 
section on two separate days by the same scorer. Mean apoptotic index from 4 
mice following 8Gy γ-irradiation (e) and mean basal mitotic index from 4 mice (f) 
were also scored on two separate occasions. No statistical differences were 
found by modified median test. 
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Figure 2.4: Individual mouse variability in apoptosis and mitosis levels within the 
same group and treatment. Small intestinal apoptotic index were assessed from 4 
individual C57BL/6 wild-type mice following 8Gy γ-irradiation (a) and basal 
mitotic index were also assessed from 4 individual C57BL/6 wild-type mice (b).  
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2.4.1 Cell positional scoring of crypt apoptosis and mitosis 
Apoptosis and mitosis have distinguishable morphological features which can be 
obviously seen in H and E stained intestinal tissue. Apoptosis is characterised by 
cellular shrinking, fragmentation and nuclear chromatin condensation which 
appears in H and E sections as spherical eosinophilic areas around dark condensed 
genetic material usually in place of a cell nucleus. Mitotic cells are characterised by 
visibly separating chromosomes and tend to be larger than normal cells and located 
towards the lumen of the crypt as demonstrated in Figure 2.5 (a). A cell positional 
scoring system was used to quantify crypt intestinal apoptosis and mitosis. This 
scoring system which relies upon the observation of well oriented intestinal crypts 
has been previously validated (61, 64). Assessment of apoptosis and mitosis within 
each hemi-crypt was performed on a cell positional basis in which the cell at the 
crypt base was designated cell position 1 and the next cell above was designated 
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Figure 2.5: Cell positional scoring procedure from H and E stained intestinal 
tissue. (a) apoptotic bodies are shown by black arrows and mitotic bodies are 
shown by blue arrows in an H and E stained intestinal crypt. (b) schematic 
representation of a crypt and (c) subsequent analysis of apoptosis on a cell 
positional basis. 
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cell position 2 and so on until the crypt-villus junction or inter-crypt table were 
reached in the small intestine and colon respectively. These cell positions were 
classified as normal, apoptotic or mitotic according to the histological findings on H 
and E stained sections. It has been shown that scoring 200-300 well oriented hemi-
crypts from 4-6 mice produces reliable and reproducible results (60). Therefore, we 
scored 50 hemi-crypts per mouse from a minimum of 5-6 mice per experimental 
group (Figure 2.5 b). Inter-scorer variability, intra-scorer variability and inter-mouse 
variability are illustrated in Figure 2.2, Figure 2.3 and Figure 2.4 respectively. 
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2.4.2 Measurement of AOM/DSS induced colon tumour number and size 
At the end of the AOM/DSS experiment described previously in section 2.2.4, mice 
were sacrificed and the whole colon was dissected and flushed with PBS. The colon 
was cut open longitudinally along its main axis and gently washed by PBS to remove 
any remaining faecal content. The opened colon was carefully inspected 
macroscopically for the presence and location of polyps. The size and the number of 
polyps were then carefully measured as previously described (283). 
2.4.3  Disease activity index scoring in DSS induced colitis 
To evaluate the clinical signs of colitis severity, a disease activity index (DAI) was 
determined on a daily basis by assessing the following clinical parameters: body 
weight loss, stool consistency and presence of rectal bleeding. These parameters 
provide comprehensive functional measures similar to the clinical symptoms 
observed in human IBD. DAI was scored using a validated method described in 
previous studies (284-286). The method of scoring is shown in Table 2.2. 
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Table 2.2: Disease activity index (DAI) scoring. DAI = (combined score of weight 
loss, stool consistency and bleeding)/3. Normal stool = well formed pellets; 
loose stools = pasty stools that do not stick to the anus; and diarrhoea = liquid 
stools that stick to the anus. 
 
Score Weight loss (%) Stool consistency Occult/gross 
bleeding
0 none Normal Normal
1 1 − 5 − −
2 5 − 10 Loose stools Hemoccult +
3 10 − 15 − −
4 > 15 Diarrhoea Gross bleeding
 
 
 
 
 
 
 
 
 
 
 
2.4.4 Histological scoring of colitis severity 
Mice were sacrificed on day 6 from the start of DSS induced colitis, the colon was 
removed and colonic length was measured. Following fixation in 4% formalin and 
embedding in paraffin, sections were stained with H and E as described previously 
in section 2.3.2. In order to quantify inflammatory changes following DSS 
administration, a histological scoring system was applied as described by Bauer et al 
(287). The histological colitis severity score (range from 0 to 6) was determined as 
shown in Table 2.3. 
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2.4.5 Determination of tumour proliferation (Ki67) index 
In order to estimate the growth rate of AOM/DSS induced colonic tumours, the 
proliferation marker Ki67 was used. AOM/DSS induced tumours from each mouse 
were firstly scanned under a light microscope using a 10x objective lens for areas 
with the highest Ki67 labelling. Because of the small size of the tumours that 
developed in NFκB2-null mice, only one area of 0.25mm2 could be evaluated in each 
animal. Hence, the proliferation index for each mouse colonic tumour section was 
determined manually by counting the number of positively labelled neoplastic cells 
per 0.25mm2 area (which showed the highest Ki67 staining) using a light microscope 
(at 40x objective) using a 0.25 mm2 optical grid reticule and a manual cell counter as 
described previously (288). For the accuracy and validation of the scoring procedure 
for Ki67 index, the intra-scorer variability was assessed as shown in Figure 2.6. In 
Score Cell infiltration Tissue damage 
0 None None 
1 Focally increased numbers of 
inflammatory cells in the lamina 
propria 
Discrete epithelial lesions 
2 Confluence of inflammatory cells 
extending into the submucosa 
Mucosal erosions 
3 Transmural extension of the infiltrate Extensive mucosal damage and/or 
extension through deeper 
structures of the bowel wall 
Table 2.3: Histological scoring of colitis severity. The combined histological colitis 
severity score which ranges from 0 to 6 is the sum of the two equally weighted 
subscores (cell infiltration and tissue damage). 
99 
 
 
Figure 2.6: Intra-scorer variability in Ki67 index. (a) Ki67 index for AOM/DSS 
induced tumour from 5 individual C57BL/6 wild-type mice is demonstrated 
after assessment and reassessment of the same area of the same tumour by 
the same investigator (Author). (b) mean Ki67 index of these mice after 
assessment and reassessment was also determined. No statistical differences 
were found between the initial scores and rescores of Ki67 positively stained 
neoplastic cells by student’s t-test. 
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addition, the degree of variability between individual tumours within the same 
mouse and the degree of variability between individual animals within the same 
experimental group were assessed and this is demonstrated in Figure 2.7. 
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Figure 2.7: Individual tumour and mouse variabilities in Ki67 index. (a) Ki67 index 
was assessed in 3 individual AOM/DSS induced colonic tumours within the same 
animal in 6 individual c-Rel-null mice. This demonstrates the degree of variability 
of Ki67 index between individual tumours within the same mouse. (b) mean Ki67 
index of these 3 tumours within each c-Rel-null mouse was determined. This 
shows the degree of variability between individual animals within the same 
strain of mice. 
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2.5 Cell culture 
2.5.1 Cell line maintenance  
The human colon adenocarcinoma cell line HCT116 was obtained from John 
Hopkins Medical Institute, MD, USA. Cells were grown as monolayers in McCoy’s 5A 
media supplemented with 10% foetal calf serum (FCS-Gibco® Invitrogen Ltd, Paisley, 
UK), 0.5% 2mM L-glutamine (L-glu) and 0.4% pencillin/streptomycin mixture (P/S). 
The cells were cultured in T75 flasks (Appleton Woods Ltd, Birmingham, UK) at 37oC 
and 5% CO2 in a humidified atmosphere. Cells were maintained by sub-culturing at 
80% confluence using trypsin/ethylenediaminetetaacetic acid (EDTA) in phosphate 
buffered saline (PBS). 
2.5.2 Calculation of cell number  
Floating cell number was counted by adding 40μl of the media that contained 
floating cells to a coverslipped haemocytometer. Following trypsinisation, 40μl of 
the cell suspension was added to a coverslipped haemocytometer to allow the 
number of attached cells to be counted. 
2.5.3 Small interfering RNA transfection (siRNA) of HCT116 cells 
RNA interference technologies have provided a tool for genetic manipulation in 
vitro and in vivo at the level of gene transcription and consequent protein 
translation. Therefore, siRNA inhibition of target gene expression with subsequent 
reduction in the level of the encoded protein translation can be a powerful tool for 
investigating gene-specific functions (289).  
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2.5.3.1 SiRNA transfection optimisation in HCT116 cell line 
To achieve effective silencing with minimum cell toxicity, experimental conditions 
were initially optimised. When this work started, siRNA transfection of the HCT116 
cell line was not among the previously validated protocols from Dharmacon and 
there was no detailed protocol available in the literature. Optimisation of the 
experimental conditions (such as transfection reagent (lipid) type, siRNA type, 
siRNA concentration, siRNA : lipid ratio) procedures was therefore conducted in our 
laboratories by Dr. Fei Song using the transfection efficiency control siTOX, a non-
target siRNA negative control and DharmaFECT 1 Transfection Reagent. The siRNA 
along with transfection reagents were selected from Dharmacon. The criteria to 
select the appropriate siRNA : lipid ratio were to identify the lowest cell viability in 
siTOX treatment with minimal reduction of cell viability in the no siRNA control 
(water) and siGENOME not-target siRNA control. Following these optimisation 
procedures, the recommended optimal conditions were established as illustrated in 
Table 2.4. 
 
Cell line Flask 
size 
Cell density Type of lipid Lipid 
volume 
siRNA volume 
/20µM stock 
Incubation 
volume 
HCT116 T25 
flasks 
10 x 10
5 
per flask 
DharmaFECT 1 10µl 25µl 5000µl 
Table 2.4: Recommended optimal experimental conditions for siRNA transfection of 
the HCT16 cell line. 
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2.5.3.2 NFκB2 siRNA and RelB siRNA transfection of HCT116 cells  
The optimal experimental conditions developed by Dr. Fei Song were employed in 
NFκB2 siRNA and RelB siRNA transfection procedures as described in Table 2.4. A 
suspension of HCT116 cells (10x105) was seeded into T25 flasks (Appleton Woods 
Ltd, Birmingham, UK) and the total volume was made up to 5ml with complete 
McCoy’s media lacking P/S. The cells were allowed to adhere for 24 hours before 
transfection with siRNA. 
For each flask to be transfected, 25μl of 20μM targeting siRNA (siGENOME 
SMARTpool, Thermo Scientific Dharmacon Products, Epsom, UK) was added to 
475μl of antibiotic and serum free media and allowed to mix for 5 minutes at room 
temperature (RT). 10μl of DharmaFECT 1 Transfection Reagent (Thermo Scientific 
Dharmacon Products, Epsom, UK) was added to 490μl of antibiotic and serum free 
media and allowed to mix for 5 minutes at RT. Following addition of the siRNA 
mixture to DharmaFECT 1 mixture, the resultant 1ml solution was allowed to mix 
for 20 minutes at RT. 4ml of antibiotic free complete media was then added to this 
solution to give 5ml total volume. Then the media in the flasks was replaced by this 
transfection media and the cells were incubated as mentioned above for a 
predetermined period according to the experimental protocol.  
A non-targeting siRNA (siGENOME Non-Targeting siRNA Pool, Thermo Scientific 
Dharmacon Products, Epsom, UK) (25μl of 20μM) was also used as described to 
transfect a duplicate flask (so that each targeting siRNA flask had a corresponding 
control siRNA flask). This represented a control to demonstrate any off-target 
effects of siRNA transfection. Following the incubation period, the media was 
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removed and the floating cells were counted to give an estimate of apoptosis. The 
attached cells were liberated by 1ml of trypsin and then neutralised by adding 4ml 
of complete media. The total number of attached cells was counted to give a 
measure of cellular proliferation.  
A time course of 24, 48 and 72 hours incubation was performed in duplicate for 
each time point using both NFκB2 siRNA and RelB siRNA transfection to initially 
determine the time point of maximal knock down of the expression of NFκB2 and 
RelB respectively. Also, longer time points (5 and 6 days) were performed for NFκB2 
siRNA transfection to confirm successful depletion of p52 (the processed and active 
form of NFκB2) protein stores. 
The 48 hour time point showed maximal reduction in the expression of NFκB2 and 
RelB following NFκB2 siRNA and RelB siRNA transfection respectively. This 48 hour 
time point was therefore initially chosen for the subsequent experiments that 
assessed apoptosis and proliferation following either knocking down the expression 
of NFκB2 or RelB in presence or absence of Etoposide as shown in Figure 2.8. 
2.5.4 Etoposide treatment  
For further assessment of the effects of knocking down NFκB2 and RelB gene 
expression on apoptosis and proliferation in the HCT116 cell line, Etoposide (a 
chemotherapeutic agent which inhibits topoisomerase ІІ) was used to induce 
apoptosis. The cells were treated with Etoposide (final concentration, 20μM) for 24 
hours following 24 hours of siRNA transfection (Figure 2.8).  
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Figure 2.8: Schematic overview of experimental design for siRNA transfection  
(for 48 hours) and Etoposide treatment using HCT116 cells. Cells was seeded and 
allowed to attach for 24 hours before being transfected with siRNA. 24 hours 
after siRNA transfection, Etoposide was added and cells were harvested 24 hours 
later. 
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2.6 Western blot analysis  
Following trypsinization, the cell suspension was centrifuged to produce a cell pellet 
which was then lysed using lysis buffer (5ml RIPA buffer, 50μl protease inhibitor and 
3.5μl β-mercaptoethanol) and kept on ice for 20 minutes. After centrifugation of 
this suspension at 15,000 rpm for 15 minutes at 40C, the supernatant was removed 
and its protein concentration was determined by the BradFord method (Bio-Rad). 
Twenty micrograms of protein from each sample were diluted to a final volume of 
20μl using lysis buffer and this was mixed with 5μl of 4-times loading buffer before 
denaturing at 100oC for 2 minutes and placing on ice until use. Protein samples 
were then run on SDS gels that included a stacking gel (6.17ml dH2O, 1.33ml 
acrylamide, 2.5ml 0.5M TRIS buffer (pH6.8), 100μl 10% SDS, 50μl 10% APS and 10μl 
TEMED) and a 10% running gel (8.4ml dH2O, 6.6ml acrylamide, 5ml 1.5M TRIS buffer 
(pH8.8), 200μl 10% SDS, 100μl 10% APS and 10μl TEMED) in 1x running buffer (5mM 
Tris, 38.4mM Glycine, 0.02% SDS) at 50V then at 120V when the samples had run 
through the stacking gel. This was followed by transferring the proteins onto a 
nitrocellulose membrane using the Bio-Rad Trans blot cell apparatus at 100V in 1x 
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transfer buffer (14.4g glycine, 3.03g Tris, 800ml H2O, 200ml methanol) for 1 hour. 
After this, the membranes were incubated in a blocking solution (0.1% Tween-20 
and 5% dry milk in PBS) to prevent non-specific antibody binding for 1 hour, 
followed by incubation in primary antibody diluted in 2ml of the blocking solution 
overnight at 4oC. Prior to incubation with horseradish peroxidase-congugated 
secondary antibody diluted in 2ml of blocking solution for 1 hour at room 
temperature, membranes were washed 3 times with PBS 0.01% Tween. The 
membranes were developed by enhanced chemiluminescence reagent and 
chemiluminescence was visualized using a Fluor-STM molecular imager (BIO-RAD, 
Hertfordshire, UK). Protein densitometry was quantified using Quantity One 
Software (BIO-RAD, Hertfordshire, UK). Details of the antibodies used are shown in 
Table 2.5. 
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Table 2.5: Antigens and the details of the corresponding antibodies used for 
Western blotting. 
1- It is raised against the amino acids 1-82 epitope of mouse p100 (NFκB2) 
and it was used by Caamano et al, 1996. It was donated by Dr Jorge 
Caamano, University of Birmingham, UK.  
2- Abcam, ab7972-1 
3- Santa Cruz, sc-298 
4- Santa Cruz (c-19), sc-226 
5- Oncogene research products, CAT#OP43-100UG 
6- Oncogene research products, CAT#CC12-100UG 
7- Oncogene research products, CAT#OP64-20UG 
8- Dako, Ref M0887 
9- NeoMarkers (Fremont, CA), CAT# ACTN05 
10- Dako, Cat#P0161 
11- Dako, Cat#P0217 
 
 
Antigen Primary Antibody Dilution Secondary Antibody Dilution
NFκB2 1 Mouse monoclonal 1:1000 10 Rabbit anti-mouse
HRP
1:1000
2 Rabbit polyclonal 1:200 11 Swine anti-rabbit
HRP
1:1000
3 Rabbit polyclonal (k-27) 1:200 11 Swine anti-rabbit
HRP
1:1000
RelB 4 Rabbit polyclonal 1:200 11 Swine anti-rabbit
HRP
1:1000
P53 5 Mouse monoclonal (ab-6) 1:1000 10 Rabbit anti-mouse
HRP
1:1000
Cyclin D1 6 Mouse monoclonal (ab-3) 1:100 10 Rabbit anti-mouse
HRP
1:1000
P21WAF-1/CIP1 7 Mouse monoclonal (ab-1) 1:300 10 Rabbit anti-mouse
HRP
1:1000
BCL-2 8 Mouse monoclonal 1:100 10 Rabbit anti-mouse
HRP
1:1000
(pan) Actin 9 Mouse monoclonal (ab-5) 1:1000 10 Rabbit anti-mouse
HRP
1:1000
 
 
108 
 
2.7 RNA sample collection 
Mice were sacrificed and both small intestine and colon were excised. To isolate 
epithelial-only cells, a modified version of the Weiser method was employed for 
both small intestine and colon (290) as described below.  
2.7.1 Weiser technique 
The intestine was cut longitudinally and opened out to expose the mucosal surface. 
Tissue was then washed two times with ice cold Weiser solution before harvesting 
crypts and each time the Weiser solution was substituted with clean solution 
(constituents of Weiser solutions: 5.56mM disodium hydrogen orthophosphate, 
8mM potassium dihydogen orthophosphate, 96mM sodium chloride, 1.5mM 
potassium chloride, 27mM tri-sodium citrate, 0.5mM dithiothreitol (DTT), 1.5% 
sucrose, 1% D-sorbitol, 6.07mM EDTA, 4mM EGTA, Ph 7.3). The intestine was 
transferred into a new universal tube with clean Weiser solution and shaken gently 
for 5 minutes to release crypts and villi from the intestine into the solution. The 
detached crypts and villi were viewed under a light microscope. The intestine was 
then removed into another tube with clean Weiser solution and the Weiser solution 
which contained the dissociated crypts was collected in a tube and kept on ice. This 
cycle was repeated until most of the crypts and villi had been detached and 
collected. Following centrifuging the collecting tube with crypts for 5 minutes at 
2400rpm and 4oC, the Weiser solution was removed and ice cold PBS was added to 
the crypt pellet and it was centrifuged again. Finally, the PBS was discarded and the 
pellet was resuspended in 1ml of RNA later and stored at 4oC for 24 hours then at -
20oC until RNA extraction. 
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2.7.2 RNA extraction and purification 
Epithelial enriched intestinal cell suspensions were centrifuged and the RNA later 
supernatant was removed. RNA was extracted from tissue samples using the High 
Pure RNA Tissue Kit (Roche, Burgess Hill, UK) according to the manufacturer’s 
instructions. An appropriate volume of the provided lysis buffer containing the 
chaotropic salt guanidine hydrochloride was used to lyse the tissue using a 
mechanical tissue homogeniser. Following this, nucleic acids were bound to a glass 
fleece filter column and contaminating salts and proteins were washed away. DNA 
was digested on the column using DNAse I, and fragments were subsequently 
washed through the column. Purified RNA was then eluted in TE buffer or RNAse 
free water. 
2.7.3 RNA quantification (NanoDrop) 
 RNA samples were quantified using a NanoDrop spectrophotometer (Thermo 
Scientific NanoDrop 2000c). Following adding 1µl of RNA sample (RNase free water 
was added first as a reference) to the NanoDrop, the operating software was used 
to initiate a spectral measurement. Sample concentration and quality were also 
determined by the software. Only samples with a 260nm/280nm ratio >1.9 were 
accepted as good quality RNA for subsequent use in assays.  
2.7.4 Reverse transcription of RNA to cDNA 
1μg of RNA was used for the reverse transcription process using the Transcriptor 
reverse transcriptase kit (Roche, Burgess Hill, UK) and the protocol of the 
manufacturer was followed. This kit was optimised for use with RNA extracted using 
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the High Pure RNA kit; 1μg of template RNA was incubated in the presence of 
anchored-Oligo (dT) primers to allow non-specific reverse transcription of mRNAs. 
The resulting reaction mixture was used as template cDNA for quantitative PCR 
assays. 
2.8 Quantitative (real time)-PCR 
Real time PCR (RT-PCR) was performed using a LightCycler 480 instrument (Roche, 
Burgess Hill, UK). A primer and probe technique was used in the PCR detection 
system. Probes were from the Universal Probe Library (Roche, Burgess Hill, UK) and 
when incorporated into a PCR product the 5’ conjugated fluorescein molecule emits 
light of 518nm wavelength. RT-PCR assays were designed through the Roche 
Universal Probes Library Assay Design Centre. This online tool assists in-silico assay 
design. The primers and the corresponding probes used in these assays are listed in 
Table 2.6. 
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Table 2.6: Details of primers and probes used for the target genes in RT-PCR. 
 
Target L Primer R Primer Probe Amplicon
IFN-γ ATC-TGG-AGG AAC-TGG-CAA-AA TTC-AAG-ACT-TCA-AAG-AGT-CTG-AGG-TA #21 89
IL-1β TTG-ACG-GAC-CCC-AAA-AGA-T GAA-GCT-GGA-TGC-TCT-CAT-CTG #26 75
TNF-α TCT-TCT-CAT-TCC-TGC-TTG-TGG GGT-CTG-GGC-CAT-AGA-ACT-GA #49 128
IL6 GCT-ACC-AAA-CTG-GAT-ATA-ATC-AGG-A CCA-GGT-AGC-TAT-GGT-ACT-CCA-GAA #6 78
IL14 GAG-AAG-CTG-GCT-GCA-CTG-T TCA-TCT-GCT-TCT-GCG-AGT-TC #11 73
TRAIL GCT-CCT-GCA-GGC-TGT-GTC CCA-ATT-TTG-GAG-TAA-TTG-TCC-TG #76 87 
Casp12 TGA-TGC-TTT-TTA-TGT-CCA-GGA-GT TGG-ATC-TCT-TTC-ATG-TGT-CCT-C #76 67 
BAK GGA-ATG-CCT-ACG-AAC-TCT-TCA CCA-GCT-GAT-GCC-ACT-CTT-AAA #19 62 
FAS-L ACC-GGT-GGT-ATT-TTT-CAT-GG AGG-CTT-TGG-TTG-GTG-AAC-TC #21 117
FAS TGC-AGA-CAT-GCT-GTG-GAT-CT CTT-AAC-TGT-GAG-CCA-GCA-AGC #34 60
P53 ATG-CCC-ATG-CTA-CAG-AGG-AG AGA-CTG-GCC-CTT-CTT-GGT-CT #78 74
c-IAP2 GGG-GAC-GAT-TTA-AAG-GTA-TCG TCG-GTT-TTA-CTG-CTA-GGC-TGA #5 139
XIAP GCT-TGC-AAG-AGC-TGG-ATT-TT TGG-CTT-CCA-ATC-CGT-GAG #25 88
BCL2 GTA-CCT-GAA-CCG-GCA-TCT-G GGG-GCC-ATA-TAG-TTC-CAC-AA #75 76
BCL-XL TGA-CCA-CCT-AGA-GCC-TTG-GA TGT-TCC-CGT-AGA-GAT-CCA-CAA #2 68
GAPDH GGG-TTC-CTA-TAA-ATA-CGG-ACT-GC CCA-TTT-TGT-CTA-CGG-GAC-GA #52 112
 
20μl final volume reactions were used throughout all assays. Initially, primers and 
probes were aliquoted into plates in a volume of 5μl per reaction to give 0.4μM 
final concentration of primer and 0.2μM of probe in 20μl reactions as described in 
Table 2.7. The 96 well plate was arrange in such way to complete the 10 selected 
apoptosis regulating genes or the 6 selected proinflammatory genes in triplicate for 
each mouse sample in a single plate. This resulted in 64 and 12 loaded (primers and 
probes mix) 96 well plates for small intestinal and colonic samples for apoptosis 
regulating genes and proinflammatory genes assays respectively. LightCycler 480 
Probes Master mix (Roche, Burgess Hill, UK) was used in these assays. A working 
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Table 2.7: Primer and probe mix constituents per 20µL PCR reaction. 
 
mix of master mix and of PCR grade water cDNA was prepared to be sufficient for all 
primer and probe mixes in triplicate across a single PCR plate. The constituents of 
this mix are described in Table 2.8. Assays were designed to function with an 
annealing temperature of 60°C and hence functioned under standard PCR 
conditions as described in Table 2.9. Following each PCR detection run, crossing 
point values (cp) were determined by Roche LightCycler software release 1.5.0 
using the maximal second derivative mathematical model. This algorithm is superior 
to threshold values as it excludes any bias derived from human selection of 
threshold levels. The efficiency of each PCR assay was also determined by 
generating standard curves. Crossing point data and efficiency values were 
exported to GenEx 5.3.4 (MultiD Software). Crossing point data were then 
normalised to GAPDH and represented as relative quantities compared to untreated 
wild type mice. Data were then scaled to Log2, transforming exponentially 
distributed data into normally distributed data representing fold increases before 
being statistically analysed. 
 
 
 
 
 
 
113 
 
 
Table 2.8: Master mix constituents for 20μL real-time PCR assays. 
 
Constituents Volume per  20µl reaction
LightCycler480 Probes Master 10µL
PCR grade water 4.4
Template cDNA 0.56
Primer and probe mix (already loaded in plate) 5µL
Total volume 20µL
 
Table 2.9: Cycling conditions for real-time PCR assays. 
 
Cycle description Temperature (°C) Duration (seconds) Cycles
Pre-incubation 95 600 1
Amplification 95 10 45
60 30
72 1
Cooling 40 30 1
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2.9 Statistical analysis 
Data sets consisting of multiple groups with one variable (genotype) and found to 
be both normally distributed (using the Shapiro-Wilk W test) and of equal variance 
were analysed using one-way analysis of variance (ANOVA), followed by Dunnet’s 
multiple comparison test (where all groups were compared to the control group). 
Data sets consisting of multiple groups with one variable and found to be either 
non-normally distributed or showing unequal variance were analysed using non-
parametric one-way (Kruskal-Wallis) ANOVA followed by Dunn’s multiple 
comparison test . Data sets consisting of only two groups were assessed by 
student’s t-test (two-tailed, assuming unequal variance). The modified median test 
was used to assess significant differences at individual cell positions between 
groups of mice during the scoring of histology slides as described by Potten et al 
(291). PCR data which consisted of multiple groups with two variables (genotype 
and irradiation or DSS treatment) were analysed using two-way ANOVA with 
Bonferroni post-hoc tests. All statistical analysis was performed using GraphPad 
PRISM for Widows v4 software. In the one-way ANOVA with Dunnet’s multiple 
comparison test, Kruskal-Wallis with Dunn’s multiple comparison test, two-way 
ANOVA with Bonferroni post-hoc tests and student’s t-test, differences were 
considered significant when p < 0.05. All data presented within this thesis are 
expressed as mean ± standard deviation unless otherwise stated. 
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3 Importance of specific members of the NFκB family of 
transcription factors in regulating intestinal epithelial 
apoptosis and proliferation 
3.1 Introduction 
The link between the activation of NFκB signalling and intestinal cancer and 
inflammation has been previously demonstrated in humans and animal models of 
disease. Several mechanisms are likely to be involved including modulation of the 
key cellular processes of proliferation, apoptosis and inflammation. NFκB is an 
important player in regulating cell survival and apoptosis in a cell type and stimulus 
dependent manner. Improper regulation of the cell cycle and apoptotic process 
following DNA damage is believed to contribute to cancer development and 
progression (177). Apoptosis is an important physiological process for the removal 
of unnecessary, aged or damaged cells. Abnormal inhibition of apoptosis can lead to 
the development of autoimmune diseases or cancer due to the persistence of 
unwanted cells (292). According to the established carcinogenesis hypothesis 
proposed by Vogelstein’s work in colorectal cancer, evasion of apoptosis results in 
the retention of mutations in stem cells, enhancing the progression toward 
carcinogenesis (293). Therefore, NFκB may promote carcinogenesis when its 
activation enhances cell survival and inhibit carcinogenesis when its activation leads 
to cell death. 
Various transgenic mouse models have clarified the importance of NFκB family 
members in regulating apoptosis and proliferation. One of these transgenic mouse 
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models is the RelA-null mouse which died at embryonic day 15 as a result of 
extensive liver apoptosis (224). Abrogation of classical pathway NFκB signalling by 
selective intestinal deletion of IKKβ has demonstrated that IKKβ activation (classical 
NFκB activation pathway) protects the intestinal epithelium from apoptosis as well 
as systemic inflammation following ischemia-reperfusion injury (249). This type of 
NFκB classical pathway disruption has also been shown to enhance γ-irradiation 
induced intestinal apoptosis (251). In a mouse model, germline deletion of NFκB1 
has similarly been shown to increase the amount of small intestinal apoptosis 
following γ-irradiation relative to wild-type small intestine. In the same study, NFκB 
was shown to be activated in murine intestinal epithelial cells following whole body 
γ-irradiation in a dose dependent manner (229). Additionally, NFκB1-null mice have 
previously been shown to demonstrate longer colonic crypts and increased colonic 
crypt proliferation (230). In vitro investigations of the role of NFκB in apoptosis and 
proliferation in a range of lymphoma cell lines have shown that NFκB1 and NFκB2 
promote cell survival and proliferation in these cell types (294). It has also 
previously been shown that knockdown of NFκB2 expression in U-2 OS human 
osteosarcoma cells resulted in a significant decrease in cell proliferation (218). 
However, the role of the alternative pathway or the specific roles of other NFκB 
family members in regulating intestinal epithelial apoptosis and proliferation have 
not been well defined to date. Therefore we have investigated small intestinal and 
colonic crypt epithelial apoptosis and proliferation in wild-type mice and those with 
specific germline deletions of c-Rel, NFκB1 and NFκB2 both at baseline and 
following the induction of acute epithelial apoptosis by various types of DNA 
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damage inducing stimuli. Due to lack of access to a mouse with a germline deletion 
of RelB and for further evaluation of the importance of alternative pathway in 
regulating intestinal apoptosis, an in vitro model has also been used. This was 
achieved by knocking down the expression of RelB and NFκB2 in human colon 
adenocarcinoma cells (HCT116) using the siRNA technique. Hence, the roles of RelB 
and NFκB2 in HCT116 cell proliferation and apoptosis have been investigated. 
3.2 Aims 
1. In the in vivo study, to assess whether there are any alterations in the amounts of 
small intestinal and colonic crypt epithelial apoptosis and mitosis in mice with 
specific germline deletions of c-Rel, NFκB1 and NFκB2 compared to their wild-type 
counterparts both at baseline and following the induction of acute epithelial 
apoptosis by whole-body γ-irradiation or irinotecan adminstration. Additionally to 
investigate the molecular mechanisms responsible for any altered phenotypes 
observed. 
2. In the in vitro study, to determine whether RelB or NFκB2 suppression in the 
human colon adenocarcinoma cell line HCT116 alters its proliferation and apoptosis 
in both the unstimulated state and following Etoposide treatment. 
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3.3 The effects of deleting various NFκB family members on small 
intestinal and colonic crypt epithelial cell turnover 
To assess the specific roles of each individual NFκB family member in regulating 
intestinal crypt epithelial cell turnover, groups of 6 male 10-12 weeks old mice were 
investigated. H and E sections were prepared from formalin fixed small intestine 
and distal half of the colon. Crypt cell number, apoptosis and mitosis were assessed 
on a cell positional basis as described in section 2.4.1. 
3.3.1 Untreated mice with NFκB deletions show small intestinal and colonic 
crypt hyperplasia 
NFκB1-null and NFκB2-null mice showed significant small intestinal crypt 
hyperplasia (C57BL/6 18.1 ± 1 mean number of cells per hemi-crypt ± standard 
deviation; c-Rel-null 18.2 ± 1.2; NFκB1-null 19.8± 0.6; NFκB2-null 20 ± 1.2) (Figure 
3.1). Significant distal colon crypt hyperplasia was observed in c-Rel null and NFκB1-
null mice (C57BL/6 24.4 ± 1.9 mean number of cells per hemi-crypt ± standard 
deviation; c-Rel-null 29 ± 1.9; NFκB1-null 30.6 ± 0.5; NFκB2-null 26 ± 1.6). Although 
the number of cells per hemi-crypt was increased in the distal colon of NFκB2-null 
mice compared with C57BL/6 mice, this was not statistically significant (Figure 3.1). 
 
 
 
 
 
119 
 
 
Figure 3.1: Number of cells per hemi-crypt in untreated animals. Small intestine 
(a) and distal colon (b) mean cell number per hemi-crypt ± standard deviation in 
C57BL/6, c-Rel-null, NFκB1-null and NFκB2-null mice. Statistical differences were 
assessed by one way ANOVA and Dunnett's multiple comparison tests (*p<0.05, 
**p<0.01 ***p<0.001 compared to C57BL/6) (n=6 per genotype group). 
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3.3.2 No alteration in basal levels of small intestinal and colonic crypt 
mitosis in mice with disrupted NFκB signalling 
The amounts of small intestinal and colonic crypt mitosis from untreated C57BL/6, 
c-Rel-null, NFκB1-null and NFκB2-null mice were assessed on a cell positional basis 
using H and E stained sections. Because of the differences in the mean number of 
cells per hemi-crypt observed between the strains of mice and documented above, 
we also calculated the mean number of mitotic events per hemi-crypt. 
 In the small intestine of wild-type C57BL/6 mice, 3.8% of cells showed features of 
mitosis whilst in the colon, 1.6% of cells were mitotic by morphological criteria. No 
significant differences in baseline mitosis within the small intestine and distal colon 
were observed between any of the 4 groups of mice. The amount of distal colonic 
crypt mitosis was however lower than the amount of basal small intestinal crypt 
mitosis in all cases (Figure 3.2). When plotted on a cell positional basis, wild-type 
C57BL/6 mice showed maximal numbers of mitotic events at cell position 6 in the 
small intestine and 5 in the distal colon. c-Rel-null, NFκB1-null and NFκB2-null mice 
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showed no differences in these distributions either in the small intestine or colon by 
the modified median test (Figure 3.2). 
3.3.3 NFκB2-null mice show elevated levels of small intestinal spontaneous 
apoptosis 
The amounts of apoptosis in the small intestinal and distal colonic crypts of 
untreated C57BL/6, c-Rel-null, NFκB1-null and NFκB2-null mice were also assessed 
on a cell positional basis using H and E stained sections. Because of differences in 
the crypt lengths observed between the strains of mice as mentioned previously, 
we also calculated the mean number of apoptotic bodies per hemi-crypt. Untreated 
wild-type mice showed predictably low epithelial apoptotic indices in the intestine; 
in the small intestine 0.1% of cells had features of apoptosis, whilst in the distal 
colon 0.05% of cells were morphologically apoptotic. In the small intestine of these 
mice, apoptotic bodies were distributed at a low frequency between cell positions 3 
to 18 (Figure 3.3). NFκB1-null mice displayed a small increase in spontaneous small 
intestinal apoptosis, but this was not statistically significant relative to C57BL/6 
mice. A significant fourfold increase in mean apoptotic index and average number 
of apoptotic bodies per hemi-crypt was however found in the untreated small 
intestinal crypts of NFκB2-null mice compared to C57BL/6 mice. No significant 
differences were seen in apoptosis distribution in comparison to the wild-type mice. 
Levels of spontaneous apoptosis in distal colonic crypts were very low and barely 
detectable and no significant differences were detected between any of the strains 
of mice tested (Figure 3.3). 
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Figure 3.2: Quantitative analysis of intestinal crypt epithelial mitosis in untreated 
mice. Small intestinal (a) and distal colon (b) mean mitotic index ± standard 
deviation separated by genotype. Small intestinal (c) and distal colon (d) mean 
number of mitotic figures per hemi-crypt ± standard deviation separated by 
genotype. Cell positional distribution of baseline mitosis in small intestine (e) and 
distal colon (f) separated by genotype. Statistical differences were assessed by 
Kruskal–Wallis test followed by Dunn’s multiple comparison tests in (a), (b), (c) 
and (d). Statistical differences were assessed by modified median test in (e) and 
(f). (n=6 per genotype group). 
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Figure 3.3: Quantitative analysis of intestinal crypt epithelial apoptosis in 
untreated mice. Small intestinal (a) and distal colon (b) mean apoptotoc index ± 
standard deviation separated by genotype. Small intestinal (c) and distal colon 
(d) mean number of apoptotic bodies per hemi-crypt ± standard deviation 
separated by genotype. Cell positional plot demonstrating baseline small 
intestinal (e) and distal colon (f) apoptosis separated by genotype. Statistical 
differences were assessed by Kruskal–Wallis test followed by Dunn’s multiple 
comparison tests in (a), (b), (c) and (d) (*p<0.05 compared to C57BL/6). Statistical 
differences were assessed by modified median test in (e) and (f) (n=6 per 
genotype group). 
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3.4 The effects of deleting various NFκB family members on small 
intestinal and colonic crypt epithelial cell proliferation and 
apoptosis following γ-irradiation 
To investigate the specific roles of each individual member of the NFκB family of 
transcription factors in regulating intestinal epithelial cell proliferation and 
apoptosis following DNA damage inducing stimuli, these parameters were assessed 
in mice with various NFκB family member deletions following whole body γ-
irradiation. Previous studies have established that a dose of 8Gy whole body γ-
irradiation for 4.5 hours induces maximal differences in intestinal apoptosis 
between different groups of mice. Hence, 6 mice per genotype were subjected to 
8Gy whole body γ-irradiation and culled 4.5 hours later. Apoptosis and mitosis were 
quantified by cell positional scoring from H&E stained sections of both small 
intestine and distal colon as described in section 2.4.1. 
3.4.1 No alteration in small intestinal and colonic crypt mitosis in mice with 
disrupted NFκB signalling following γ-irradiation 
Mitosis was barely detectable in the small intestinal crypts of C57BL/6 and NFκB1-
null mice and was completely suppressed in c-Rel-null and NFκB2-null small 
intestine 4.5 hours after 8Gy γ-irradiation. In the distal colon, mitosis was 
completely absent in most strains of mice and only persisted in NFκB1-null mice at a 
very low level. However, no significant differences were seen between any of the 
genotypes of mice (Figure 3.4). 
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3.4.2 NFκB1-null and NFκB2-null small intestine and colon demonstrate 
increased epithelial apoptosis in response to γ-irradiation 
In the small intestine of wild-type mice, 12% of crypt epithelial cells were apoptotic 
following irradiation and these were predominantly located at the base of crypts 
with maximum apoptotic events occurring at cell position 5. In the distal colon of 
these mice, 12.6% of epithelial cells were morphologically apoptotic and these were 
mainly seen at the crypt base with the maximum frequency of apoptosis being 
observed at cell positions 1 and 2 (Figure 3.5). These positions of maximal apoptotic 
frequency are similar to the cell positions of the putative stem cell zone in the small 
intestine and colon. 
In the small intestine, irradiation-induced crypt epithelial apoptosis was significantly 
increased by 3-fold and 2-fold in NFκB1-null and NFκB2-null mice respectively 
compared to C57BL/6 mice. Significant differences in the cell positional distributions 
of apoptotic scores were observed between cell positions 2 to 14 in NFκB1-null mice 
and 3 to 15 in NFκB2-null mice compared to wild-type mice following the same 
treatment using the modified median test. c-Rel-null small intestine did not show 
any significant alteration in the amount of irradiation-induced apoptosis or in the 
cell positional distribution of apoptotic events relative to wild-type mice (Figure 
3.5). 
In the distal colon, there was also a significant increase in both mean apoptotic 
indices and average number of apoptotic bodies per hemi-crypt in NFκB2-null mice 
compared to wild-type mice following the same treatment. As result of colonic 
crypt hyperplasia, NFκB1-null distal colon showed only a significant increase in 
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average number of apoptotic bodies per hemi-crypt compared to C57BL/6 mice 
following the same treatment. NFκB1-null and NFκB2-null distal colon showed 
significantly increased apoptotic scores at cell position 4 to 5 and 2 to 10 
respectively relative to wild-type mice. Although c-Rel-null distal colon did not 
demonstrate any alteration in the amount of irradiation-induced epithelial 
apoptosis, a significant increase in apoptotic scores was observed at cell positions 
10 to 14 compared to wild-type mice using the modified median test (Figure 3.5). 
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Figure 3.4: Quantitative analysis of intestinal crypt epithelial mitosis 4.5 hours 
after 8Gy γ-irradiation. Small intestinal (a) and distal colon (b) mean mitotic index 
± standard deviation separated by genotype. Small intestinal (c) and distal colon 
(d) mean number of mitotic figures per hemi-crypt ± standard deviation 
separated by genotype. Cell positional distribution of mitosis in small intestine (e) 
and distal colon (f) separated by genotype. Statistical differences were assessed 
by Kruskal–Wallis test followed by Dunn’s multiple comparison tests in (a), (b), (c) 
and (d). Statistical differences were assessed by modified median test in (e) and 
(f). (n=6 per genotype group). 
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Figure 3.5: Quantitative analysis of intestinal crypt epithelial apoptosis 4.5 hours 
after 8Gy γ-irradiation. Small intestinal (a) and distal colon (b) mean apoptotic 
index ± standard deviation separated by genotype. Small intestinal (c) and distal 
colon (d) mean number of apoptotic bodies per hemi-crypt ± standard deviation 
separated by genotype. Cell positional plot demonstrating small intestinal (e) and 
distal colon (f) apoptosis separated by genotype. Statistical differences were 
assessed by one way ANOVA and Dunnett's multiple comparison tests in (a), (b), 
(c) and (d)  (*p<0.05, **p<0.01, ***p<0.001 compared to C57BL/6). Statistical 
differences were assessed by modified median test in (e) and (f). Dashed line 
denotes cell positions over which there was a significant difference in apoptotic 
scores compared to wild-type. Colour of dashed line denotes comparison 
genotype.  (n=6 per genotype). 
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3.5 The effects of deleting various NFκB family members on small 
intestinal and colonic crypt epithelial cell proliferation and 
apoptosis following irinotecan treatment 
3.5.1 Intestinal damage and mitotic and apoptotic indices in wild-type mice 
following irinotecan time course 
Although it has been shown that intestinal apoptosis is induced following irinotecan 
administration, we could find no validated protocol in the literature describing the 
use of irinotecan as a stimulus to induce murine intestinal apoptosis. In view of a 
previous study that showed the extent of intestinal damage and mortality of mice 
following a dose of 280mg/kg irinotecan (295), the consequences of a single dose of 
250mg/kg irinotecan were assessed in C57BL/6 wild-type mice (5 mice per group) as 
described in section 2.2.1.2.  
3.5.1.1 Reduction in crypt length in the small intestine and colon of C57BL/6 mice 
following irinotecan administration 
A single dose of 250mg/kg irinotecan was injected (i.p.) into C57BL/6 mice and the 
number of epithelial cells per hemi-crypt in the small intestine and the colon was 
assessed after 0, 6, 12, 24, 48, 72 and 96 hours. In the small intestine, irinotecan 
resulted in a significant decrease in the number of epithelial cells per hemi-crypt at 
24 and 48 hours and the maximum reduction was observed at 48 hours. In response 
to irinotecan damage, a significant compensatory increase in the number of 
epithelial cells per hemi-crypt in the small intestine was observed at 96 hours 
129 
 
 
Figure 3.6: Intestinal epithelial cell number per hemi-crypt in wild-type mice 
following irinotecan time course. Small intestine (a) and distal colon (b) mean cell 
number per hemi-crypt ± standard deviation in C57BL/6 mice at 0, 6, 12, 24, 48, 
72 and 96 hours following administration (i.p.) of a single dose of 250mg/kg 
irinotecan. Statistical differences were assessed by one way ANOVA and 
Dunnett's multiple comparison test (*p<0.05, **p<0.01, ***p<0.001 compared to 
untreated C57BL/6) (n=5 per group). 
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(Figure 3.6). In the colon, a significant reduction in the number of crypt epithelial 
cells was also observed at 24 and 48 hours following irinotecan administration 
(Figure 3.6). However the effect of irinotecan on the number of crypt epithelial cells 
was more pronounced in the small intestine than the colon.  
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3.5.1.2 Mitosis is suppressed and apoptosis is induced in murine crypt intestinal 
epithelia following irinotecan treatment  
A single dose of 250mg/kg of irinotecan was administrated (i.p.) to C57BL/6 mice, 
and crypt intestinal mitosis and apoptosis were quantified on a cell positional basis 
from H and E stained sections after 0, 6, 12, 24, 48, 72 and 96 hours. In the small 
intestine, a significant suppression of mitosis was found at the 6, 12, 24 and 48 hour 
time points. This was followed by a sharp increase in mitosis in the small intestine at 
72 hours when the amount of mitosis returned to the basal levels seen in untreated 
small intestine. Small intestinal mitosis was significantly and rapidly increased by 3-
fold at the 96 hour time point compared to untreated small intestine and this 
mitosis was predominantly observed in the lower half of intestinal crypts (Figure 
3.7). This increase in the mitosis of crypt epithelial cells in response to irinotecan 
damage correlated with the significant increase observed in the number of crypt 
cells in the small intestine at the 96 hour time point as mentioned above (Figure 
3.6). In the distal colon, a significant suppression of mitosis was also observed at the 
6, 12, 24, 48 and 72 hours time points and this mitosis was mainly observed in the 
lower half of colonic crypts. At 96 hours, the amount of mitosis returned to the 
basal levels observed in untreated colon (Figure 3.7).  
In the small intestine, a significant increase in irinotecan-induced small intestinal 
apoptosis was observed at 6, 12, 24, 48, 72, and 96 hours. The maximum amounts 
of apoptosis were observed at the 6 and 12 hour time points. Apoptosis then 
gradually decreased over time, but remained at significantly higher levels than 
untreated small intestine until the 48 hour time point (Figure 3.8). In the distal 
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colon, a significant and maximum increase in irinotecan-induced distal colonic 
apoptosis was observed at 12 and 24 hours. Apoptosis then gradually decreased 
over time but remained at higher than baseline levels at 48, 72 and 96 hours, 
athough this was not statistically significant. Colonic crypt cell apoptosis was mainly 
located at the crypt base (Figure 3.8).  
According to these findings, 6 hours after irinotecan administration was chosen as 
an early time point which showed an increase in apoptosis induction and mitosis 
suppression and 48 hours was chosen as a late time point that demonstrated 
maximum intestinal damage. Therefore 6 hour and 48 hour time points were 
chosen for further studies of irinotecan-induced apoptosis and intestinal damage in 
transgenic mice. 
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Figure 3.7: Quantitative analysis of intestinal crypt epithelial mitosis in wild-type 
mice at 0, 6, 12, 24, 48, 72 and 96 hours following administration (i.p.) of a single 
dose of 250mg/kg irinotecan. Small intestinal (a) and distal colon (b) mean 
mitotic index ± standard deviation separated by time. Small intestinal (c) and 
distal colon (d) mean number of mitotic figures per hemi-crypt ± standard 
deviation separated by time. Cell positional distribution of small intestinal (e) and 
distal colon (f) mitosis separated by time. Statistical differences were assessed by 
one way ANOVA and Dunnett's multiple comparison tests in (a), (b), (c) and (d)  
(*p<0.05, **p<0.01, ***p<0.001 compared to untreated C57BL/6) (n=5 per 
group). 
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Figure 3.8: Quantitative analysis of intestinal crypt epithelial apoptosis in wild-
type mice at 0, 6, 12, 24, 48, 72 and 96 hours following administration (i.p.) of a 
single dose of 250mg/kg irinotecan. Small intestinal (a) and distal colon (b) mean 
apoptotic index ± standard deviation separated by time. Small intestinal (c) and 
distal colon (d) mean number of apoptotic bodies per hemi-crypt ± standard 
deviation separated by time. Cell positional distribution of small intestinal (e) and 
distal colon (f) apoptosis separated by time. Statistical differences were assessed 
by one way ANOVA and Dunnett's multiple comparison tests in (a), (b), (c) and (d) 
(*p<0.05, ***p<0.001 compared to untreated C57BL/6). (n=5 per group). 
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3.5.2 c-Rel-null and NFκB1-null mice continue to show elongated colonic 
crypts 48 hours following irinotecan administration 
In keeping with crypt length in untreated mice as shown earlier in Figure 3.1, 
NFκB1-null mice continued to show elongated small intestinal crypts 6 hours after 
irinotecan administration, with a mean crypt length of 19.5 cells per hemi-crypt 
compared to 18.0 cells per hemi-crypt in similarly treated wild-type mice. This 
difference in small intestinal crypt length was not however observed at 48 hours 
following irinotecan treatment compared to similarly treated wild-type mice (Figure 
3.9 a and c). 
A similar pattern of crypt elongation was observed in the distal colon of NFκB1-null 
mice both at 6 and 48 hours following irinotecan administration, with mean crypt 
lengths of 32.6 and 26.5 cells per hemi-crypt compared to 24.6 and 22.1 cells per 
hemi-crypt in wild-type mice at the 6 and 48 hours time points respectively. c-Rel-
null mice also continued to show significantly longer colonic crypts at the 48 hour 
time point, with 25.4 cells per hemi-crypt compared to 22.1 cells per hemi-crypt in 
wild-type mice (Figure 3.9 b and d). 
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Figure 3.9: Number of intestinal epithelial cells per hemi-crypt in mice 6 hours 
and 48 hours following administration (i.p.) of a single dose of 250mg/kg 
irinotecan. Small intestine (a) and distal colon (b) mean cell number per hemi-
crypt ± standard deviation in C57BL/6, c-Rel-null, NFκB1-null and NFκB2-null 
mice 6 hours following irinotecan. Small intestine (c) and distal colon (d) mean 
cell number per hemi-crypt ± standard deviation in C57BL/6, c-Rel-null, NFκB1-
null and NFκB2-null mice 48 hours following irinotecan. Statistical differences 
were assessed by one way ANOVA and Dunnett's multiple comparison test 
(*p<0.05, **p<0.01 ***p<0.001 compared to similarly treated C57BL/6) (n=5 per 
genotype group). 
 
0
5
10
15
20
25
C57BL/6 c-Rel-null NFκB1-null NFκB2-null
C
e
ll 
n
u
m
b
e
r/
h
e
m
i-
cr
yp
t
**
0
5
10
15
20
25
30
35
40
C57BL/6 c-Rel-null NFκB1-null NFκB2-null
C
e
ll 
n
u
m
b
e
r/
h
e
m
i-
cr
yp
t
***
dc
a b
0
5
10
15
20
C57BL/6 c-Rel-null NFκB1-null NFκB2-null
C
e
ll 
n
u
m
b
e
r/
h
e
m
i-
cr
yp
t
0
5
10
15
20
25
30
C57BL/6 c-Rel-null NFκB1-null NFκB2-null
C
e
ll 
n
u
m
b
e
r/
h
e
m
i-
cr
yp
t
*
**
 
 
 
 
 
 
 
 
 
136 
 
3.5.3 Intestinal epithelial mitosis is suppressed following irinotecan 
administration 
Following administration of 250mg/kg irinotecan to C57BL/6, c-Rel-null, NFκB1-null 
and NFκB2-null mice, small intestines and colons were harvested after 6 and 48 
hours (5 mice per group). The amounts of mitosis and apoptosis were quantified 
using H and E stained sections. In comparison to untreated animals (Figure 3.2 a and 
c), mitosis was suppressed and barely detectable in C57BL/6 small intestine and 
completely suppressed in c-Rel-null and NFκB2-null small intestine 6 hours following 
irinotecan. However, this mitosis suppression in c-Rel-null, NFκB1-null and NFκB2-
null small intestine was not statistically significant compared to C57BL/6 small 
intestine (Figure 3.10 a and c). Mitosis in the small intestine 48 hours following 
irinotecan was suppressed in all groups of mice but to a lesser extent than that 
which observed at the 6 hour time point and no significant alterations were 
observed between transgenic mice compared to wild-type mice (Figure 3.10 b and 
d). 
Although colonic epithelial mitosis was reduced at greater extent in transgenic mice 
6 hours following irinotecan administration relative to similarly treated wild-type 
mice, this was not statistically significant. This mitosis suppression remained until 48 
hours relative to untreated mice (as previously shown in Figure 3.2 b and d), there 
were also no significant alterations between transgenic mice and wild-type mice 
following the same treatment and duration. Mitosis continued to occur in the lower 
quarter of colonic crypts at both the 6 hour and 48 hour time points (Figure 3.11).  
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Figure 3.10: Quantitative analysis of small intestinal crypt epithelial mitosis 6 
and 48 hours after administration (i.p.) of a single dose of 250mg/kg irinotecan. 
Mean mitotic index ± standard deviation 6 hours (a) and 48 hours (b) following 
irinotecan in small intestine separated by genotype. Mean number of mitotic 
figures per hemi-crypt ± standard deviation 6 hours (c) and 48 hours (d) 
following irinotecan in small intestine separated by genotype. Cell positional 
distribution of small intestinal crypt epithelial mitosis 6 hours (e) and 48 hours 
(f) following Irinotecan separated by genotype. Statistical differences were 
assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison tests in 
(a), (b), (c) and (d) compared to similarly treated C57BL/6. Statistical differences 
were assessed by modified median test in (e) and (f). (n=5 per genotype group). 
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Figure 3.11: Quantitative analysis of distal colonic crypt epithelial mitosis 6 and 
48 hours after administration (i.p.) of a single dose of 250mg/kg irinotecan. 
Mean mitotic index ± standard deviation 6 hours (a) and 48 hours (b) following 
irinotecan in distal colon separated by genotype. Mean number of mitotic figures 
per hemi-crypt ± standard deviation 6 hours (c) and 48 hours (d) following 
Irinotecan in distal colon separated by genotype. Cell positional distribution of 
distal colonic crypt epithelial mitosis 6 hours (e) and 48 hours (f) following 
irinotecan separated by genotype. Statistical differences were assessed by 
Kruskal–Wallis test followed by Dunn’s multiple comparison tests in (a), (b), (c) 
and (d). Statistical differences were assessed by modified median test in (e) and 
(f). Dotted line denotes cell positions over which there was a significant 
difference from wild-type. Colour of dotted line denotes comparison genotype. 
(n=5 per genotype group). 
 
 
0
0.5
1
1.5
2
0 5 10 15 20 25 30 35 40
M
it
o
ti
c 
in
d
e
x 
%
Cell position
C57BL/6
c-Rel-null
NFκB1-null
NFκB2-null
3....6
0
0.1
0.2
0.3
C57BL/6 c-Rel-null NFκB1-null NFκB2-null
M
it
o
ti
c 
fi
gu
re
/h
e
m
i-
cr
yp
t
0
0.2
0.4
0.6
0.8
1
C57BL/6 c-Rel-null NFκB1-null NFκB2-null
M
e
an
 m
it
o
ti
c 
in
d
e
x 
%
0
0.2
0.4
0.6
0.8
1
C57BL/6 c-Rel-null NFκB1-null NFκB2-null
M
e
an
 m
it
o
ti
c 
in
d
e
x 
%
0
0.5
1
1.5
2
0 5 10 15 20 25 30 35 40
M
it
o
ti
c 
in
d
e
x 
%
Cell position
C57BL/6
c-Rel-null
NFκB1-null
NFκB2-null
0
0.1
0.2
0.3
C57BL/6 c-Rel-null NFκB1-null NFκB2-null
M
it
o
ti
c 
fi
gu
re
/h
e
m
i-
cr
yp
t
b
f
d
a
e
c
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
139 
 
3.5.4 NFκB1-null and NFκB2-null mice showed an increase in both small 
intestinal and colonic epithelial apoptosis at both 6 and 48 hours 
following irinotecan treatment 
Intestines were obtained 6 and 48 hours after mice being subjected to a single dose 
of 250mg/kg irinotecan (5 mice per group). Amounts of apoptosis were quantified 
from H and E stained sections. In the small intestine of wild-type mice, 15.2% and 
4.1% of the crypt epithelial cells were morphologically apoptotic 6 and 48 hours 
following irinotecan treatment respectively. This irinotecan induced apoptosis was 
predominantly located at the base of crypts and maximum apoptotic events 
occurred at cell position 5 following irinotecan adminstration (Figure 3.12). In the 
distal colon of these mice, apoptosis was also induced by irinotecan treatment, but 
to a lesser extent than that observed in the small intestine. According to 
morphological criteria, 0.57% and 0.97% of colonic crypt epithelial cells were 
apoptotic 6 and 48 hours following irinotecan administration respectively and 
apoptosis was mainly seen at the crypt base. The maximum frequency of irinotecan 
induced colonic crypt epithelial apoptosis was observed at cell position 2 (Figure 
3.13). These positions of maximal apoptotic frequency of irinotecan induced 
apoptosis both in the small intestine and colon are similar to the cell positions of 
the proposed stem cell zone in these tissues.  
 In the small intestine, deletion of either NFκB1 or NFκB2 resulted in a significant 
increase in crypt epithelial apoptosis 6 hours following irinotecan (by 2-fold relative 
to similarly treated C57BL/6 mice). Significant differences in the cell positional 
distributions of apoptotic scores were observed between cell positions 10 to 15, 3 
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to 16 and 3 to 17 in c-Rel-null, NFκB1-null and NFκB2-null mice respectively 
compared to similarly treated wild-type mice using the modified median test (Figure 
3.12 a, c and e). A similar pattern was seen at the 48 hour time point, where 
approximately 2-fold and 3-fold increases in irinotecan induced small intestinal 
crypt epithelial apoptosis were observed in NFκB1-null and NFκB2-null mice 
respectively relative to C57BL/6 mice following the same treatment. Significant 
differences in the distribution of apoptotic events were observed between cell 
positions 8 to 13 in NFκB1-null mice and 3 to 15 in NFκB2-null mice respectively 
using the modified median test (Figure 3.12 b, d and f). Maximum small intestinal 
crypt apoptosis was observed at cell position 5 in all strains of mice at both 6 and 48 
hours following irinotecan. 
In the distal colon, there was also a significant increase in the number of apoptotic 
events observed in NFκB1 null (6.8-fold increase) and NFκB2 null (6.8-fold increase) 
mice 6 hours following irinotecan administration compared to C57BL/6 mice 
following the same treatment. This correlated with significantly increased apoptotic 
scores between cell positions 3 to 17 in NFκB1-null mice and 2 to 8 in NFκB2-null 
mice using the modified median test (Figure 3.13 a, c and e). 48 hours after 
irinotecan administration, mice with germline deletions of either NFκB1 or NFκB2 
continued to show significantly elevated apoptotic scores in the distal colon in 
comparison to similarly treated wild-type mice, with 2.5- fold and 2-fold increases in 
apoptosis being observed respectively. These transgenic mice (NFκB1-null and 
NFκB2-null) demonstrated significant increases in apoptotic scores at cell positions 
3 to 12 and 3 to 5 respectively compared to similarly treated wild-type mice (Figure 
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Figure 3.12: Quantitative analysis of small intestinal crypt epithelial apoptosis 6 
and 48 hours after administration (i.p.) of a single dose of 250mg/kg irinotecan. 
Mean apoptotic index 6 hours (a) and 48 hours (b) following irinotecan in small 
intestine separated by genotype. Mean number of apoptotic scores per hemi-
crypt ± standard deviation 6 hours (c) and 48 hours (d) following irinotecan in 
small intestine separated by genotype. Cell positional distribution of small 
intestinal crypt epithelial apoptosis 6 hours (e) and 48 hours (f) following 
irinotecan separated by genotype. Statistical differences were assessed by one 
way ANOVA and Dunnett's multiple comparison tests in (a), (b), (c) and (d) 
(*p<0.05,**p<0.01, ***p<0.001 compared to C57BL/6). Statistical differences 
were assessed by modified median test in (e) and (f). Dashed line denotes cell 
positions over which there was a significant difference in apoptotic scores 
compared to wild-type. Colour of dashed line denotes comparison genotype. 
(n=5 per genotype group). 
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3.13 b, d and f). Comparisons between wild-type and c-Rel-null mice at the 6 and 48 
hour time points demonstrated no significant differences in apoptosis scores in 
either the small intestine or distal colon. 
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Figure 3.13: Quantitative analysis of distal colonic crypt epithelial apoptosis 6 
and 48 hours after administration (i.p.) of a single dose of 250mg/kg Irinotecan. 
Mean apoptotic index ± standard deviation 6 hours (a) and 48 hours (b) following 
Irinotecan in distal colon separated by genotype. Mean number of apoptotic 
scores per hemi-crypt ± standard deviation 6 hours (c) and 48 hours (d) following 
Irinotecan in distal colon separated by genotype. Cell positional distribution of 
distal colonic crypt epithelial apoptosis 6 hours (e) and 48 hours (f) following 
Irinotecan separated by genotype. Statistical differences were assessed by one 
way ANOVA and Dunnett's multiple comparison tests in (a), (b), (c) and (d) 
(*p<0.05,**p<0.01 compared to C57BL/6). Statistical differences were assessed 
by modified median test in (e) and (f). Dashed line denotes cell positions over 
which there was a significant difference in apoptotic scores compared to wild-
type. Colour of dashed line denotes comparison genotype. (n=5 per genotype 
group). 
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3.6 Expression of apoptosis regulating genes in untreated and 
irradiated mice with disrupted NFκB signalling 
To investigate the molecular mechanisms responsible for the increased irradiation 
induced apoptosis observed in small intestine and colon of NFκB1-null and NFκB2-
null mice, the mRNA expression of 10 key apoptosis regulating genes was assessed 
in the small intestinal and colonic epithelia of untreated and treated mice by real 
time PCR. 8 of these 10 genes were known NFκB-regulated genes. 2 novel genes 
(TRAIL and caspase 12) were also included, due to preliminary observations that 
showed that they were up-regulated on an apoptosis pathway specific microarray in 
NFκB2-null colon following azoxymethane treatment (A. Hanedi, MRes project 
2008). Depending on function, 6 of these genes were pro-apoptotic namely TRAIL, 
Caspase12, BAK, FAS-L, FAS and p53 and the remaining 4 genes were anti-apoptotic 
namely BCL2, BCL-XL, c-IAP2 and XIAP. Adult male c-Rel-null, NFκB1-null and NFκB2-
null mice and their wild-type (C57BL/6) counterparts (4 mice per genotype) were 
subjected to 8Gy γ-irradiation and mice were culled 4.5 hours later. Corresponding 
untreated mice of the same age and genotype were also culled as control animals (4 
mice per genotype). RNA samples were extracted from small intestinal and colonic 
epithelia before being reverse transcribed to cDNA and quantified by real-time PCR. 
Values of relative mRNA expression in transgenic mice were compared to similarly 
treated wild-type (C57BL/6) mice.  
In untreated groups, NFκB1-null and NFκB2-null mice showed reduced relative 
mRNA expressions of the anti-apoptotic genes BCL2, BCL-XL, c-IAP2 and XIAP in the 
small intestine compared to untreated wild-type mice (Figure 3.15). These 
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molecular changes might explain the increased susceptibility to small intestinal 
spontaneous apoptosis observed in these strains particularly in NFκB2-null mice 
where it reached statistical significance. In untreated distal colon, changes in the 
relative mRNA expression of apoptosis regulating genes were also observed in 
transgenic mice compared to wild-type mice. In particular NFκB1-null and NFκB2-
null distal colon showed reduction in the relative mRNA expression of the anti-
apoptotic genes c-IAP2 and XIAP (Figure 3.17). Untreated c-Rel-null mice showed 
increased expression of BCL2 and reduced expression of XIAP in the small intestine 
(Figure 3.15), while untreated c-Rel-null colon showed increased expression of BAK 
(Figure 3.16) and reduced expression c-IAP2 (Figure 3.17). However, these slight 
alterations in the expression of apoptosis regulating genes were not associated with 
changes in baseline apoptosis in the distal colon of these transgenic mice as shown 
earlier (Figure 3.3). 
Following irradiation, NFκB1-null mice showed significant increases in the 
expression of the pro-apoptotic genes TRAIL and Caspase12 in the small intestine 
(Figure 3.14). Irradiated NFκB1-null colon also showed a significant increase in the 
expression of the pro-apoptotic gene TRAIL and reduced expression of the anti-
apoptotic gene c-IAP2 compared to irradiated wild-type mice (Figure 3.16 and 
Figure 3.17). Irradiated NFκB2-null mice also demonstrated significant increases in 
the expression of the pro-apoptotic genes Caspase12, BAK, p53 and FAS-L in the 
small intestine (Figure 3.14) and TRAIL, Caspase12 and FAS-L in the colon relative to 
irradiated wild-type mice (Figure 3.16). Strikingly, a huge increase in relative mRNA 
expressions of FAS-L by 15-fold in the small intestine and 40-fold in the colon was 
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observed only in NFκB2-null mice following irradiation compared to similarly 
treated wild-type mice. This suggests that NFκB2 plays a crucial role in the 
transcriptional regulation FAS-L expression in the intestine. These increases in the 
mRNA expression of pro-apoptotic genes in NFκB2-null small intestine were 
associated with modest increases in the expression of the anti-apoptotic genes BCL-
XL, c-IAP2 and XIAP following irradiation compared to wild-type mice (Figure 3.15). 
The increased expressions of pro-apoptotic genes which were observed in both the 
small intestine and colon of irradiated NFκB1-null and NFκB2-null mice may be the 
mechanisms responsible for the increased irradiation induced apoptosis observed in 
these animals. 
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Figure 3.14: Quantification of relative mRNA expression of pro-apoptotic genes in 
the small intestinal epithelia of untreated mice and mice 4.5 hours following 8Gy 
whole body γ-irradiation. Relative mRNA expression of TRAIL (a), FAS-L (b), 
Caspase12 (c), FAS (d), BAK (e) and p53 (f) were assessed by real-time PCR in the 
small intestinal epithelial cells from untreated and irradiated strains of mice as 
indicated above using real-time PCR. Statistical analysis was performed by 2-way 
ANOVA with Bonferroni post-hoc tests (*p<0.05, **p<0.01, ***p<0.001 
compared to similarly treated C57BL/6) (n=4 mice per genotype group). 
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Figure 3.15: Quantification of relative mRNA expression of anti-apoptotic genes in 
the small intestinal epithelia of untreated mice and mice 4.5 hours following 8Gy 
whole body γ-irradiation. Relative mRNA expressions of BCL2 (a), c-IAP2 (b), BCL-
XL (c) and XIAP (d) were assessed in the small intestinal epithelial cells from 
untreated and irradiated strains of mice as indicated above using real-time PCR. 
Statistical analysis was performed by 2-way ANOVA and with Bonferroni post-hoc 
tests (*p<0.05, **p<0.01, ***p<0.001 compared to similarly treated C57BL/6) 
(n=4 mice per genotype group). 
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Figure 3.16: Quantification of relative mRNA expression of pro-apoptotic genes in 
the colonic epithelia of untreated mice and mice 4.5 hours following 8Gy whole 
body γ-irradiation. Relative mRNA expressions of TRAIL (a), FAS-L (b), Caspase12 
(c), FAS (d), BAK (e) and p53 (f) were assessed in the colonic epithelial cells from 
untreated and irradiated strains of mice as indicated above using real-time PCR. 
Statistical analysis was performed by 2-way ANOVA with Bonferroni post-hoc 
tests (*p<0.05, ***p<0.001 compared to similarly treated C57BL/6) (n=4 mice per 
genotype group). 
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Figure 3.17: Quantification of relative mRNA expression of anti-apoptotic genes 
in the colonic epithelia of untreated mice and mice 4.5 hours following 8Gy 
whole body γ-irradiation. Relative mRNA expressions of BCL2 (a), c-IAP2 (b), BCL-
XL (c) and XIAP (d) were assessed in the colonic epithelial cells from untreated 
and irradiated strains of mice as indicated above using real-time PCR. Statistical 
analysis was performed by 2-way ANOVA and with Bonferroni post-hoc tests 
(*p<0.05, **p<0.01 compared to similarly treated C57BL/6) (n=4 mice per 
genotype group). 
 
 
BCL2
Untreated -irradiated
0.0
1.0
2.0
3.0
4.0
C57BL/6
c-Rel-null
NFB1-null
NFB2-null
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
BCL-XL
Untreated -irradiated
0.0
0.5
1.0
1.5
2.0
C57BL/6
c-Rel-null
NFB1-null
NFB2-null
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
c-IAP2
Untreated -irradiated
0.0
0.5
1.0
1.5
C57BL/6
c-Rel-null
NFB1-null
NFB2-null
** ** **
**
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
XIAP
Untreated -irradiated
0.0
0.5
1.0
1.5
C57BL/6
c-Rel-null
NFB1-null
NFB2-null
* *
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
a
c
b
d
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
150 
 
3.7 Investigating the effect of NFκB2 and RelB suppression upon 
HCT116 cell proliferation and apoptosis in vitro  
Due to lack of access to RelB-null mice and to further characterise the role of 
alternative pathway of NFκB signalling in regulating intestinal epithelial apoptosis 
and proliferation, in vitro assessment of the effects of suppression of RelB and 
NFκB2 expression on these cellular processes was performed. 
3.7.1 Assessment of NFκB2 expression in various colon cancer cell lines using 
three NFκB2 antibodies from different suppliers 
In order to identify a suitable cell line for the in vitro study, a number of different 
colon cancer cell lines were tested to investigate the expression of NFκB2. These 
cell lines include Caco2, DLD-1, HCT116, HT29 and LS1747. Alongside these cells, 
Raji (human Burkitt's lymphoma cell line) and AGS (human gastric cancer cell lines) 
were also used as positive controls. Western blotting was performed upon the 
protein extracted from these cell lines using NFκB2 antibodies from three suppliers 
(Dr Caamano’s antibody, Abcam and Santa Cruz) as described in section 2.6. NFκB2 
was expressed in all cell lines. HCT116 cells showed the strongest expression and 
clearly showed the two bands of NFκB2 (the precursor p100 and the processed form 
p52). Not the all antibodies clearly detected the two bands of NFκB2. However, the 
NFκB2 antibody which was provided by Dr. Caamano appeared to generate the 
clearest image (Figure 3.18). Therefore, HCT116 cells and Dr Caamano’s anti-NFκB2 
antibody were used for further studies.  
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3.7.2 Time course of NFκB2 siRNA transfection in HCT116 cells 
In order to evaluate the time required for knockdown of the expression of NFκB2, a 
time course following NFκB2 siRNA transfection was performed. Protein expression 
of NFκB2 was assessed 24, 48 and 72 hours following transfection using Western 
blot. All time points showed reduced expression of the precursor form of NFκB2 
(p100), but no change was seen in the abundance of the processed form (p52). 
Changes were observed only in target siRNA transfected cells (Figure 3.19). The 
percentage of knockdown was approximately 45% at all the time points tested in 
one experiment, as assessed by protein densitometry. Unaltered protein expression 
 
Figure 3.18: Immunoblotting of protein samples obtained from Raji B and AGS 
(as positive controls), Caco2, DLD-1, HCT116, HT29, and LS1747-3 (colon cancer 
cells) using anti-NFκB2 antibodies from three different suppliers (Dr Caamano, 
Abcam and Santa Cruz) and an anti-actin antibody. 
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Figure 3.19: Western blot to assess NFκB2 protein expression 24, 48 and 72 
hours following NFκB2 siRNA transfection of HCT116 cells. Knockdown of the 
p100 but not the p52 form of NFκB2 was observed at all the time points 
tested. 
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of the processed form (p52) of NFκB2 during this time course may be due to a 
longer half life of this protein (thus slowing the rate of turnover). Hence, it may take 
longer for p52 protein stores to be depleted to allow actual knockdown to be 
observed. Therefore, a longer time course was also performed. p100 and p52 
protein expressions were analysed 5 and 6 days after NFκB2 siRNA transfection. 
Although the percentage knockdown of p100 was more than 80% at these longer 
time points, as assessed by protein densitometry, no change was observed in the 
abundance of the processed form (p52) as shown in Figure 3.20. 
 
 
 
 
 
153 
 
 
Figure 3.20: Western blot to assess NFκB2 protein expression 5 and 6 days 
following NFκB2 siRNA transfection of HCT116 cells. (a) Western blotting of 
protein samples obtained from HCT116 cells following 5 and 6 days of siRNA 
transfection as indicated above. Knockdown of the p100 but not the p52 form of 
NFκB2 was observed at all the time points tested. Anti-actin antibody was used 
as a loading control. (b) Relative expression of p100 compared to its expression 
in control siRNA transfected cells. NFκB2 siRNA treatment resulted in reduced 
expression of the p100 but not the p52 form of NFκB2 by 83% and 90% at the 5 
and 6 day time points respectively compared to control siRNA at the same time 
points. This figure demonstrates the findings from one representative 
experiment. 
 
NFκB2
Actin
P100
P52
U
n
tr
e
a
te
d
C
on
tr
ol
 s
iR
N
A
N
Fκ
B
2
 s
iR
N
A
U
n
tr
e
a
te
d
C
on
tr
ol
 s
iR
N
A
N
Fκ
B
2
 s
iR
N
A
5 days 6 days
HCT116
0
0.5
1
Control siRNA NFκB2 siRNA Control siRNA NFκB2 siRNA
5 days 6 days
R
e
la
ti
ve
 e
xp
re
ss
io
n
p100
(a)
(b)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
154 
 
3.7.3 Effect of NFκB2 suppression upon cell proliferation and apoptosis with 
and without Etoposide treatment  
24 hours following seeding of HCT116 cells, they were transfected with NFκB2 
siRNA or control siRNA. 24 hours after this siRNA transfection, Etoposide treatment 
was performed. Etoposide, which is a chemotherapeutic agent that inhibits 
topoisomerase ІІ was used to induce apoptosis (at a final concentration of 20μM). 
Etoposide treated and untreated cells were incubated for a further 24 hours. 
Floating cells (as a measure of apoptosis) and attached cells (as a measure of cell 
proliferation) were then counted as outlined in Figure 3.21 a. Because there was a 
difference between the number of attached cells in the control and NFκB2 siRNA 
treated cells, apoptosis was calculated as a percentage of apoptotic cells to total 
cells [number of floating cells/number of (floating cells + attached cells) x100%]. The 
percentage of apoptotic cells in NFκB2 siRNA treated cells compared to the 
percentage of apoptotic cells in control siRNA treated cells was then calculated. The 
percentage of attached cells following NFκB2 siRNA treatment was also compared 
to the percentage of attached cells following control siRNA treatment. 
In Etoposide-untreated HCT116 cells, knocking down NFκB2 protein expression 
using siRNA resulted in a significant decrease in the percentage of attached cells 
compared with control siRNA treated cells (p<0.05, student’s t-test) (Figure 3.21 b). 
Knockdown of NFκB2 protein expression however did not alter the percentage of 
apoptotic cells compared to control siRNA (Figure 3.21 d). 
Etoposide treatment resulted in a reduction in attached cells by 33% and 30% 
following control siRNA and NFκB2 siRNA treatments respectively compared with 
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Etoposide-untreated cells of corresponding siRNA treatments. Also, Etoposide 
resulted in increases of 33% and 46% respectively in apoptosis in control siRNA and 
NFκB2 siRNA transfected cells, compared with Etoposide-untreated cells of 
corresponding siRNA treatment. 
In Etoposide treated HCT116 cells, there was again a significant decrease in the 
percentage of attached cells following NFκB2 siRNA treatment compared with 
control siRNA treated cells (p<0.05, student’s t-test) (Figure 3.21 c). Also, a 
significant increase in the percentage of apoptotic cells was observed in NFκB2 
siRNA transfected cells compared to control siRNA transfected cells following 
Etoposide treatment (p<0.05, student’s t-test) (Figure 3.21 e).  
Therefore, these data demonstrated that reducing the protein expression of the 
precursor form of NFκB2 (p100) decreased HCT116 cell proliferation both with and 
without Etoposide treatment and also increased apoptosis following Etoposide 
treatment.  
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Figure 3.21: Effects of NFκB2 suppression using siRNA technique on HCT116 
cell proliferation and apoptosis in either untreated or Etoposide treated cells. 
(a) Schematic diagram showing siRNA transfection and Etoposide treatment 
protocol in HCT116 cells. % of attached cells compared to control siRNA 
transfected cells (± standard deviation) in untreated (b) and Etoposide treated 
(c) cells respectively. % of apoptotic cells compared to control siRNA 
transfected cells (± standard deviation) in untreated (d) and Etoposide treated 
(e) cells respectively (± standard deviation) (*p<0.05 by student’s t-test). The 
data are from 3 independent experiment (n=3). 
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3.7.4 Effect of NFκB2 suppression on the expression of proteins that regulate 
cell proliferation, differentiation and apoptosis 
To investigate the mechanisms by which NFκB2 regulates HCT 116 cell proliferation 
and apoptosis, the expression of key proteins that are known to regulate 
proliferation and apoptosis was assessed following siRNA treatment using Western 
blot. These proteins included p53 and its target genes cyclin D1 and p21 that are 
involved in regulating cell proliferation. The protein expression of an NFκB2 
regulated anti-apoptotic target gene BCL-2 was also assessed. 
Etoposide treatment resulted in a significant increase in the expression of NFκB2, 
p53 and its target gene p21 in both control siRNA and NFκB2 siRNA transfected cells 
compared to Etoposide-untreated cells. However, no change in the expression of 
p53, p21, cyclin D1 or BCL2 was observed in NFκB2 siRNA transfected cells 
compared to control siRNA transfected cells either before or after Etoposide 
treatment (Figure 3.22). 
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Figure 3.22: Protein expression of NFκB2 and other key genes that regulate 
proliferation and apoptosis in HCT116 cells following NFκB2 siRNA and 
Etoposide treatment. (a) Western blotting of protein samples obtained from 
HCT116 cells following siRNA transfection and then Etoposide treatment using 
anti-NFκB2, p53, cyclin D1, p21 and BCL-2 antibodies. Anti-actin antibody was 
also used as a loading control. (b) Relative expression of p100, p53 and p21 
compared to their expression in control siRNA and Etoposide-untreated cells (± 
standard deviation). NFκB2 siRNA treatment resulted in reduced expression of 
the p100 but not the p52 form of NFκB2 by 45% compared to control siRNA. 
Etoposide treatment caused a significant increase in the expression of NFκB2, 
p53 and p21 (*p<0.05, **p<0.01, ***p<0.001 by student’s t-test). This figure 
demonstrates the findings from triplicate samples. 
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Figure 3.23: Western blot to assess RelB protein expression 24, 48 and 72 
hours following RelB siRNA transfection of HCT116 cells. Knockdown of 
RelB was observed at all the time points tested. 
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3.7.5 Time course of RelB siRNA transfection in HCT116 cells 
To determine the optimal time point required for efficient knockdown of RelB 
expression, a time course following RelB siRNA transfection was performed using 
HCT116 cells. Protein expression of RelB was assessed 24, 48 and 72 hours following 
transfection using Western blot. All time points showed reduced expression of RelB. 
Changes were observed only in target siRNA transfected cells (Figure 3.23). The 
percentage of knockdown was approximately 60%, 75% and 75% at the 24, 48 and 
72 hour time points respectively as assessed by protein densitometry. Therefore, 
the 48 hour time point was chosen for subsequent studies. 
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3.7.6 Effect of RelB suppression upon cell proliferation and apoptosis with 
and without Etoposide treatment  
24 hours following seeding of HCT116 cells, they were transfected with RelB siRNA 
or control siRNA. 24 hours after this siRNA transfection, Etoposide was added and 
Etoposide treated and untreated cells were incubated for a further 24 hours. 
Floating cells (as a measure of apoptosis) and attached cells (as a measure of cell 
proliferation) were then counted as outlined in Figure 3.24 a. To avoid the effect of 
any possible differences between the number of attached cells in the control and in 
the RelB siRNA treated cells as shown above in NFκB2 siRNA transfection, apoptosis 
was calculated as a percentage of apoptotic cells to total cells [number of floating 
cells/number of (floating cells + attached cells) x100%]. The percentage of apoptotic 
cells in RelB siRNA treated cells was then compared to the percentage of apoptotic 
cells in control siRNA treated cells. The percentage of attached cells following RelB 
siRNA treatment was also compared to the percentage of attached cells following 
control siRNA treatment. 
In Etoposide-untreated HCT116 cells, knocking down RelB protein expression using 
siRNA did not cause any alterations in the percentage of attached cells or apoptotic 
cells compared to control siRNA. In Etoposide treated HCT116 cells, RelB 
suppression by siRNA also did not result in change in the percentage of attached 
cells or apoptotic cells compared to control siRNA (Figure 3.24).  
Although the RelB suppression did not affect HCT116 proliferation and apoptosis, 
the molecular consequences of RelB suppression on these cellular processes were 
further evaluated by assessing the expression of key proteins that are known to 
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regulate proliferation and apoptosis following RelB siRNA treatment. These proteins 
were p53 and its target genes cyclin D1 and p21 that are involved in regulating cell 
proliferation and differentiation along with the pro-apoptotic protein BAX and the 
anti-apoptotic protein BCL2. Etoposide treatment resulted in an increase in the 
expression of p53 and its target gene p21 in both control siRNA and RelB siRNA 
transfected cells compared to Etoposide-untreated cells. No changes in the 
expression of p53, p21, cyclin D1, Bax or BCL2 were observed in RelB siRNA 
transfected cells compared to control siRNA transfected cells either before or after 
Etoposide treatment (Figure 3.25). 
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Figure 3.24: Effects of RelB suppression using siRNA technique on HCT116 cell 
proliferation and apoptosis in either untreated or Etoposide treated cells. (a) 
Schematic diagram showing siRNA transfection and Etoposide treatment 
protocol in HCT116 cells. % of attached cells compared to control siRNA 
transfected cells (± standard deviation) in untreated (b) and Etoposide treated 
(c) cells respectively. % of apoptotic cells compared to control siRNA 
transfected cells (± standard deviation) in untreated (d) and Etoposide treated 
(e) cells respectively (± standard deviation). Statistical analysis was performed 
by student’s t-test. The data are from 3 independent experiment (n=3). 
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Figure 3.25: Protein expression of RelB and other key genes that regulate 
proliferation and apoptosis in HCT116 cells following RelB siRNA and Etoposide 
treatment. Western blotting of protein samples obtained from HCT116 cells 
following siRNA transfection and then Etoposide treatment using anti-RelB, p53, 
cyclin D1, p21, Bax and BCL-2 antibodies. Anti-actin antibody was also used as a 
loading control. (b) Relative expression of RelB, p53 and p21 compared to their 
expression in control siRNA and Etoposide-untreated cells (± standard deviation). 
RelB siRNA treatment resulted in reduced expression of RelB by approximately 
80% compared to control siRNA. Etoposide treatment caused a significant 
increase in the expression of RelB and also resulted in an increase in expression 
of p53 and p21 (* p<0.05, ** p<0.01 by student’s t-test). RelB protein 
densitometry is the average of 3 independent experiments. p53 and p21 protein 
densitometry is the average of readings from duplicate samples in one 
experiment. 
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3.8 Discussion 
NFκB has been shown to regulate cell proliferation and apoptosis in a number of 
cell types and has been found to both promote and inhibit apoptosis in different 
contexts. The role of NFκB in regulating apoptosis appears to be dependent on both 
the cell type and the nature of the death-triggering stimulus (241, 242, 296, 297).  
In the current study, disruption of the classical pathway of NFκB activation by 
deletions of c-Rel or NFκB1 altered murine small intestinal and colonic crypt lengths 
as measured by cell number per hemi-crypt. Longer small intestinal and colonic 
crypts were found in NFκB1-null mice and longer colonic crypts were seen in c-Rel-
null mice compared to wild-type counterparts. This is consistent with a previous 
study by Inan et al who demonstrated that NFκB1-null mice had longer colonic 
crypts and a more extensive proliferative zone (as determined by proliferating cell 
nuclear antigen staining and in vivo bromodeoxyuridine labeling) than their wild-
type counterparts (230). In our present study the elongations of intestinal crypts 
observed in c-Rel-null and NFκB1-null mice were not associated with changes in 
crypt epithelial proliferation as determined by mitotic indices. However the number 
of mitotic figures with defining morphological criteria is far fewer than the number 
of proliferating cells determined by proliferating cell nuclear antigen (PCNA) 
staining or in vivo bromodeoxyuridine (BrdU) labelling. This might partially explain 
our inability to detect any changes in proliferation by mitotic indices in the intestinal 
epithelia of either c-Rel-null or NFκB1-null mice. In contrast to previous studies 
using cell culture which have revealed that NFκB promotes cell proliferation and 
inhibits apoptosis (298, 299), these observations in untreated mice suggest that the 
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classical NFκB activation pathway plays a complex role in whole intestinal tissue, 
where all cell types are present. Taken as a whole, these finding suggest that the 
classical NFκB activation pathway via both c-Rel and NFκB1 plays a role in 
maintaining intestinal homeostasis. Real time PCR data from untreated animals 
showed alterations in the expression of some apoptosis regulating genes. NFκB1-
null mice showed reduced relative mRNA expression of the anti-apoptotic genes 
BCL2, BCL-XL, c-IAP2 and XIAP in the small intestine and c-IAP2 and XIAP in the 
colon compared to wild-type mice. However, the increase in small intestinal 
spontaneous epithelial apoptosis seen in NFκB1-null mice was not statistically 
significant and no alteration in basal epithelial apoptosis was found in NFκB1-null 
colon.  
The influence of the alternative NFκB activation pathway in regulating intestinal 
epithelial turnover has not previously been studied in detail. Disruption of this 
pathway by deleting NFκB2 resulted in elongation of small intestinal crypts and an 
increase in epithelial apoptosis in the small intestine, but not in the colon compared 
with wild-type mice. In keeping with this, NFκB2-null mice showed reduced relative 
mRNA expression of the anti-apoptotic genes BCL2, BCL-XL, c-IAP2 and XIAP in the 
small intestine and down regulation of c-IAP2 and XIAP in the distal colon compared 
to untreated wild-type mice. No alterations in mitotic indices were observed in 
either the small intestine or colon of NFκB2-null mice relative to wild-type mice. 
Ishikawa et al have previously shown that a mouse model with deleted ankyrin 
repeats at the C-terminus of p100 (the precursor form of NFκB2) leading to 
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constitutive activation of p52 (the active form of NFκB2) showed marked gastric 
hyperplasia (300).  
Activation of NFκB is considered to be one of the important physiological responses 
of cells to external stresses such γ-irradiation. DNA damage induced by 8Gy γ-
irradiation has been shown to cause a 219-fold increase in small intestinal epithelial 
NFκB activity in wild-type mice and this activation mainly consisted of p50/RelA 
heterodimers (229) . However, ablation of the p50 (NFκB1) gene in mice resulted 
only in a 43-fold increase in small intestinal epithelial NFκB activity, consisting 
mainly of p52/RelA heterodimers, following the same treatment. NFκB1-null small 
intestinal epithelia have also been reported to show a significant increase in 
apoptosis 24 hours following 8Gy γ-irradiation (229). These findings suggest that 
although activation of the classical pathway of NFκB signalling appears to 
predominately occur in the small intestine following DNA damage, the alternative 
pathway is also implicated in regulating the small intestinal response to injury. In a 
previous study, abrogation of the classical NFκB activation pathway by selective 
intestinal deletion of IKKβ resulted in an increase in small intestinal epithelial 
apoptosis following γ-irradiation compared to similarly treated wild-type mice 
(251). With the exception of NFκB1 in the small intestine, the specific roles of other 
individual NFκB family members, particularly those involved in the alternative 
activation pathway in regulating DNA damage induced apoptosis in small intestinal 
and colonic epithelia have not previously been assessed. Additionally, the molecular 
changes associated with either perturbed classical or alternative NFκB activation 
pathways have not previously been investigated. In this current study, consistent 
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with previous studies, NFκB1-null mice demonstrated a significant increase in small 
intestinal crypt epithelial apoptosis 4.5 hours following 8Gy γ-irradiation relative to 
similarly treated wild-type mice. Although NFκB has not previously been shown to 
be activated in colonic epithelia following γ-irradiation (229), NFκB1-null mice also 
showed a significant increase colonic epithelial apoptosis following 8Gy γ-irradiation 
relative to wild-type animals. However, disruption of the same NFκB activation 
pathway (classical) by deleting c-Rel did not cause any alteration in the amount of 
epithelial apoptosis observed in either the small intestine or colon following γ-
irradiation compared to wild-type mice. This suggests that the role of the classical 
NFκB signalling pathway in limiting intestinal epithelial apoptosis after DNA damage 
is mediated through NFκB1-dependent but c-Rel-independent mechanisms. We 
provide the first evidence that alternative NFκB pathway signalling plays a role in 
the regulation of radiation induced intestinal epithelial apoptosis, as we observed 
increased irradiation induced epithelial apoptosis in both the small intestine and 
colon of NFκB2-null mice. 
For further evaluation of the specific roles of c-Rel, NFκB1 and NFκB2 in regulating 
DNA damage induced intestinal apoptosis, a chemical method of apoptosis 
induction was also investigated. Our findings showed that the small intestine was 
more susceptible to damage, apoptosis induction and mitosis suppression than the 
distal colon following administration of the chemotherapeutic agent irinotecan to 
wild-type mice. These differences in extent of tissue damage between the small 
intestine and the colon have previously been attributed to the finding that the in 
vivo intestinal concentration of irinotecan is highest in the ileum and lowest in the 
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colon (77). In comparison with untreated mice, c-Rel-null and NFκB1-null mice 
continued to show elongated colonic crypts 48 hours following irinotecan 
administration. In keeping with observations in previous irradiation studies, NFκB1-
null mice were more susceptible to irinotecan induced intestinal epithelial apoptosis 
in both the small intestine and colon and at both the 6 and 48 hour time points. 
Similar to the phenotype observed following irradiation, c-Rel-null mice did not 
show any altered apoptosis in the small intestine or in colon at both the 6 and 48 
hour time points following irinotecan administration compared to similarly treated 
wild-type mice. NFκB2-null mice, which were more susceptible to irradiation 
induced intestinal apoptosis, were also more susceptible to irinotecan induced 
apoptosis in both the small intestine and colon and at both the 6 and 48 hour time 
points compared to similarly treated wild-type animals. These observations at 6 and 
48 hours post irinotecan treatment at two sites within the intestine therefore 
reinforce our previous findings at 4.5 hours following 8Gy γ-irradiation. This 
suggests that classical NFκB pathway signalling via NFκB1, but not through c-Rel 
regulates the susceptibility of intestinal epithelia to apoptosis following two 
different types of DNA damage inducing stimuli. Additionally we provide evidence 
for major participation of the alternative NFκB activation pathway in regulating 
intestinal epithelial apoptosis following administration of two different types of 
injury.  
For the first time, the molecular mechanisms responsible for these altered 
responses have been investigated using quantitative PCR assays. In agreement with 
the observed increase in irradiation induced apoptosis observed in the intestinal 
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epithelia of NFκB1-null mice relative to their wild-type counterparts, NFκB1-null 
mice showed significant increases in the expression of the pro-apoptotic genes 
TRAIL and Caspase12 in the small intestine and TRAIL in the colon following 
irradiation compared to wild-type mice after the same treatment. Following 
irradiation, c-Rel-null mice did not show major alterations in the expression of the 
apoptosis regulating genes that were assessed either in the small intestine or colon 
relative to wild-type mice, with only a modest increase in the expression of anti-
apoptotic BCL-XL being observed in the small intestine.  
The increased susceptibility to irradiation-induced intestinal epithelial apoptosis 
observed in NFκB2-null mice was associated with significant increases in the 
expression of the pro-apoptotic genes Caspase12, BAK, p53 and FAS-L in the small 
intestine and Caspase12, TRAIL, and FAS-L in the colon. Noticeably, the increase in 
the transcriptional expression of FAS-L was substantial in both the small intestine 
(19-fold) and colon (21-fold) of NFκB2-null mice following irradiation relative to 
similarly treated wild-type mice. Thus, FAS-L may play a major role in the increased 
susceptibility to irradiation-induced intestinal epithelial apoptosis observed in 
NFκB2-null mice. It has previously been shown that TRAIL can induce apoptosis in 
normal colonic epithelial cells and that irinotecan can increase the susceptibility of 
these cells to TRAIL-induced apoptosis (301). TRAIL has not previously been shown 
to be a downstream target gene of NFκB in intestinal epithelia. In a previous study 
however it has been demonstrated that NEMO/IKKγ-dependent NFκB activation 
was required for the up-regulation of TRAIL in T cells (302). However, our data 
suggest that NFκB1-dependent classical activation pathway signalling in intestinal 
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epithelia leads to down-regulation of TRAIL. Although Caspase12 belongs to the 
inflammatory group of Caspases including Caspases 1, 4, 5 and 11 (303), it has been 
demonstrated that Caspase12 is processed in many pro-apoptotic conditions and 
thus it has been proposed that Caspase12 influences the apoptotic process (304). 
Caspase12 has not previously been shown to be a target gene of NFκB in the 
published literature. In this study, we provide strong evidence for a transcriptional 
regulation of Caspase12 expression by NFκB, as we demonstrate up-regulation of 
Caspase12 at two sites within the intestine (the small intestine and colon) and in 
both NFκB1-null and NFκB2-null strains of mice.  
It is important to bear in mind certain limitations that can influence the 
interpretation of our quantitative PCR results. For example, post transcriptional 
effects such as post-transcriptional decay of mRNAs may not lead to altered protein 
translation. Additionally, protein function can be affected by post translational 
modifications that do not directly depend on transcriptional regulation. However as 
the pathway under investigation relies on a transcription factor system, quantifying 
transcriptional levels can potentially determine the apparent functions of this 
pathway. For more robust analysis, our findings of the altered transcriptional 
expression of apoptosis regulating genes in these transgenic mice require further 
confirmation at the protein level either by immunohistochemical staining or 
Western blotting.  
Mitosis (as proliferation index) was suppressed in both the small intestine and colon 
of all groups of mice following irradiation, hence no significant alterations were 
observed between any strains of mice following this stimulus. Although c-Rel-null 
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and NFκB1-null mice continued to show elongated colonic crypts 48 hours following 
irinotecan treatment, no significant alterations in mitosis suppression were 
observed in either of these strains of mice at this time point. Similar to a study 
performed by Inan et al (230), we demonstrated that abrogation of the classical 
NFκB activation pathway either by deleting c-Rel or NFκB1 resulted in significant 
increases in distal colonic crypts lengths. However, this elongation of colonic crypts 
in c-Rel-null and NFκB1-null mice was not associated with any observed increase in 
cell proliferation (as determined by mitotic indices). In the cell cycle, the duration of 
the mitosis phase is relatively shorter than the S phase which marked by PCNA 
staining or in vivo BrdU labelling. Thus, the absolute numbers of mitotic figures are 
much less than the numbers of proliferating cells determined by PCNA staining or in 
vivo BrdU labelling. This may have been responsible for our inability to detect any 
significant alteration in proliferation. Moreover, as colonic crypt length is 
determined by the balance between the rates of cell input (proliferation) and 
output (apoptosis and cell shedding), other mechanisms may be responsible for the 
elongated colonic crypts that we observed in mice with an abrogated classical NFκB 
activation pathway. Future work is needed to assess intestinal epithelial 
proliferation in these animals using techniques such as immunohistochemical 
staining for PCNA or Ki67. Additionally, investigating intestinal epithelial shedding 
rates would be helpful to better characterise the role of NFκB in regulating 
intestinal epithelial homeostasis.  
In vitro studies involving NFκB2 siRNA transfection for a short period of time (up to 
3 days) resulted in reduction of the protein expression of the precursor form of 
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NFκB2 (p100), but not the processed form (p52) by approximately 45% at all-time 
points tested. The unchanged expression of p52 might be due to the stability and 
longer half-life of this protein. Therefore a longer time course was performed. 
Despite a greater reduction in the expression of the precursor form of NFκB2 (p100) 
(more than 80%) at 5 and 6 day time points, the expression of the processed form 
of NFκB2 (p52) was still not altered at all these longer time points. Although a 
similar pattern of increased protein abundance of p52 and p100 was observed 
following Etoposide (a chemotherapeutic agent) treatment, non-specific binding of 
the antibody to another similar sized protein to p52 cannot be excluded. However, 
suppression of NFκB2 expression (at least of its precursor form p100) in HCT116 
cells resulted in a significant reduction in cell proliferation in the un-stimulated 
condition and following administration of a DNA damage inducing stimulus 
(Etoposide). It has previously been shown that knockdown of NFκB2 expression in 
U-2 OS human osteosarcoma cells resulted in a significant decrease in cell 
proliferation and this was associated with downregulation of Cyclin D1. However, 
examination of cell cycle distribution of these NFκB2 siRNA treated cells, suggested 
that decreased Cyclin D1 expression could not account for all the effects on 
proliferation observed following NFκB2 (p52/p100) suppression. Therefore, a Cyclin 
D1-independent role of NFκB2 in regulating cell proliferation has been suggested 
(218). This might explain at least in part our findings that p100 suppression resulted 
in a decrease in HCT116 cell proliferation, without causing any change in Cyclin D1 
protein abundance. Our findings also indicate that NFκB2 inhibits the apoptosis of 
HCT116 cells following treatment with apoptosis inducing stimuli. This is consistent 
with previous findings which showed that lymphoma cell lines with constitutive 
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activation of NFκB were resistant to apoptosis induction and that suppression of 
p100 using siRNA resulted in a 2- to 3-fold increase in apoptosis following Etoposide 
treatment (294). The increased susceptibility to Etoposide-induced apoptosis 
following NFκB2 suppression in HCT116 cells was not associated with any changes in 
the protein expression of any of the assessed apoptosis regulating genes. However, 
this in vitro study was performed before the investigations of transcriptional 
expressions of 10 apoptosis regulating genes in the intestinal epithelia of NFκB2-null 
mice. It would therefore now be helpful to assess the protein expressions of those 
apoptosis regulating genes (such as TRAIL, Caspase12, FAS-L which showed altered 
expression in NFκB2-null mice in vivo) in HCT116 cells following NFκB2 siRNA 
treatment. However, time was not available to conduct these additional studies 
during my PhD.  
On the other hand, suppression of RelB protein expression by approximately 70% 
did not result in any alteration in HCT116 cell proliferation or apoptosis either with 
or without Etoposide treatment. Suppression of RelB protein expression was also 
not associated with any changes in the abundance of any of the assessed 
proliferation and apoptosis regulating proteins. In contrast to our findings in 
transformed intestinal epithelial cells, RelB has previously been shown to promote 
proliferation and inhibit apoptosis in transformed lymphocytes and breast cancer 
cells (305, 306). Our in vitro findings therefore suggest that NFκB2 but not RelB 
promotes colon cancer cell proliferation and similar to our in vivo observations in 
normal intestinal epithelial cells, NFκB2 inhibits apoptosis following DNA damage 
inducing stimuli.  
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Further work is required to further characterise the roles of both the classical and 
alternative NFκB activation pathways in regulating intestinal epithelial turnover. For 
example, studying DNA binding activity of specific NFκB proteins using 
electrophoretic mobility shift assays (EMSA) would provide a clearer picture of gene 
regulation by these proteins. It would also be interesting to assess transgenic mice 
with germline deletions of RelB, particularly their intestinal epithelial apoptotic 
responses in order to dissect the importance of individual components of the 
alternative NFκB activation pathway in regulating intestinal epithelial turnover. As 
NFκB can modulate both immune and intestinal epithelial cells responses, selective 
tissue deletions of various NFκB family members in either murine intestinal 
epithelial or immune cells could also help to determine the precise mechanisms 
involved in regulating intestinal epithelial turnover. This could be accomplished 
through either bone marrow chimaeras or transgenic technology. 
In summary, consistent with previous studies, we have shown that the classical 
NFκB activation pathway is implicated in regulating intestinal homeostasis and 
protects intestinal epithelia from apoptosis induced by two different types of DNA 
damage inducing stimuli. Our data suggest that this is mainly mediated by NFκB1-
dependent mechanisms. We also provide the first evidence that alternative NFκB 
pathway signalling via NFκB2 plays a major role in regulating intestinal epithelial 
apoptosis in vivo and in vitro. The increased susceptibility to intestinal apoptosis 
resulting from deletion of NFκB1 or NFκB2 may occur as a result of altered 
expression of a number of known NFκB dependent apoptosis regulating genes as 
well as the novel genes TRAIL and caspase12. NFκB1 and NFκB2 may therefore also 
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play important roles in regulating the susceptibility of intestinal epithelia to the 
consequences of DNA damage such as cancer.  
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4 The impact of deletion of various NFκB family of members 
on intestinal inflammatory responses 
4.1 Introduction 
NFκB is known to play crucial roles in regulating gastrointestinal inflammation. In 
particular, NFκB signalling has been implicated in the pathogenesis of inflammatory 
bowel disease (IBD). This has been mainly attributed to the pro-inflammatory 
function of NFκB through its transcriptional regulation of several genes which 
encode proteins that are involved in inflammation, including pro-inflammatory 
cytokines, cell surface receptors and adhesion molecules (264). However, several 
recent murine studies have also demonstrated an anti-inflammatory role for 
classical NFκB activation pathway in the intestine. This anti-inflammatory role has 
been attributed to the ability of NFκB to protect intestinal epithelial cells from 
apoptosis and necrosis, thus protecting tissue from damage and helping to maintain 
the intestinal barrier following injury. Therefore, NFκB can act indirectly in an anti-
inflammatory fashion (268). Similarly in previous studies, researchers have shown 
that specific intestinal deletion of IKKγ or both IKKα and IKKβ subunits, 
spontaneously resulted in the development of severe chronic intestinal 
inflammation in mice and impaired the expression of antimicrobial peptides and the 
translocation of bacteria into the mucosa (252). However, selective intestinal 
deletion of IKKβ or IKKα alone did not spontaneously induce colitis (249-251). This 
might be due to a compensatory mechanism exerted by either IKKα or IKKβ in the 
absence of the other subunit. The role of the alternative NFκB activation pathway or 
the specific roles of individual NFκB family members in modulating intestinal 
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inflammation have not previously investigated. In fact, there is only one previous 
study and this investigated the intestinal responses to a helminth parasite (Trichuris 
muris). In this study, unlike c-Rel deficient mice, NFκB1 and NFκB2 deficient mice 
were both unable to clear infection with this parasite, but only chronically infected 
NFκB1-null mice developed destructive colitis-like pathology (272). 
These recent studies have raised a concern about the potential of using NFκB 
inhibitors to treat IBD. A role of the alternative (via NFκB2) and the classical NFκB 
pathways (mainly mediated by NFκB1) in protecting intestinal epithelial cells from 
apoptosis following two types of stimuli was demonstrated in chapter 3. This 
suggests that the alternative activation pathway might also be implicated in 
modulating intestinal inflammatory responses. Therefore, the impact of deleting 
specific NFκB family members on intestinal inflammatory responses was 
investigated in this chapter. This was achieved utilising an established murine model 
of DSS-induced colitis. 
4.2 Aims 
To investigate the susceptibility of mice deficient in various NFκB family members to 
DSS-induced colitis and the molecular mechanisms responsible for any altered 
susceptibility. 
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4.3 Effects of deleting various NFκB family members on clinical 
parameters of DSS-induced colitis 
The clinical signs that developing following exposure to DSS for 5 days have been 
documented in several previous studies. These clinical signs are loss of body weight, 
loose faeces/watery diarrhoea and faecal blood/rectal bleeding (111). 
4.3.1 c-Rel-null and NFκB1-null mice showed significantly more body weight loss 
whereas NFκB2-null mice showed significantly less body weight loss 
following dextran sulphate sodium treatment 
C57BL/6, c-Rel-null, NFκB1-null and NFκB2-null mice (10 mice per strain) were 
administrated 2% DSS in their drinking water for 5 days to induce colitis. This was 
followed by one day of DSS-free water before they were sacrificed on day 6 after 
the start of the experiment. The body weight of these mice was recorded daily to 
monitor the percentage of body weight change as shown in Figure 4.1. Strikingly, 
NFκB2-null mice only lost 2.2% and 3.5% of their starting body weight on days 5 and 
6 respectively. This was significantly less than C57BL/6 mice which lost 8% and 
14.6% of their starting body weight on days 5 and 6 respectively from the start of 
the experiment. However, c-Rel-null and NFκB1-null mice both showed a significant 
2-fold increase in the percentage of body weight loss compared to wild-type mice 
on days 5 and 6. c-Rel-null mice showed 14% and 23% weight loss while NFκB1-null 
mice showed 14.7% and 23% weight loss on days 5 and 6 respectively (Figure 4.1). 
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Figure 4.1: Percentage weight change observed in mice during the course of 
dextran sulphate sodium induced colitis. 2% DSS was orally administered for 5 
days and mice were sacrificed on day 6. Percentage body weight change was 
recorded daily for C57BL/6 (blue), c-Rel-null (red), NFκB1-null (yellow) and NFκB2-
null mice (green). Data are presented as mean ± standard error of the mean. 
Statistical differences were assessed by one way ANOVA and Dunnett's multiple 
comparison test (*p<0.05, **p<0.01, ***p<0.001 compared to C57BL/6). (n=10 
male mice per genotype). 
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4.3.2 c-Rel-null and NFκB1-null mice showed significantly higher disease activity 
indices whereas NFκB2-null mice showed a significantly lower disease 
activity index following dextran sulphate sodium treatment 
To evaluate the general condition of mice, a disease activity index (DAI) ranging 
from 0 to 4 was calculated on daily basis. This was based on the following clinical 
parameters: weight loss, stool consistency and presence of rectal bleeding. 
Exposure of mice to DSS in their drinking water profoundly affected the general 
health of most strains of mice with the exception of the NFκB2-null strain and 
resulted in the development of weight loss and the production of loose, bloody 
stools. The disease activity index markedly increased from day 4 to day 6 at which 
point the mice were sacrificed. NFκB1-null mice showed an earlier onset of 
increased severity of the disease, which was significant at day 2 (Figure 4.2). The 
DAI was higher in c-Rel-null and NFκB1-null mice than C57BL/6 mice and this was 
significant at day 4 in c-Rel-null mice, and on days 2 and 3 in NFκB1-null mice. 
Consistent with the weight loss changes, NFκB2-null mice showed a lower DAI and 
this was significant on days 5 and 6 compared to wild-type mice (Figure 4.2). 
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Figure 4.2: Changes in disease activity index (DAI) (clinical score) during the course 
of dextran sulphate sodium induced colitis. 2% DSS was orally administered for 5 
days and mice were sacrificed on day 6. DAI was daily determined for C57BL/6 
(blue), c-Rel-null (red), NFκB1-null (yellow) and NFκB2-null mice (green). Data are 
presented as mean ± standard error of the mean. Statistical differences were 
assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison tests 
(*p<0.05, **p<0.01 compared to C57BL/6). (n=10 male mice per genotype). 
 
0 1 2 3 4 5 6
0
1
2
3
4
C57BL/6
c-Rel-null
NFB1-null
NFB2-null
* *
*
**
**
days
D
is
e
a
s
e
 A
c
ti
v
it
y
 I
n
d
e
x
 (
D
A
I)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
182 
 
4.4 Effects of deleting various NFκB family members on severity of 
histopathological changes in DSS-induced colitis 
Several previous studies have reported that the colon shortens during colitis 
induction and this has been proven to be a useful indicator of colitis severity (110, 
307, 308). Histological changes and inflammatory responses are typical microscopic 
features of colitis. Therefore, H and E stained colonic sections were examined under 
the light microscope to assess histological and inflammatory changes.  
4.4.1 c-Rel-null and NFκB1-null mice showed a significantly shorter colon 
whereas NFκB2-null mice showed a significantly longer colon following 
dextran sulphate sodium administration 
Mice were given 2% DSS in their drinking water for 5 days and were sacrificed on 
day 6. The colon was dissected and the entire colon length was measured to assess 
the colon shortening due to inflammation, scarring and damage. Colons from c-Rel-
null and NFκB1-null mice were significantly shorter and colons from NFκB2-null 
mice were significantly longer than those from C57BL/6 mice (Figure 4.3).  
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Figure 4.3: Colon lengths in mice subjected to DSS-induced colitis. 2% DSS 
was orally administered for 5 days and mice were sacrificed on day 6. 
Length of colon from C57BL/6 (blue), c-Rel-null (red), NFκB1-null (yellow) 
and NFκB2-null mice (green) was measured. Data are presented as mean ± 
standard deviation. Statistical differences were assessed by one way 
ANOVA and Dunnett's multiple comparison test (*p<0.05, ***p<0.001 
compared to C57BL/6). (n=10 male mice per genotype). 
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4.4.2 NFκB2-null mic  displayed less colonic inflammation following dextran 
sulphate sodium administration  
Following dissection, colons were divided into 3 segments, fixed, sectioned and 
stained with H and E for histological analysis. Distal colon from all untreated strains 
of mice had similar histological findings showing normal crypts without any 
noticeable inflammation (Figure 4.4 a, c, e and g). Histological assessment of DSS 
treated animals revealed severely damaged and inflamed distal colons from 
C57BL/6, c-Rel-null and NFκB1-null mice. The epithelial layer was completely 
destroyed and submucosal oedema was prominent. Neutrophils were the main type 
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of inflammatory cell infiltrate which was intense and present throughout the colon 
wall (Figure 4.4 b, d and f). A marked reduction in the severity of these histological 
changes was observed in the distal colon of NFκB2-null mice compared to all other 
strains of mice. Crypts maintained a normal morphological appearance with only 
mild histological damage observed. This was associated with only a mild 
inflammatory cell infiltrate that was predominantly confined to the mucosa and no 
oedema was observed in the submucosal layer (Figure 4.4 h).  
In order to translate the previous histological findings to a quantifiable measure of 
inflammation, a histological score was performed. This histological score, which has 
been described and validated previously, is based on the severity of inflammation 
and tissue damage (287). The severity of inflammation which was observed in the 
distal colon from DSS treated C57BL/6, c-Rel-null and NFκB1-null mice was matched 
by a higher histological score in these strains of mice. In agreement with previous 
observations, NFκB2-null mice displayed a significant lower score compared to their 
wild-type counterparts (Figure 4.5).  
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Figure 4.4: Microscopic examination of H/E stained distal colonic sections from 
untreated and 2% DSS treated mice. Histology (H/E) of distal colonic sections 
which were taken from C57BL/6 (a, b), c-Rel-null (c, d), NFκB1-null (e, f) and 
NFκB2-null (g, h) mice receiving either water (control) (a, c, e, g) or 2% DSS for 5 
days and sacrificed on day 6 (b, d f, h). (Arrows indicate damaged crypts with 
inflammatory cell infiltrate, triangles indicate the submucosal layer with oedema 
and inflammatory cell infiltrate). 
 
Untreated DSS treated
C57BL/6
NFκB1-null
c-Rel-null
NFκB2-null
a
c
b
d
e f
g h
 
186 
 
 
Figure 4.5: Histological (inflammation) scores of DSS-induced colitis in mice. 
Inflammation score of distal colon taken from C57BL/6 (blue), c-Rel-null (red), 
NFκB1-null (yellow) and NFκB2-null mice (green) which received 2% DSS for 5 days 
and were sacrificed on day 6. (Each dot represents a score from one mouse and 
data are presented as mean ± standard error of the mean, **p<0.01 by Kruskal–
Wallis test followed by multiple comparison Dunn’s test). 
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4.5 Intestinal expression of cytokine-encoding genes in DSS-induced 
colitis in mice deficient in various NFκB family members 
To investigate the mechanisms responsible for the differences in the susceptibility 
to DSS-induced colitis observed in mice lacking specific NFκB proteins, real-time PCR 
for several key cytokines was performed. Colitis was induced in adult male mice by 
oral 2% DSS administration for 5 days and mice were euthanased on day 6 (n=4 per 
group). Untreated mice of the same age were also sacrificed at the same time as 
control animals. The small intestine and colon were removed and processed for 
RNA extraction and subsequent cDNA quantification by real-time PCR as described 
in sections 2.7 and 2.8. 
The small intestine is not the target organ of DSS treatment and therefore these 
cytokines were assesses in the small intestine of only the untreated groups of mice. 
This allowed us to evaluate the effect of deleting specific NFκB family members on 
the small intestinal mRNA expression of these cytokines namely TNF-α, IL-β, IFN-γ, 
IL-4, IL-6 and IL-14. All the transgenic strains assessed did not show any significant 
alteration in the small intestinal mRNA expression of the assessed cytokines 
compared to wild-type mice with the exception of significant increases in IL-14 and 
IFN-γ in the small intestinal samples from NFκB1-null and NFκB2-null mice 
respectively relative to wild-type mice (Figure 4.6).  
Generally, the abundance of the assessed cytokines was low in the colons of 
untreated mice. In C57BL/6 mice, all the assessed cytokines showed massive 
dynamic changes in the distal colon in response to DSS treatment. DSS treatment 
caused huge increases in the abundance of most of the assessed cytokines which 
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reached approximately a 600-fold increase in some cases compared to untreated 
wild-type distal colon (Figure 4.7). 
The colon of untreated NFκB1-null mice demonstrated small increases in the mRNA 
levels of TNF-α and IL-14 but these did not reach statistical significance when 
compared to untreated wild-type mice. Consistent with the clinical and histological 
findings described above, the relative mRNA expressions of IL-1β and IL-6 were 
significantly increased in colonic samples from NFκB1-null mice following DSS 
administration relative to wild-type mice following the same treatment (Figure 4.7).  
The relative mRNA expressions of the assessed cytokines in untreated c-Rel-null 
mouse colon were similar to those in untreated wild-type colon. Following DSS 
administration however, c-Rel-null mice also showed a similar pattern of dynamic 
changes in the assessed cytokines compared to wild-type mice. Despite the 
increased clinical severity of colitis observed in c-Rel-null mice following 2% DSS 
treatment, the transcriptional expression of colonic TNF-α was significantly less in 
DSS-treated c-Rel-null mice than in DSS treated wild-type mice.  
The transcriptional expression of the pro-inflammatory cytokine IFN-γ was reduced 
in all transgenic mice relative to C57BL/6 mice (Figure 4.7). Hence, it is unlikely that 
IFN-γ contributes to the differences in colitis susceptibility which were seen 
between the different transgenic mice. 
No significant alterations were observed in the mRNA expression of the assessed 
cytokines in the colons of untreated NFκB2-null mice compared to wild-type mice. 
In agreement with the clinical and histological observations described above, we 
observed a significant suppression of the relative mRNA expression of the pro-
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inflammatory cytokine TNF-α and a significant increase in the transcriptional 
expression of the anti-inflammatory cytokine IL-4 in colonic tissue from DSS-treated 
NFκB2-null mice compared to wild-type mice following the same treatment. This 
increase in the transcriptional expression of IL-4 in the colon of NFκB2-null mice 
following 2% DSS was approximately 400-fold relative to wild-type mice following 
the same treatment. Additionally, the mRNA abundance of the other assessed pro-
inflammatory cytokines was generally less in NFκB2-null colon than wild-type mice 
following DSS administration, but these differences were not statistically significant 
with the exception of IFN-γ as mentioned above (Figure 4.7). 
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Figure 4.6: Quantification of relative mRNA expression of several cytokines in 
the small intestine of untreated mice. Relative mRNA expression of TNF-α (a), IL-
4 (b), IL-1β (c), IL-6 (d), IFN-γ (e) and IL-14 (f) in small intestinal epithelial cells 
from untreated strains of mice as indicated above using real-time PCR. Data are 
presented as mean ± standard error of the mean. Statistical analysis was 
performed by 1-way ANOVA with Bonferroni post-hoc tests (**p<0.01, 
***p<0.001 compared C57BL/6) (n=4 mice per genotype group). 
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Figure 4.7: Quantification of relative mRNA expression of several cytokines in the 
colon of untreated and 2% DSS treated mice. Relative mRNA expression of TNF-α 
(a), IL-4 (b), IL-1β (c), IL-6 (d), IFN-γ (e) and IL-14 (f) in the colon of untreated 
animals and 5 days following 2% DSS treatment in the strains of mice indicated 
above using real-time PCR. Data are presented as mean ± standard error of the 
mean. Statistical analysis was performed by 2-way ANOVA with Bonferroni post-
hoc tests (*p<0.05, ***p<0.001 compared to similarly treated C57BL/6) (n=4 mice 
per genotype group). 
 
TNF-
Untreated 2%DSS
0.00
0.04
0.5
1.0
1.5
2.0
C57BL/6
c-Rel-null
NFB1-null
NFB2-null
***
*
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
IL-1
Untreated 2%DSS
0.00
0.04
2
4
6
C57BL/6
c-Rel-null
NFB1-null
NFB2-null
*
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
IFN-
Untreated 2%DSS
0.00
0.04
0.5
1.0
1.5
2.0
C57BL/6
c-Rel-null
NFB1-null
NFB2-null
***
******R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
IL-6
Untreated 2%DSS
0.000
0.001
10
20
30
40
50
60
70
80
C57BL/6
c-Rel-null
NFB1-null
NFB2-null
*
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
IL-4
Untreated 2%DSS
0
4
8
100
200
300
400
500
600
700
800
C57BL/6
c-Rel-null
NFB1-null
NF-kB2 null
***
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
IL-14
Untreated 2%DSS
0.00
1.00
2.00
3.00
C57BL/6
c-Rel-null
NFB1-null
NFB2-null
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
a
e
c
b
f
d
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
192 
 
4.6 Discussion  
In this chapter, mice deficient in various NFκB family members were used to dissect 
the importance of specific NFκB family members in the development of 
experimental colitis. DSS-induced colitis in mice is a recognised model for human 
ulcerative colitis and shares similar manifestations. However, the mechanism by 
which DSS induces colitis remains unclear. Several mechanisms have been proposed 
such as direct toxic effects on colonic epithelial cells, by altering the microbiota and 
by activation of macrophage inflammatory responses (110). Like human IBD, DSS-
induced colitis in mice is manifested by clinical signs such as body weight loss, rectal 
bleeding and diarrhoea. Additionally colitis in this model has histological similarities 
to those observed in humans (309). To increase the accuracy of this study, colitis 
was therefore assessed on the basis of both clinical and histological manifestations. 
Data in this chapter clearly demonstrate the importance of both the classical and 
alternative pathways of NFκB signalling in regulating acute colonic intestinal 
inflammatory responses. Disrupting the classical NFκB activation pathway by 
deleting c-Rel or NFκB1 resulted in increased susceptibility of mice to developing 
DSS-induced colitis. Both c-Rel-null and NFκB1-null mice showed more weight loss 
than wild-type mice at days 5 and 6 following DSS administration. The disease 
activity index was also significantly higher in c-Rel-null and NFκB1-null mice than 
wild-type mice. In addition, the colons from mice with either c-Rel or NFκB1 
deletions were significantly shorter than those from their wild-type counterparts. 
Finally microscopic examination revealed extensive damage and increased 
inflammatory cell infiltration in wild-type, c-Rel-null and NFκB1-null mice. However, 
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this technique did not allow detection of differences in inflammatory scores 
between these strains of mice. These findings suggest that the classical activation 
pathway of NFκB signalling plays an anti-inflammatory role in the colon. NFκB has 
long been thought the prototypical pro-inflammatory signalling pathway that is 
implicated in the pathogenesis of IBD. This is demonstrated for example by its 
activation by pro-inflammatory cytokines and by its role in the transcriptional 
regulation of these cytokines (205). In keeping with this, genetic manipulations that 
result in increased NFκB activity have been shown to cause inflammation-related 
pathologies (310). Additionally, it has been shown that in vivo suppression of NFκB 
activity in certain tissues resulted in attenuation of inflammatory responses (250, 
311). In the colon, it has been demonstrated that inhibition of NFκB by an antisense 
oligonucleotide for RelA (P65) (266) or by a small-molecule inhibitor of IKKβ (267) 
resulted in attenuation of inflammation in a murine model of colitis. However, 
several recent murine studies unexpectedly demonstrated that specific deletion of 
IKKγ in intestinal epithelial cells resulted in the development of a spontaneous 
colitis (252) and deletion of IKKβ from intestinal epithelial cells resulted in increased 
inflammation in the DSS-induced colitis model (250, 268). This implies that classical 
NFκB pathway signalling in non-immune, epithelial cells might play an anti-
inflammatory role. This anti-inflammatory function has been attributed to the 
ability of NFκB to promote epithelial cell survival and maintenance of tissue 
integrity (243). In a recent study, the mechanisms responsible for the anti-
inflammatory role of classical NFκB pathway signalling in intestinal epithelial cells 
were investigated. Selective deletion of IKKβ in murine intestinal epithelia was 
associated with more severe mucosal inflammation 16 days after a course of 5 days 
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of DSS in drinking water. To exclude the possibility that the increased inflammation 
observed in these mice was due to increased early damage induced by increased 
apoptosis in IKKβ deficient enterocytes (250), wild-type mice were treated with a 
highly specific IKKβ inhibitor (ML120B) following completion of DSS treatment, and 
histological examination was performed on day 10 after the start of DSS 
administration. Similar to enterocyte specific IKKβ genetic deletion, pharmacological 
inhibition of IKKβ resulted in more severe mucosal inflammation relative to vehicle-
treated controls. These results indicate that the anti-inflammatory function of IKKβ 
in intestinal epithelial cells is independent of the initial damage (268). Furthermore, 
as described in a previous study, NFκB has a pro-apoptotic role in neutophils during 
inflammation, which might represent an additional anti-inflammatory mechanism 
played by NFκB during the development of acute inflammation (2, 312, 313). In 
agreement with these studies, data in this chapter have shown that c-Rel and 
NFκB1, which are both involved in the classical NFκB activation pathway have an 
overall anti-inflammatory role in the colon. Similarly, in a recent study conducted by 
Steinbrecher et al, selective intestinal deletion of RelA was shown to increase 
intestinal epithelial apoptosis and aggravate acute intestinal inflammation in a 
murine model of DSS-induced colitis (271). 
In humans, a previous study has identified a polymorphism within the NFκB1 
promoter (termed -94ins/delATTG) and the variant allele with a 4-bp deletion (-
94delATTG) has been shown to be associated with decreased promoter activity 
(314). Several recent studies have investigated the association of this functional 
polymorphism of NFκB1 with IBD. Some of these studies have found an association 
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between this polymorphism and IBD (315, 316). However, other studies have not 
detected any association between this polymorphism and IBD (317-319). Genome-
wide association studies have recently identified 99 susceptibility loci/genes that 
are significantly associated with ulcerative colitis and/or Crohn’s disease. Rel gene 
which encodes c-Rel is one of these genes which have been shown to confer 
susceptibility to both colitis and Crohn’s disease (82, 320, 321).  
 As we showed in chapter 3, NFκB1 deletion caused increased intestinal epithelial 
apoptosis following administration of two different stimuli. This loss of barrier 
function could lead to increased exposure of mucosal immune cells to luminal 
contents and trigger a more severe inflammatory response. Thus, disruption of the 
intestinal epithelial barrier might be a plausible explanation for the increased 
clinical severity of colitis which was observed in NFκB1-null mice. Although c-Rel-
null mice did not show an increase in intestinal epithelial apoptosis following γ-
irradiation or irinotecan treatment compared to wild-type mice, c-Rel deletion also 
sensitised mice to DSS-induced colitis. This supports the notion that the classical 
NFκB activation pathway has an additional function in intestinal epithelia beyond 
protection against apoptosis and its anti-inflammatory function is also mediated by 
other mechanisms which are independent of the initial damage (268).  
Given the importance of cytokines in regulating inflammation, the mRNA expression 
of several cytokines was assessed to investigate the molecular mechanisms 
responsible for the increased colitis susceptibility observed in c-Rel-null and NFκB1-
null mice. Pro-inflammatory cytokines have previously been shown to play a vital 
role in the pathogenesis of inflammatory bowel diseases. It has been reported that 
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inflammatory bowel disease is associated with up-regulation of several pro-
inflammatory cytokines such as TNF-α, IL-1β and IL-6 (322, 323). As expected, the 
quantification of the transcriptional expression of several key cytokines namely 
TNF-α, IL-1β, IFN-γ, IL-4, IL-6 and IL-14 in this study, revealed dynamic changes in 
response to DSS treatment. Consistent with the increased severity of colitis 
observed in NFκB1-null mice, the relative mRNA expressions of IL-1β and IL-6 were 
significantly increased in colonic samples from NFκB1-null mice following DSS 
administration relative to similarly treated wild-type mice. Moreover, NFκB1-null 
distal colon also demonstrated small increases in the mRNA expression of the pro-
inflammatory cytokines TNF-α and IL-14, but these increases were not statistically 
significant. It has been shown that IL-1β expression is increased in the colorectal 
mucosa in patients with ulcerative colitis during the acute phase of the disease 
(324-326). It has also been demonstrated that administration of an anti-murine IL-
1β antibody reduced the weight loss and shortening of colon in a model of 
experimental colitis induced by DSS treatment (327). The importance of IL-6 in 
colonic inflammation has come from various studies which have shown up-
regulation of tissue and circulating IL-6 and sIL-6R abundance in patients with acute 
Crohn’s disease and ulcerative colitis (328-330). Additionally, it has been shown that 
treatment of mice with an anti-IL-6 receptor antibody ameliorated intestinal 
inflammation in murine models of experimental colitis. Recent studies have also 
demonstrated that mice deficient in IL-6 were partially protected from 
development of TNBS-induced (331) and DSS-induced (332) acute experimental 
colitis. Hence, the more severe colitis observed in NFκB1-null mice might be 
explained by a significant transcriptional up-regulation of IL-1β and IL-6 in colonic 
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samples from DSS-treated NFκB1-null mice compared to similarly treated wild-type 
mice. However, the increased susceptibility of c-Rel mice to DSS-induced colitis was 
associated with a significant decrease in the mRNA expression of TNF-α and was not 
associated with any increase in the mRNA expression of the other assessed 
cytokines relative to similarly treated wild-type mice. It has been shown that c-Rel is 
transcriptional activator for TNF-α in the peritoneal macrophages and in c-Rel 
deficient mice, these cells were shown to secrete lower amounts of TNF-α than 
wild-type cells following their stimulation (333). This suggests that the assessed 
cytokines are unlikely to be involved in determining the increased susceptibility of c-
Rel-null mice to DSS-induced colitis and thus the mechanism responsible for 
increased colitis severity in c-Rel-null mice is different from NFκB1-null mice. Given 
that the severity of colonic inflammation depends on the overall changes of all 
cytokines, other cytokines that were not assessed in this study could be involved.  
In contrast to the findings in NFκB1-null and c-Rel-null mice, NFκB2 deletion 
(disrupting the alternative NFκB activation pathway) resulted in resistance of mice 
to developing colitis. This was manifested by measurement of both clinical and 
histological parameters. Although, the colons of NFκB2-null mice were more 
susceptible to epithelial apoptosis following two different types of damage inducing 
stimuli (as shown in the chapter 3), they showed significantly less inflammation and 
damage following DSS administration compared to wild-type mice. For the first time 
therefore, we have shown an important role of the alternative NFκB activation 
pathway in regulating colonic inflammatory responses. Genetic manipulation of the 
two major components of the alternative pathway RelB and NFκB2, has previously 
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demonstrated a vital role of this pathway in lymphoid organogenesis (204). 
Moreover, studies of RelB and NFκB2 deficient mice have demonstrated important 
roles for these proteins in regulating dendritic cell function and in the generation of 
cellular immunity (232, 334). For example, RelB-null mice demonstrated T cell 
mediated inflammation in multiple organs and showed impaired cell-mediated 
immunity (233). However, the role of these components of the alternative pathway 
in regulating intestinal inflammation has not been previously studied in vivo. Here 
for the first time, we have demonstrated that disruption of the alternative pathway 
by deleting NFκB2 resulted in protection of mice from developing the severe colitis 
which was observed in wild-type animals. To investigate the underlying mechanisms 
responsible for the reduced colonic inflammation observed in NFκB2-null mice, the 
mRNA abundance of several cytokines were assessed by real-time PCR. NFκB2-null 
mice showed a significant reduction in the transcriptional expression of the pro-
inflammatory cytokine TNF-α and a significant increase in the transcriptional 
expression of the anti-inflammatory cytokine IL-4 following DSS treatment, 
compared to similarly treated wild-type mice.  
Nenci et al demonstrated that TNF-α was involved in the pathogenesis of colitis 
observed in IKKγ-null mice (252). It has been suggested that TNF-α orchestrated the 
inflammatory response in IKKγ-null colon by enhancing stromal, endothelial and 
immune cells to up-regulate the expression of pro-inflammatory cytokines and 
chemokines leading to the subsequent recruitment and activation of inflammatory 
cells. Alternatively, TNF-α might act on intestinal epithelial cells to induce epithelial 
apoptosis and facilitate bacterial translocation to induce a high inflammatory 
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response (270). TNF-α is a potent pro-inflammatory cytokine and its inhibition in 
human patients by targeted therapy is an effective treatment for IBD (270, 335, 
336). 
 IL-4 is considered to be an anti-inflammatory cytokine. It inhibits the secretion of 
the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 by monocytes for prolonged 
periods of time (337). This inhibition by IL-4 has been shown to be impaired in IBD. 
The IL-4-mediated suppression of secretion of these pro-inflammatory cytokines has 
been thought to be a crucial inflammation limiting function (338). A study 
conducted by Togawa et al illustrated that lactoferrin (Natural immunomodulator) 
exerted an anti-inflammatory effect in rats subjected to TNBS-induced colitis via 
induction of IL-4 and IL-10 secretion (339). A previous study conducted by Melgar et 
al, also showed very low protein levels of IL-4 in the colon following induction of 
DSS-induced colitis (7). However, there are also a limited number of studies that 
have revealed a pro-inflammatory role of IL-4 in intestinal inflammation (340, 341). 
Taken together, the substantial attenuation of DSS-induced colitis observed in 
NFκB2-null mice might be mediated by the significant down-regulation of the pro-
inflammatory cytokine TNF-α and by up-regulation of anti-inflammatory IL-4.  
Collectively, this chapter demonstrates that disruption of the classical NFκB 
signalling pathway by deleting NFκB1 or c-Rel exacerbated colonic inflammation and 
damage during the development of acute intestinal inflammatory conditions. 
Consistent with previous studies, the classical pathway therefore appears to play an 
overall anti-inflammatory function in the colon. The increased susceptibility of 
NFκB1-null, but not c-Rel-null mice to DSS-induced colitis might be mediated by up-
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regulation of IL-1β and IL-6. This therefore has negative implications for the 
potential therapeutic use of classical NFκB pathway inhibitors in IBD. However, 
disruption of the alternative pathway by deleting NFκB2 substantially protected 
murine colon from developing acute inflammation following DSS administration and 
this was associated with reduced transcriptional expression of the pro-inflammatory 
cytokine TNF-α and increased transcriptional expression of the anti-inflammatory 
cytokine IL-4. Thus, this study provides the first evidence of a major role of the 
alternative NFκB activation pathway in regulating colonic inflammation. In contrast 
to the classical activation pathway, the NFκB2-dependent alternative NFκB 
activation pathway appears to play an overall pro-inflammatory function in the 
colon. This finding raises the potential of specific inhibition of NFκB2 as a therapy 
for IBD treatment. However current conclusions have been based on an acute colitis 
model. Thus, further studies in a DSS-induced chronic colitis model are required to 
assess the outcome of deletion of NFκB2 or other NFκB family members on chronic 
colitis. This will be described in the next chapter by exposing mice to repeated 
cycles of a lower DSS concentration to avoid the death of mice before the end of 
the experiment.  
Given that NFκB can modulate intestinal inflammatory responses by acting on both 
immune and intestinal epithelial cells, our current experiments have not yet 
distinguished which compartment plays the dominant role. Therefore, selective 
tissue deletion of specific NFκB family members either in epithelial or immune cells 
could help to determine the exact cellular mechanisms responsible for the altered 
susceptibility to DSS-induced colitis observed in transgenic mice. This could be 
performed by utilising either bone morrow chimaeras or transgenic technology. 
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Investigating the susceptibility to DSS-induced colitis in mice with a germline 
deletion of RelB would also help to characterise of the role of individual members of 
the alternative NFκB activation pathway in regulating intestinal inflammation. Since 
the increased susceptibility to colitis in NFκB1-null mice and the reduced severity of 
colitis in NFκB2-null mice were associated with particular cytokine responses, it 
would be also useful to investigate the outcome of using pharmacological or 
transgenic methods to manipulate these responses. For example, it would be 
interesting to assess whether administering an anti-IL-6 receptor antibody to 
NFκB1-null mice rescued these animals from developing an increased severity of 
colitis following DSS treatment.  
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5 The impact of deletion of specific NFκB family members 
on inflammation associated colonic carcinogenesis 
5.1 Introduction 
The contribution of NFκB signalling to cancer promotion and progression has been 
well documented in several recent studies. Hanahan and Weinberg suggested that 
tumourigenesis requires six essential alterations to normal cell physiology that 
collectively lead to neoplastic growth: self-sufficiency in growth signals, insensitivity 
to growth-inhibitory (antigrowth) signals, evasion of programmed cell death 
(apoptosis), limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis (177). NFκB is a key regulator of cell survival and apoptosis 
in a cell type and stimulus dependent manner. Dysregulation of the cell cycle and 
apoptotic process following DNA damage is believed to contribute to cancer 
development and progression (177). Therefore, NFκB may promote carcinogenesis 
when its activation enhances cell survival and inhibit carcinogenesis when its 
activation leads to cell death. Chronic inflammation sometimes occurs after the 
development of colorectal cancer, which is initially caused without any obvious 
inflammation (276). Although NFκB activation has been observed in many 
inflammation related cancers, it has been suggested that inflammation is not 
involved in tumour promotion in all cases of cancer (342). It was shown in chapter 3 
that both NFκB1 and NFκB2 have a strong anti-apoptotic role in intestinal epithelia 
and that they protect intestinal epithelial cells from apoptosis following two types 
of DNA damage inducing stimuli. This suggests that these NFκB family members 
may have important roles in regulating colonic carcinogenesis. Given that NFκB’s 
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functions depend on tissue context, these roles should be specifically investigated in 
the setting of inflammation associated colonic carcinogenesis. 
In addition to the central role of NFκB in promoting cancer cell survival, it also 
functions in a paracrine manner to enhance cancer cell growth. Several recent 
studies have suggested that the inflammatory process is mainly mediated by 
activation of the NFκB pathway (236). Persistent activation of NFκB in epithelial cells 
has been linked to the development of inflammation-associated cancer as 
demonstrated in colitis-associated cancer (CAC). This suggests that persistent NFκB 
activation in epithelial cells in response to chronic inflammation is a key factor in 
the process of intestinal carcinogenesis (250, 343). This is illustrated by several 
mouse models of inflammation-associated cancer (241, 250). Mouse models of CAC 
provide direct evidence that classical NFκB signalling (IKKβ-dependent classical NFκB 
activation) links inflammation and cancer. In one model of CAC, deleting IKKβ 
selectively in intestinal epithelial cells resulted in a reduction in tumour incidence 
and this effect was attributed to increased apoptosis of IKKβ deficient-epithelial 
cells. However, deleting IKKβ specifically in myeloid cells reduced tumour number 
and size without affecting apoptosis. This decrease in tumour size resulted from 
reduced expression of pro-inflammtory cytokines which are required for tumour 
growth (250). The expression of major inflammatory factors such as TNFα, IL-1, IL-6, 
IL-8 is regulated by NFκB and these cytokines in turn activate NFκB expression. This 
therefore represents a positive feedback loop whereby cellular and DNA damage 
promote cell proliferation and transformation, ultimately leading to the initiation, 
promotion and progression of cancer (175, 273, 275). However, the role of the 
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alternative pathway and the specific roles of NFκB family members in inflammation 
associated colon cancer have not previously been investigated. In chapters 3 and 4 
of this thesis, it was shown that specific NFκB family members belonging to either 
the classical or alternative activation pathways differentially regulate intestinal 
epithelial cell survival and colonic inflammation. This suggests that specific NFκB 
family members from both pathways may differentially regulate the development 
of inflammation related colon cancer. Therefore, this hypothesis was investigated 
using a murine model of colitis associated cancer. 
5.2 Aims 
To investigate the susceptibility of mice deficient in various NFκB family 
members to inflammation associated colonic carcinogenesis using a murine 
model of colitis associated colon cancer. 
To investigate the cellular mechanisms responsible for any altered 
susceptibility to colitis associated colon cancer in mice deficient in various 
NFκB family members by assessing the amount of intestinal epithelial 
proliferation and apoptosis in response to the pro-carcinogen azoxymethane 
(AOM). 
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5.3 Effects of deleting specific NFκB family members on susceptibility 
to inflammation associated colon tumours 
To evaluate the role of specific NFκB family members in intestinal carcinogenesis, 
the susceptibility of mice deficient in various NFκB family members to initiating 
intestinal solid tumour formation particularly inflammatory driven colonic tumours 
was assessed using a murine model of colitis associated cancer. 
5.3.1 Finding the optimal DSS concentrations for the colitis associated tumour 
experiment (AOM/DSS regimen) 
As demonstrated in chapter 4, 2% DSS administration for 5 days resulted in a 
dramatic loss of body weight (more than 20%) and severe toxicity at day 6 
particularly in c-Rel-null and NFκB1-null strains of mice. Hence, it was necessary to 
optimise the DSS concentration for the repeated cycles of DSS administration which 
were required for colitis associated tumour induction, in order to avoid the death of 
mice before the end of the experiment. Therefore the effects of various lower DSS 
concentrations on the body weight of the susceptible animal strains (c-Rel-null and 
NFκB1-null mice) were assessed for 10 days following the start of DSS 
administration (Figure 5.1). Groups of mice (3 to 5 mice per group from c-Rel-null 
and NFκB1-null strains) received a particular DSS concentration (1.5%, 1%, 0.75% or 
0.5% DSS) in their drinking water for 5 days and were sacrificed on day 10. Body 
weight loss was assessed throughout the whole experiment. All mice that received 
1.5% DSS became severely ill and showed a substantial loss of weight before dying 
between days 5 and 8 (Figure 5.1 a). Two mice which received 1% DSS lost more 
than 20% of their body weight before dying between days 6 and 9. The remaining 
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two mice treated with 1% DSS survived until day 10, but one was very ill and lost 
27.9% of its body weight and did not show any signs of recovery (Figure 5.1b). 
Groups of mice that received either 0.75% or 0.5% DSS lost weight which was more 
profound in the 0.75% DSS group but they were able to survive and recover (and 
regain weight) before being sacrificed at day 10, with the exception of one mouse 
from the 0.75% DSS group which died before day 9 (Figure 5.1 c and d). Therefore 
0.5% and 0.75% DSS concentrations were chosen as the doses for subsequent cycles 
of AOM/DSS administration in the following experiments.  
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Figure 5.1: Percentage weight change observed in mice following different 
concentrations of dextran sulphate sodium administration. 1.5% (a), 1% (b), 
0.75% (c) and 0.5% DSS (d) was orally administered to groups of mice from c-
rel-null and NFκB1-null strains as indicated for 5 days and mice were 
sacrificed on day 10. Percentage body weight change was daily recorded. 
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5.3.2 c-Rel-null and NFκB1-null mice showed a significant increase and NFκB2-
null mice a substantial decrease in weight loss following AOM/DSS regime 
In order to evaluate the severity of colitis in mice deficient in various NFκB family 
members during the course of tumour induction, mice were weighed daily and % 
body weight loss was determined as an indicator of the severity of colitis. 5 days 
following a single dose of 12.5mg/kg AOM (pro-carcinogen), DSS was orally 
administrated to mice for 5 days and this was followed by 16 days of DSS-free 
water. This cycle was repeated twice and mice were sacrificed 12 days after the last 
DSS cycle. 0.5% DSS was used in the first cycle and because this was very well 
tolerated the dose was increased to 0.75% DSS for the second and third cycles as 
illustrated in Figure 5.2 a. 
Similar to the observations from mice which were treated with DSS alone as shown 
in chapter 4, c-Rel-null and NFκB1-null mice treated with AOM/DSS appeared to be 
more susceptible to developing colitis (as determined by weight loss during the DSS 
cycles) particularly during the 0.75% DSS cycles. During the second cycle of DSS, % 
body weight loss in both c-Rel-null and NFκB1-null mice was significantly increased 
(maximum approximately 11%) compared to wild-type mice (maximum 
approximately 3%). This increased susceptibility to DSS-induced colitis was even 
more pronounced in c-Rel-null mice in the last DSS cycle where they lost more than 
20% of their body weight compared to 7.8% and 7% body weight loss seen in 
NFκB1-null and wild-type mice respectively (Figure 5.2 b). Consistent with the 
observations following 2% DSS treatment shown in chapter 4, NFκB2-null mice lost 
less weight than wild-type mice particularly during the third DSS cycle and this was 
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statistically significant (Figure 5.2 b). These observations along with previous 
findings in chapter 4 suggest that deletion of the classical NFκB family member c-Rel 
or NFκB1 sensitised mice to DSS-induced colitis whereas deleting the alternative 
NFκB family member NFκB2 resulted in resistance to developing DSS-induced colitis. 
Body weight loss is a characteristic clinical feature of DSS-induced colitis and 
positively correlates with the activity of the disease. Hence, c-Rel-null and NFκB1-
null mice may have more colonic inflammation, while NFκB2-null mice may have 
less colonic inflammation compared to their wild-type counterparts during the 
course of tumour induction. However, the increased body weight loss seen in c-Rel-
null mice may also have resulted from increased colon tumour load rather than due 
to increased severity of DSS-induced colitis. 
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Figure 5.2: Colitis-associated cancer model and percentage of weight change 
observed in mice during the course of AOM/DSS treatment. 5 days following a 
single dose of 12.5mg/kg AOM (pro-carcinogen), DSS was orally administrated 
to mice for 5 days and this was followed by 16 days of DSS-free water. This 
cycle was repeated twice and mice were sacrificed 12 days after the last DSS 
cycle (a). Percentage of body weight change was recorded for C57BL/6 (blue), c-
Rel-null (red), NFκB1-null (yellow) and NFκB2-null mice (green) throughout the 
AOM/DSS course (b). Data are presented as mean ± standard error of the mean. 
Statistical differences were assessed by one way ANOVA and Dunnett's multiple 
comparison test (*p<0.05, **p<0.01, ***p<0.001 compared to C57BL/6). (n=10 
male mice per genotype). 
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5.3.3 Deleting c-Rel increased colitis associated tumour incidence whereas 
deleting NFκB2 greatly reduced colitis associated tumour incidence 
Mice were administered a single dose of 12.5mg/kg AOM (pro-carcinogen) followed 
by three cycles of DSS as illustrated in Figure 5.2 a. Repeated DSS exposure induces 
chronic inflammation in the colon that resembles human IBD. This in turn greatly 
increases the incidence of AOM-induced tumours in the colon (108). In this study, 
all mice from the different genotypes that underwent AOM/DSS treatment 
developed colonic tumours with the exception of 40% of the NFκB2-null mice which 
did not develop any detectable tumours. Tumours were mainly located within the 
distal and middle thirds of the colon as shown in Figure 5.3. This tumour location 
correlates with the parts of the colon that show severe inflammatory changes 
following DSS administration (110). c-Rel deficient mice which were more 
susceptible to colitis showed a larger number of AOM/DSS-induced tumours. These 
tumours coalesced together and only minimal normal intervening colonic mucosa 
was apparent. In contrast, the tumours which developed in wild-type mice were 
more scattered in the colon and were separated by larger areas of normal colonic 
mucosa. On the other hand, NFκB2-null mice, which more resistant to developing 
colitis either did not develop tumours or only a few small polyps were seen (Figure 
5.3). Microscopic examination of H and E stained colonic sections showed that, 
these tumours were mainly broad-based adenomas and they did not penetrate the 
muscularis mucosa in any genotype group (Figure 5.4). 
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Figure 5.3: Macroscopic view of longitudinally open colon from mice following 
tumour induction by AOM/DSS treatment as illustrated in Figure 5.2 a. After 
washing the longitudinally open colon with saline, images were taken. A scaled 
ruler was used to measure the size of the formed tumours. Tumour load was 
markedly increased in c-Rel-null colon and substantially reduced or absent in 
NFκB2-null colon compared to C57BL/6 (wild-type) colon (green arrows indicate 
visible tumours). 
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Figure 5.4: Photomicrographs of representative H and E stained colonic sections 
from mice following tumour induction by AOM/DSS treatment. Histology (H/E) 
of colonic tumours in sections (Swiss roll) from C57BL/6 (a, b), c-Rel-null (c, d), 
NFκB1-null (e, f) and NFκB2-null (g, h) mice following AOM/DSS treatment at 4x 
objective magnification (a, c, e, g) and 40x objective magnification (b, d f, h). 
(Arrows indicate the formed polyps). 
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Following careful macroscopic inspection, the number and size of colonic tumours 
was determined. c-Rel-null mice showed a significant 3.5-fold increase in the 
number of colonic tumours relative to wild-type mice (Figure 5.5). These tumours 
were also larger in size than those observed in C57BL/6 animals (Figure 5.6). 
However, NFκB1-null mice which were also more sensitive to colitis development 
did not show any increase in the number or size of colonic tumours relative to wild-
type mice as shown in Figure 5.5 and Figure 5.6. On the other hand, disruption of 
the alternative pathway by deleting NFκB2 resulted in a decrease of 77% in the 
number of tumours compared to wild-type mice (Figure 5.5). The colonic tumours 
which developed in NFκB2-null mice were also smaller than those seen in wild-type 
mice (Figure 5.6). Additionally, 40% of NFκB2-null mice did not develop any colonic 
tumours. This substantial decrease in tumour incidence and size seen in NFκB2-null 
mice correlated with the reduced severity of colitis that was also observed in this 
strain of mice following administration of either DSS alone or AOM/DSS.  
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Figure 5.5: Tumour incidence in mice following colitis associated tumour 
induction using AOM/DSS. Number of visible colonic tumours per mouse in 
C57BL/6 (blue), c-Rel-null (red), NFκB1-null (yellow) and NFκB2-null (green) 
genotypes was determined following AOM/DSS administration (as illustrated in 
Figure 5.2). Statistical differences were assessed by one way ANOVA and 
Dunnett's multiple comparison test (**p<0.01, ***p<0.001 compared to 
C57BL/6). (n=10 male mice per genotype). 
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Figure 5.6: Size distribution of AOM/DSS induced colonic tumours in mice. 
Following tumour induction by AOM/DSS treatment as illustrated in Figure 5.2 a, 
the diameter of visible colonic tumours in C57BL/6 (blue), c-Rel-null (red), 
NFκB1-null (yellow) and NFκB2-null (green) animals was measured using a ruler. 
Percentages of tumours with a diameter <1mm, 1-2mm or >2mm to total 
tumours in the same strain of mice were determined as shown above. 
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5.3.4 Deleting c-Rel significantly increased the proliferation rate of colonic 
tumour cells induced by AOM/DSS treatment 
Given that proliferation is an important cellular process for tumour growth, the 
differences in tumour size which were observed between the different genotypes of 
mice might have arisen due to differences in the proliferation rates of neoplastic 
cells within polyps. Therefore, a proliferation (Ki67) index was determined in these 
tumours by counting the number of Ki67 positive neoplastic cells per 0.25mm2 area 
in the tumour section which showed the highest Ki67 staining for each mouse as 
described in section 2.4.5. In addition to this quantitative measure, the grade of 
dysplasia of AOM/DSS induced tumours was reported by a qualified veterinary 
pathologist (Jonathon Williams) blinded to the genotype of mice. Consistent with 
the increased incidence and increased proportion of larger tumours observed in c-
Rel-null mice, the tumours in these animals showed a significantly increased 
proliferation index and a greater percentage of these tumours also showed high-
grade dysplasia compared to their wild-type counterparts (Figure 5.7,Figure 5.8 and 
Figure 5.9). Although, NFκB2-null mice showed a greater percentage of tumours 
measuring <1mm diameter and with low-grade dysplasia compared to wild-type 
mice, no differences in tumour proliferation indices were observed in this genotype 
of mice compared to wild-type animals. Tumours from NFκB1-null mice exhibited 
no alteration in proliferation index or in degree of dysplasia compared to wild-type 
mice as shown in Figure 5.7, Figure 5.8 and Figure 5.9.  
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Figure 5.7: Photomicrographs of Ki67 immunohistochemistry of representative 
colonic sections from mice following tumour induction by AOM/DSS. Ki67 
positive cells are shown in colonic sections (Swiss roll) from C57BL/6 (a), c-Rel-
null (c), NFκB1-null (e) and NFκB2-null (g) mice following AOM/DSS treatment 
(as illustrated in Figure 5.2) at 5x objective magnification (tumours are 
indicated by arrows). b, d f and h shows Ki67 positive cells in these  tumours 
(marked by arrows) at 40x objective magnification. 
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Figure 5.8: Proliferation index of colonic tumours in mice subjected to 
colitis associated cancer regimen. Following AOM/DSS administration, 
colonic sections were subjected to Ki67 immunohistochemical staining. A 
proliferation index was then determined by counting the number of Ki67 
positive cells per 0.25mm2 area of the tumour which showed the highest 
Ki67 staining in each mouse. Statistical differences were assessed by one 
way ANOVA and Dunnett's multiple comparison test (***p<0.001 
compared to C57BL/6). (n=5-9 male mice per genotype as 4 NFκB2-null 
mice did not develop colonic tumours and some of the colonic sections 
particularly from this strain did not include any tumour tissue. 
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Figure 5.9: Degree of dysplasia in AOM/DSS induced colonic tumours in mice. 
Degree of dysplasia (either low-grade or high-grade) of AOM/DSS induced 
colonic tumours was reported by a veterinary pathologist blinded to genotype 
of mice. Percentage of tumours with either low-grade or high-grade dysplasia 
relative to total tumours in the same strain of mice is shown. 
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5.4 Effects of deleting specific NFκB family members on intestinal 
crypt regeneration 
Impairment of the regulation of cell proliferation following injury is considered to 
be a potential trigger of carcinogenesis. Thus, investigating the role of specific NFκB 
family members in regulating intestinal epithelial cell proliferation following injury 
may help to reveal the cellular mechanisms responsible for the differential 
susceptibility to colitis associated tumourigenesis observed in c-Rel-null and NFκB2-
null mice. Therefore, the effect of deleting specific NFκB family members on 
intestinal crypt regeneration following whole body γ-irradiation was assessed. Mice 
deficient in various NFκB family members along with wild-type mice (5 mice per 
genotype group) were subjected to a single dose of 12Gy γ-irradiation and then 
sacrificed 96 hours later. Regenerating crypts were scored from H and E stained 
small intestinal and colonic sections. NFκB2-null mice demonstrated a significant 
reduction in small intestinal crypt regeneration compared with wild-type mice, but 
no significant alterations in small intestinal crypt regeneration were observed in 
either c-Rel-null or NFκB1-null mice as shown in Figure 5.10 and Figure 5.12 a. 
However in the colon, c-Rel-null mice showed a significant increase in colonic crypt 
regeneration while NFκB1-null and NFκB2-null mice did not demonstrate any 
significant change in colonic crypt regeneration as shown in Figure 5.11 and Figure 
5.12 b. These findings suggest that NFκB2 deletion suppresses epithelial crypt 
regeneration (proliferation) in the small intestine and that c-Rel deletion increases 
epithelial regeneration in the colon following injury.  
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Figure 5.10: Representative photomicrographs showing small intestinal 
crypt regeneration in mice subjected to 12Gy γ-irradition and killed 96 
hours later along with untreated mice. Histological assessment (H/E) of 
small intestinal sections taken from C57BL/6 (a, b), C-Rel-null (c, d), 
NFκB1-null (e, f) and NFκB2-null (g, h) mice. Mice were either untreated 
(a, c, e, g) or subjected to 12 Gy γ-irradition and sacrificed 96 hours later 
(b, d, f, h). Regenerating small intestinal crypts in irradiated mice are 
indicated by arrowheads. 
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Figure 5.11: Representative photomicrographs showing colonic crypt 
regeneration in mice subjected to 12Gy γ-irradition and killed 96 hours later 
along with untreated mice. Histological assessment (H/E) of colonic sections 
taken from C57BL/6 (a, b), C-Rel-null (c, d), NFκB1-null (e, f) and NFκB2-null (g, 
h) mice. Mice were either untreated (a, c, e, g) or subjected to 12 Gy γ-irradition 
and sacrificed 96 hours later (b, d, f, h). Regenerating colonic crypts in irradiated 
mice are indicated by arrowheads. 
 
 
C57BL/6
NFκB1-null
c-Rel-null
NFκB2-null
Untreated 12Gy γ-irradiation
a
c
e
g
b
d
f
h
 
 
224 
 
 
Figure 5.12: Small intestinal and colonic crypt survival in mice 96 
hours after 12Gy γ-irradiation. Small intestinal crypt survival (a) and 
colonic crypt survival (b) in different genotypes of mice as indicated 
above 96 hours following 12 Gy of γ-irradiation. Statistical 
differences assessed by one way ANOVA and Dunnett's multiple 
comparison test (*p<0.05, ***p<0.001 compared to C57BL/6). (n=5 
male mice per genotype). 
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5.5 Effects of deleting specific NFκB family members on intestinal 
epithelial mitosis and apoptosis 8 and 24 hours following 
carcinogen (azoxymethane) administration 
Given the importance of apoptosis and proliferation in carcinogenesis, intestinal 
epithelial apoptosis and mitosis were assessed at 8 and 24 hours following 
administration of the carcinogen azoxymethane (AOM). These initial responses of 
intestinal epithelial cells to the carcinogen at two different time points might reveal 
the principal cellular mechanisms responsible for the altered susceptibility to colitis 
associated carcinogenesis observed in mice deficient in various NFκB family 
members. This possibility is supported by the observations from NFκB1-null and 
NFκB2-null mice shown in chapter 3. We demonstrated increased susceptibility to 
intestinal epithelial apoptosis in these genotypes of mice following γ-irradiation and 
irinotecan. Therefore, a single dose of 10mg/kg carcinogen (AOM) was injected 
intraperitoneally into all groups of mice. Small intestinal and colonic epithelial 
mitosis and apoptosis were assessed 8 and 24 hours following (6 male mice per 
genotype group at each time point). 
5.5.1 NFκB2-null mice were more susceptible to small intestinal epithelial 
apoptosis at both 8 and 24 hours following AOM treatment 
Small intestinal crypt epithelial apoptosis and mitosis were quantified from H and E 
stained small intestinal sections from mice killed either at 8 or 24 hours after 
10mg/kg AOM. Mitosis was observed mainly in the lower 2/3 of small intestinal 
crypts and was suppressed in all strains of mice 8 and 24 hours following AOM 
treatment (see the basal levels of small intestinal mitosis in chapter 3). No 
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significant differences were observed between any of the genotypes of mice (Figure 
5.13). Small intestinal crypt epithelial apoptosis was induced in all strains of mice at 
both 8 and 24 hours following AOM (see the basal levels of small intestinal 
apoptosis in chapter 3) and maximum apoptosis were observed at cell position 5. 
Only NFκB2-null mice showed a significant increase in the amount of small intestinal 
crypt apoptosis and this was observed at both 8 and 24 hours following AOM 
compared to similarly treated C57BL/6 mice. Significant differences in apoptotic 
scores were observed at cell positions 2 to 14 and 3 to 17 at the 8 and 24 hour time 
points respectively in NFκB2-null small intestine relative to wild-type mice following 
the same treatment by the modified median test (Figure 5.14).  
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Figure 5.13: Quantitative analysis of small intestinal crypt epithelial mitosis 8 
and 24 hours after 10mg/kg AOM (i.p). Mean mitotic index 8 hours (a) and 24 
hours (b) following 10mg/kg AOM in small intestine separated by genotype as 
indicated above. Mean number of mitotic figures per hemi-crypt 8 hours (c) 
and 24 hours (d) following 10mg/kg AOM in small intestine separated by 
genotype as indicated above. Cell positional distribution of mitotic scores 8 
hours (e) and 24 hours (f) following 10mg/kg AOM in small intestine 
separated by genotype as indicated above. Statistical differences were 
assessed by Kruskal–Wallis test followed by Dunn’s multiple comparison tests 
in (a), (b), (c) and (d). Statistical differences were assessed by modified 
median test in (e) and (f). (n=6 per genotype group). 
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Figure 5.14: Quantitative analysis of small intestinal crypt epithelial apoptosis 8 
and 24 hours after 10mg/kg AOM (i.p). Mean apoptotic index 8 hours (a) and 24 
hours (b) following 10mg/kg AOM in small intestine separated by genotype as 
indicated above. Mean number of apoptotic events per hemi-crypt 8 hours (c) 
and 24 hours (d) following 10mg/kg AOM in small intestine separated by 
genotype as indicated above. Cell positional distribution of apoptotic scores 8 
hours (e) and 24 hours (f) following 10mg/kg AOM in small intestine separated 
by genotype as indicated above. Statistical differences were assessed by one way 
ANOVA and Dunnett's multiple comparison tests in (a), (b), (c) and (d) (**p<0.01, 
***p<0.001 compared to C57BL/6). Statistical differences were assessed by 
modified median test in (e) and (f). Dashed line denotes cell positions over which 
there was a significant difference in apoptotic scores compared to wild-type. 
Colour of dashed line denotes comparison genotype (n=6 per genotype group). 
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5.5.2 c-Rel-null mice showed persistent colonic epithelial mitosis and NFκB2-null 
mice showed increased colonic epithelial apoptosis at 8 and 24 hours 
following AOM treatment 
Following administration of 10mg/kg AOM to C57BL/6, c-Rel-null, NFκB1-null and 
NFκB2-null mice, distal colons were harvested after either 8 or 24 hours. The 
amounts of colonic crypt epithelial mitosis and apoptosis were again quantified 
using H and E stained sections. Mitosis was suppressed in all strains of mice at both 
time points compared to the corresponding untreated similar strain of mice (see the 
basal colonic mitosis in chapter 3) and mitosis was mainly observed in the lower half 
of colonic crypts. However, colonic epithelial mitosis was suppressed to a lesser 
extent in c-Rel-null mice and remained significantly higher than similarly treated 
C57BL/6 mice by 4- fold at the 8 hour time point and 2.5-fold at the 24 hour time 
point. The significant differences in mitotic scores in c-Rel-null colon were observed 
at cell positions 10 to 12 at the 8 hour time point and 5 to 10 at the 24 hour time 
point using the modified median test (Figure 5.15). These findings of persistent 
elevated mitosis observed in c-Rel-null colon at two different time points following 
AOM administration are compatible with the increased colonic crypt regeneration 
observed in c-Rel-null mice following irradiation compared to similarly treated wild-
type mice. Both NFκB1-null and NFκB2-null mice did not show any changes in 
colonic epithelial mitosis at 8 and 24 hours following AOM compared to wild-type 
mice following the same treatment (Figure 5.15). 
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Figure 5.15: Quantitative analysis of colonic crypt epithelial mitosis 8 and 24 
hours after 10mg/kg AOM (i.p). Mean mitotic index 8 hours (a) and 24 hours (b) 
following 10mg/kg AOM in the colon separated by genotype as indicated above. 
Mean number of mitotic figures per hemi-crypt 8 hours (c) and 24 hours (d) 
following 10mg/kg AOM in the colon separated by genotype as indicated above. 
Cell positional distribution of mitotic scores 8 hours (e) and 24 hours (f) following 
10mg/kg AOM in the colon separated by genotype as indicated above. Statistical 
differences were assessed by one way ANOVA and Dunnett's multiple 
comparison tests in (a), (b), (c) and (d) (*p<0.05, ***p<0.001 compared to 
C57BL/6).  Statistical differences were assessed by modified median test in (e) 
and (f). Dashed line denotes cell positions over which there was a significant 
difference in mitotic figures compared to wild-type. Colour of dashed line 
denotes comparison genotype (n=6 per genotype group). 
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AOM-induced colonic crypt epithelial apoptosis occurred predominantly at the crypt 
base in all strains of mice. Similar to observations in the small intestine, NFκB2-null 
mice also showed a significant increase in susceptibility to colonic apoptosis at both 
8 (as determined by increased mean apoptotic events per hemi-crypt) and 24 hour 
time points following AOM relative to their wild-type counterparts following the 
same treatment. Significant differences in apoptotic scores were also observed at 
cell positions 5 to 9 at 8 hours following AOM in NFκB2-null colon relative to wild-
type mice using the modified median test (Figure 5.16). However, disruption of the 
classical NFκB activation pathway by deleting c-Rel but not NFκB1 resulted in a 
significant decrease in colonic crypt apoptosis at 24 hours following AOM compared 
to similarly treated wild-type mice (Figure 5.16). 
 In summary therefore, c-Rel deletion was associated with increased colonic 
epithelial mitosis at the 8 hour and 24 hour time points and decreased colonic 
epithelial apoptosis at the 24 hour time point following carcinogen (AOM) 
administration. NFκB2 deletion was associated with increased small intestinal and 
colonic epithelial apoptosis at both 8 and 24 hour time points following AOM 
administration. 
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Figure 5.16: Quantitative analysis of colonic crypt epithelial apoptosis 8 and 24 
hours after 10mg/kg AOM (i.p). Mean apoptotic index 8 hours (a) and 24 hours 
(b) following 10mg/kg AOM in the colon separated by genotype as indicated 
above. Mean number of apoptotic scores per hemi-crypt 8 hours (c) and 24 
hours (d) following 10mg/kg AOM in the colon separated by genotype as 
indicated above. Cell positional distribution of apoptotic scores 8 hours (e) and 
24 hours (f) following 10mg/kg AOM in the colon separated by genotype as 
indicated above. Statistical differences were assessed by one way ANOVA and 
Dunnett's multiple comparison tests in (a), (b), (c) and (d) (*p<0.05 compared 
to C57BL/6).  Statistical differences were assessed by modified median test in 
(e) and (f). Dashed line denotes cell positions over which there was a significant 
difference in apoptotic scores compared to wild-type. Colour of dashed line 
denotes comparison genotype (n=6 per genotype group). 
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5.6 Discussion 
The findings in this chapter have shown that deleting either c-Rel or NFκB1 from the 
germline of mice was associated with increased severity of colitis following DSS 
administration. However, only deletion of c-Rel was associated with a significant 
increase in the number of colonic tumours and these were also larger than those 
observed in wild-type mice following administration of the colitis associated tumour 
regimen. On the other hand, NFκB2 deletion resulted in a marked reduction in the 
severity of colitis and an associated decrease in both the number and size of colonic 
tumours compared to wild-type mice following administration of the same colitis 
associated tumour regimen. Nowadays, a positive correlation between 
inflammation and cancer in many tissues is widely accepted. This relationship is 
particularly evident in the human gastrointestinal tract where ulcerative colitis and 
Crohn’s disease are both associated with an increased risk for developing colon 
cancer (153, 344, 345). This positive relationship between IBD and colon cancer has 
also been demonstrated in animal models of colitis associated colon cancer (346-
348). Consistent with these observations, the marked decrease in the severity of 
DSS-induced colitis observed in NFκB2-null mice was associated with a substantial 
reduction in tumour load, and the increased severity of colitis observed in c-Rel-null 
mice was associated with an increased colonic tumour load.  
Several previous reports have described a pro-inflammatory role for NFκB in the 
intestine (267, 349). However, several recent studies have also demonstrated an 
anti-inflammatory function of NFκB in the colon. For instance, it has been 
demonstrated that selective disruption of the classical NFκB activation pathway by 
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deleting IKK-β specifically in intestinal epithelial cells resulted in increased severity 
of DSS-induced colitis (268). Moreover, Greten et al (250) showed that selective 
deletion of IKK-β (resulting in disruption of the classical NFκB activation pathway) in 
either intestinal epithelial or myeloid cells exacerbated the severity of DSS-induced 
colitis and resulted in a marked reduction in tumour incidence in a mouse model of 
colitis associated cancer. In relation to the role of classical NFκB activation pathway 
in regulating intestinal inflammation, the results of these studies correlate with our 
findings that have shown increased colitis severity following administration of DSS 
alone (as described in chapter 4) or AOM plus DSS in both c-Rel-null and NFκB1-null 
mice. In contrast to the decreased susceptibility to colitis associated cancer 
observed in animals with either IKK-β deficiency in intestinal epithelial or myeloid 
cells as described by Greten et al (250), we have demonstrated that disruption of 
the classical NFκB activation pathway by germline deletion of c-Rel but not NFκB1 
was associated with an increased susceptibility to colitis associated carcinogenesis.  
Colorectal carcinogenesis can be divided into three stages: tumour initiation, 
tumour promotion and tumour progression. At tumour initiation, cellular DNA is 
mutated, resulting in activation of proto-oncogenes and inhibition of tumour 
suppressor genes. This initiated cell then enters into a tumour promotion phase 
which is characterised by increased cell proliferation and/or decreased apoptosis. 
The third stage of carcinogenesis is tumour progression which involves invasion, 
metastasis and an increase in tumour size (177, 348). It has been shown that 
inflammation may affect all these stages of tumourigenesis in various ways. Several 
pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6, whose transcriptional 
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expressions are regulated by the classical NFκB activation pathway, have been 
shown to contribute to tumour development (350). Several previous studies which 
have used various murine models of inflammation associated cancer have shown 
that NFκB’s ability to enhance tumour growth can also be attributed to its role in 
modulating the tumour microenvironment via the transcriptional induction of 
inflammatory mediators such as pro-inflammatory cytokines (175, 351).  
The study of inflammation associated cancer conducted by Greten et al (250) and 
discussed above suggested that the IKK-β-dependent NFκB activation pathway links 
inflammation to cancer in the colon, and also explored the mechanisms by which 
inflammation enhances tumour promotion and progression. The authors of this 
paper demonstrated that IKK-β-dependent NFκB activation in the epithelium 
promoted carcinogenesis by inhibiting apoptosis in chemically induced 
premalignant cells. However, IKK-β-dependent NFκB activation in myeloid cells 
enhanced the production of pro-inflammatory cytokines (such as IL-1β and IL-6) in 
order to influence tumour promotion in colitis associated cancer. Our findings show 
that global disruption of the classical NFκB activation pathway by germline deletion 
of c-Rel but not NFκB1 resulted in a significant increase in the number and size of 
colonic tumours in a murine model of colitis associated cancer. Consistent with this 
increased tumour incidence, c-Rel-null mice also demonstrated increased severity 
of colitis. We investigated whether this was related to altered tumour cell 
proliferation and detected a significant increase in proliferation (Ki67) index in 
tumours from c-Rel-null mice compared to those from their wild-type counterparts.  
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IKK-β is an upstream component of the classical NFκB activation pathway compared 
to the NFκB family members c-Rel and NFκB1. Therefore, IKK-β deletion can globally 
affect all downstream components of the classical NFκB activation pathway. This 
may partially explain the differences between the effects of deleting IKK-β and 
deleting the classical NFκB family members c-Rel and NFκB1 during colitis 
associated carcinogenesis.  
On the other hand, disrupting the alternative NFκB activation pathway by deleting 
NFκB2 resulted in a substantial reduction in the severity of colitis and in the number 
and size of colonic tumours compared to wild-type mice following administration of 
the colitis associated tumour regimen. This finding represents the first direct 
evidence for an important role for the alternative NFκB activation pathway in 
regulating inflammation associated carcinogenesis in the colon. This finding of 
reduced susceptibility to the effects of AOM/DSS is consistent with our observations 
in the acute experimental colitis model following administration of DSS alone as 
described in chapter 4. Additionally, we detected reduced transcriptional 
expression of the pro-inflammatory cytokine TNF-α and increased transcriptional 
expression of the anti-inflammatory cytokine IL-4 in NFκB2-deficent colon 6 days 
following 2% DSS administration. In a recent study, in addition to its role in colitis, 
TNF-α has been shown to be directly implicated in the development of colitis 
associated carcinogenesis (343). Given the importance of inflammation and the 
direct role of the pro-inflammatory cytokine TNF-α in colitis associated 
carcinogenesis, the reduced colonic tumour number and size observed in NFκB2-
null mice following AOM/DSS administration may possibly result from impaired 
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production of TNF-α and overproduction of IL-4. This hypothesis could be further 
investigated by assessing the mRNA and/or protein expression of these along with 
other cytokines in all strains of mice following AOM/DSS administration.  
A previous study that explored the anti-inflammatory role of NLR family pyrin 
domain containing 12 (Nlrp12) protein in the colon conducted by Zaki et al. The 
researchers in this study showed that the increased colonic inflammation and 
tumour burden observed in Nlrp12-deficient mice was associated with increased 
activity of the classical NFκB activation pathway (352). These observations were also 
confirmed in a recent publication by Allen et al (353). However, in agreement with 
our observations, this study also showed that the increased colonic inflammation 
and tumour burden observed in Nlrp12-deficient mice was associated with 
increased activation of the alternative NFκB pathway (353). The authors suggested 
that Nlrp12, through its interaction with NIK and subsequent interference with the 
processing of the precursor form of NFκB2 (p100) to generate the active form p52, 
represents a robust negative regulator of the alternative NFκB activation pathway, 
and that the modest in increase in classical NFκB signalling following Nlrp12 loss 
may be mediated by the fact that the alternative NFκB activation pathway can 
influence the classical NFκB activation pathway via IKK-α and TRAF3-dependent 
mechanisms (353-355).  
Enhanced cell proliferation and escape from apoptosis are the key features of neo-
plastic transformed cells during the tumour promotion phase. Indeed the 
chemopreventive properties of several drugs are mainly based on their ability to 
induce apoptosis during the tumour promotion stage. As already discussed, the 
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NFκB family of transcription factors are considered to be major regulators of 
apoptosis and cell cycle progression (241, 356). Therefore, it appears that in 
addition to its crucial role in inflammation induced tumour promotion, NFκB plays 
an important role in tumour promotion by regulating cell apoptosis and 
proliferation. We firstly used a crypt regeneration assay as a tool to measure crypt 
intestinal epithelial cell proliferation in different strains of mice. NFκB2 deficient 
mice showed reduced crypt regeneration in the small intestine while c-Rel deficient 
mice demonstrated a marked increase in crypt regeneration in the colon 96 hours 
following 12Gy γ-irradiation. This suggests that NFκB2 loss suppresses epithelial cell 
proliferation in the small intestine whereas c-Rel loss enhances epithelial cell 
proliferation in the colon following injury. Thus the increased tumour incidence in c-
Rel-null mice may be caused by enhanced colonic epithelial cell proliferation 
following exposure of these animals to the AOM/DSS regimen.  
Thus, we also measured intestinal crypt epithelial mitosis and apoptosis at two 
different time points following carcinogen (AOM) administration. In the small 
intestine, no alterations in mitotic indices were observed between any genotype of 
mice at either 8 or 24 hour time points following AOM administration. However in 
the colon, c-Rel-null mice showed a marked increase in epithelial mitosis at both 8 
and 24 hour time points and an associated inhibition of colonic epithelial apoptosis 
24 hours following carcinogen (AOM) administration relative to their wild-type 
counterparts. These findings suggest that the increased tumour load observed in c-
Rel-null mice may also be mediated by the increased proliferation and suppressed 
apoptosis of epithelial cells following initiation by the carcinogen. Therefore, the 
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increased susceptibility of c-Rel-null mice to colitis associated carcinogenesis may 
be mediated by two mechanisms. The first is related to the ability of c-Rel to 
suppress proliferation and induce apoptosis of pre-neoplastic cells initiated by the 
carcinogen and to its suppression to proliferation within AOM/DSS induced 
tumours. The second mechanism is attributed to the ability of c-Rel to suppress 
inflammation which subsequently inhibits tumour promotion and progression.  
NFκB2-null mice showed significant increases in small intestinal and colonic crypt 
epithelial apoptosis at both 8 and 24 hours following AOM compared to similarly 
treated C57BL/6 mice. In addition to the reduced severity of colitis observed in 
NFκB2-null mice, these findings provide an additional mechanism which may 
contributed to the reduced tumour incidence observed in NFκB2-null mice. During 
colorectal carcinogenesis, deleting DNA-damaged cells by apoptosis represents a 
key mechanism for reducing the load of mutated cells and this subsequently 
reduces the risk of neoplastic transformation and cancer formation (357, 358). 
Various published studies have suggested that non-steroidal anti-inflammatory 
drugs (NSAID) reduce the risk of colon cancer via various mechanisms. One of these 
is by induction of cell apoptosis (282, 342, 359-361). This supports our suggestion 
that the increased AOM-induced apoptosis observed in the intestinal epithelia of 
NFκB2-null mice is a second cellular mechanism which contributes to the reduced 
tumour incidence observed in this genotype of mice. 
Taken together, the results presented in this chapter suggest that disruption of the 
classical NFκB activation pathway particularly by deleting c-Rel increases 
susceptibility to developing colitis and colitis associated carcinogenesis. Along with 
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our observations in chapter 4, this provides additional evidence for an anti-
inflammatory function of the classical NFκB activation pathway in the colon. In 
addition to increased colonic inflammation, enhanced proliferation and suppressed 
apoptosis of tumour initiated cells are likely to be cellular mechanisms which 
contribute to the increased tumour number and size which was observed in c-Rel-
null animals. Together, these studies clearly indicate that inhibition of the classical 
NFκB activation pathway in the colon might lead to serious consequences and that 
classical NFκB activation pathway inhibitors as a therapy for IBD are unlikely to be 
helpful. Conversely, abrogation of the alternative NFκB activation pathway by 
deleting NFκB2 dramatically protected animals from developing colitis and colitis 
associated carcinogenesis following AOM/DSS administration. The reduced number 
and size of tumours observed in the colon of NFκB2-null mice might be explained by 
the increased apoptosis of tumour initiated cells and reduced severity of colonic 
inflammation observed in these animals following AOM and DSS administrations 
respectively. Hence, we suggest that specific inhibition of NFκB2 may be a 
promising therapeutic strategy for treating IBD and might also reduce the risk of 
cancer development in such patients. It would however first be useful to determine 
the individual contributions of epithelial and immune cells towards the altered 
susceptibility to colitis associated carcinogenesis observed in c-Rel-null and NFκB2-
null mice. Bone marrow chimaeras and transgenic technology are possible methods 
for investigating these mechanisms. This might help to determine the optimal 
approach for NFκB2 inhibition as a therapy for IBD and as a chemopreventive agent 
for colitis associated cancer. This may avoid unnecessary inhibition of NFκB2 in 
other cell types where NFκB2 activity may be protective against inflammation 
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rather than having a pro-inflammatory function. Although alterations in cell 
proliferation and survival have been identified as cellular mechanisms likely to be 
responsible for the altered susceptibilities to colitis associated carcinogenesis 
observed in c-Rel-null and NFκB2-null animals, the precise molecular mechanisms 
have not yet been investigated. It would therefore also be interesting to assess the 
expression of various cell cycle and apoptosis regulating genes in these genotypes 
of mice following carcinogen (AOM) administration as previously described in 
chapters 3 and 4 following administration of γ-irradiation and DSS. 
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6 Discussion  
6.1 Main findings and subsequent concepts 
It is now widely accepted that the NFκB family of transcription factors is a major 
regulator of various physiological and pathological processes such as proliferation, 
apoptosis, inflammation and carcinogenesis (202, 362, 363). Evidence from 
numerous studies has indicated that the pro-inflammatory role, particularly of the 
classical NFκB activation pathway is implicated in the pathogenesis of inflammatory 
bowel diseases. However, several recent studies which have investigated the effects 
of disrupting upstream components of this pathway have provided compelling 
evidence for a new paradigm of contradictory cytoprotective and pro-inflammatory 
functions of classical NFκB signalling in the intestine. However, the specific role of 
the alternative NFκB activation pathway and the functions of individual members of 
the NFκB family in regulating the susceptibility of the intestine to apoptosis, 
inflammation and carcinogenesis have not been well defined to date. We therefore 
aimed to investigate the specific roles of individual members of NFκB family of 
transcription factors in regulating intestinal epithelial cell turnover at baseline and 
in response to two types of injury in vivo and one type of cellular injury in vitro. 
Given that epithelial cell survival and proliferation are critical processes that 
influence intestinal inflammation and colorectal carcinogenesis, the roles of 
individual members of NFκB family in regulating intestinal inflammation and its 
associated carcinogenesis were also assessed. Most of the aims of this thesis were 
addressed using various mice that were deficient in individual NFκB family 
members. 
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6.1.1 Effects of deleting specific NFκB family members of the classical activation 
pathway 
Deleting the classical NFκB family member NFκB1 resulted in elongation of murine 
small intestinal and colonic crypts, while deleting c-Rel resulted only in elongation 
of colonic crypts under baseline physiological conditions. These findings are in 
keeping with a previous study by Inan et al who demonstrated that NFκB1-null mice 
had longer colonic crypts and a more extensive proliferative zone than their wild-
type counterparts (230). Although this thesis showed reduced relative mRNA 
expression of several anti-apoptotic genes in the intestinal epithelia of untreated 
NFκB1-null mice, I was not able to detect any changes in basal amounts of apoptosis 
in these genotypes of animals relative to their wild-type counterparts. 
8Gy γ-irradiation has previously been shown to cause a 219-fold increase in NFκB 
activity in the small intestinal epithelia of wild-type mice and this activation occurs 
mainly through classical NFκB pathway signalling, which is dominated by p50/RelA 
heterodimers (229). Disruption of this pathway by deleting either NFκB1 (229) or 
IKKβ (251) sensitised the small intestinal epithelia of these animal to irradiation-
induced apoptosis compared to similarly treated wild-type mice. In agreement, the 
small intestinal epithelial cells of NFκB1-null mice in this thesis were highly 
susceptible to undergoing apoptosis 4.5 hours following 8Gy γ-irradiation relative to 
similarly treated wild-type mice. Although NFκB activation has not previously been 
quantified in colonic epithelia following γ-irradiation (229), we also showed that 
deleting NFκB1 sensitised colonic epithelia to irradiation-induced apoptosis. In 
keeping with these observations from irradiation experiments, NFκB1-null mice 
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were also more susceptible than wild-type mice to irinotecan induced intestinal 
epithelial apoptosis in both the small intestine and colon and at both the 6 and 48 
hour time points. However, disruption of the classical NFκB activation pathway by 
deleting c-Rel did not cause any alterations in the amount of epithelial apoptosis 
observed in either the small intestine or colon following either γ-irradiation or 
irinotecan administration compared to wild-type mice. We also observed increases 
in the expression of the pro-apoptotic genes TRAIL and Caspase12 in the small 
intestine and TRAIL in the colon of NFκB1-null mice following irradiation compared 
to wild-type mice after the same treatment. This provides evidence for a possible 
molecular mechanism by which increased susceptibility to intestinal epithelial 
apoptosis is induced in NFκB1-null mice following irradiation and suggests that 
these observations of increased susceptibility to intestinal epithelial apoptosis seen 
in NFκB1-null mice are due to specific effects of the NFκB1 subunit and not due to 
general classical pathway disruption effects. 
In the context of acute inflammation, deleting either NFκB1 or c-Rel resulted in a 
significant increase in the severity of DSS-induced colitis. This was evident using 
both clinical and histological criteria. At the molecular level, NFκB1-null mice 
showed significant up-regulation in the transcriptional expression of the pro-
inflammatory cytokines IL-1β and IL-6 in the colon following DSS administration 
relative to similarly treated wild-type mice. The early onset of increased severity of 
colitis that was observed in NFκB1-null mice correlates with the hypersusceptibility 
of intestinal epithelial cells to undergoing apoptosis following induction of cellular 
injury in this strain of mice as discussed above. Thus, disruption of the intestinal 
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epithelial barrier by increased intestinal epithelial apoptosis as an initial response to 
DSS and the consequent increase in exposure of mucosal immune cells to the 
luminal contents of the colon and enhanced cytokine production might be plausible 
explanations for the increased clinical severity of colitis which was observed in 
NFκB1-null mice. In agreement with our observations from mice with abrogated 
classical NFκB signalling, it has previously been shown that specific IKKβ deletion in 
intestinal epithelial cells resulted in increased inflammation in the DSS-induced 
colitis model (250, 268). Similarly, Greten et al (312) showed that selective IKK-β 
deletion in myeloid cells or its specific pharmacological inhibition enhanced LPS 
toxicity and mortality. Despite reduced mRNA expression of IL-1β 4 hours following 
LPS administration in IKK-β deficient macrophages, increased secretion of IL-1β into 
the plasma by these macrophages was due to the enhanced processing of pro-IL-1β 
to IL-1β and a subsequent increase in the secretion of IL-1β. This mechanism 
appears to be different from the mechanism responsible for the increased mRNA 
expression of IL-1β in NFκB1-null colon following DSS treatment.  
Unlike NFκB1-null mice, c-Rel-null mice showed a relatively late onset of increased 
severity of colitis and they did not show any altered susceptibility toward irradiation 
or irinotecan induced intestinal epithelial apoptosis. Hence, the molecular 
mechanisms responsible for increased susceptibility of c-Rel deficient mice to DSS-
induced colitis may be different from those observed in NFκB1-null mice. In addition 
to maintaining intestinal barrier integrity as an anti-inflammatory function, there is 
evidence that NFκB activity can contribute to the resolution of an inflammatory 
response. Inhibition of this late stage of NFκB activity has been shown to inhibit the 
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apoptosis of infiltrating immune cells and prolong the inflammatory response (313, 
363). Based on the observations that (a) c-Rel is mainly expressed at high levels in 
hematopoietic cells and only at low levels in epithelial cells (364), (b) c-Rel deletion 
did not increase the susceptibility of intestinal epithelial cells to undergo apoptosis 
following two types of injury, and (c) the relatively late onset of increased severity 
of DSS induced colitis that was observed in c-Rel-null mice relative to NFκB1-null 
mice, we suggest that the increased susceptibility of c-Rel deficient mice to DSS-
induced colitis may be immune-cell mediated rather than due to the initial intestinal 
epithelial damage response to DSS. In the skin, loss of NFκB dependent c-Rel and 
RelA activation has also been shown to result in the development of several 
inflammatory skin lesions (365). In humans, several recent studies have reported 
associations between REL (82, 320, 321) (the human gene which encodes c-Rel) and 
NFκB1 polymorphisms (315, 316) and IBD. However, it is not clear whether the IBD 
associated with these SNPs is caused by either altered expression or function of the 
c-Rel and NFκB1 proteins (364). 
In the AOM/DSS murine model of inflammation related colonic carcinogenesis, our 
data clearly showed that deleting the classical NFκB family members c-Rel or NFκB1 
resulted in an increase in the severity of colitis, and this was more profound in the 
case of c-Rel loss. These results reinforce our findings in the acute DSS-induced 
colitis model and suggest anti-inflammatory roles for c-Rel and NFκB1 subunits in 
the intestine. However, c-Rel-null but not NFκB1-null mice also showed a marked 
increase in the number and size of colonic tumours following administration of 
AOM/DSS. Congruent with the increased tumour number and size which was 
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observed in c-Rel-null mice, c-Rel deficient colonic tumours showed higher 
proliferation indices and a greater percentage of these tumours showed high-grade 
dysplasia compared to those arising in their wild-type counterparts. c-Rel-null colon 
also showed enhanced epithelial proliferation and reduced epithelial apoptosis 
following carcinogen (AOM) administration. In addition colonic crypt regeneration 
was significantly increased in c-Rel-null colon following γ-irradiation. These altered 
cellular responses following c-Rel deletion might explain the enhanced 
inflammation associated colorectal carcinogenesis that we observed in c-Rel-null 
but not NFκB1-null mice. Conversely, it has previously been shown that deleting an 
upstream component of the classical NFκB activation pathway (IKK-β) selectively in 
either intestinal epithelial or immune cells resulted in a marked reduction in tumour 
load following administration of the AOM/DSS regimen despite more severe colitis 
being observed following administration of high doses of DSS. This reduction in 
tumour load was attributed to increased apoptosis of IKK-β deficient enterocytes 
and reduced colonic expression of several cytokines in the case of IKK-β deletion 
from immune cells (250). These observations from either IKK-β deficient or NFκB1 
deficient mice indicate that the increased susceptibility of c-Rel-null mice to 
inflammation associated colorectal carcinogenesis is due to specific and unique 
effects of the c-Rel subunit rather than to generic effects of disrupting the classical 
NFκB activation pathway. 
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6.1.2 Effects of deleting a NFκB family member of the alternative activation 
pathway 
For the first time, this thesis has provided evidence for major role of the alternative 
NFκB activation pathway in regulating intestinal turnover. In addition to showing 
elongated small intestinal crypts, NFκB2-null small intestine showed a significant 
increase in the amounts of epithelial apoptosis in physiological conditions. This 
increased spontaneous apoptosis might be due to the reduced relative mRNA 
expression of the anti-apoptotic genes BCL2, BCL-XL, c-IAP2 and XIAP which we 
observed in NFκB2-null small intestine. For the first time, we have also provided 
evidence that alternative NFκB pathway signalling plays a crucial role in regulating 
DNA damage induced intestinal apoptosis following two different methods of 
cellular injury (physical and chemical). We showed increased susceptibility to both 
irradiation and irinotecan induced epithelial apoptosis in both the small intestine 
and colon of NFκB2-null mice. Similar to these in vivo observations in normal 
intestinal epithelial cells, in vitro findings also demonstrated that NFκB2 but not 
RelB inhibited apoptosis following a DNA damage inducing stimulus and promoted 
colon cancer cell proliferation. Significant increases in the expression of the pro-
apoptotic genes Caspase12, BAK, p53 and FAS-L were found in the small intestine 
and Caspase12, TRAIL, and FAS-L in the colon of NFκB2-null mice following 
irradiation relative to similarly treated wild-type mice. These may therefore be 
some of the molecular mechanisms responsible for the increased susceptibility to 
irradiation induced epithelial apoptosis observed in NFκB2-null mice. The 
transcriptional regulation of Caspase12 expression by the NFκB family of 
transcription factors is a novel finding and is strongly supported by the observations 
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of up-regulated Caspase12 expression at two sites within the intestine (the small 
intestine and colon) and in both NFκB1-null and NFκB2-null strains of mice. 
Although deleting either NFκB2 or NFκB1 were associated with a dramatic increase 
in intestinal epithelial apoptosis following two types of injury as discussed above, 
intriguingly deleting NFκB2, but not c-Rel or NFκB1 protected mice from developing 
colitis following DSS administration. This suggests that the anti-inflammatory effect 
of deleting NFκB2 may be mediated by mechanisms independent of initial intestinal 
epithelial damage. The reduced severity of colonic inflammation found in NFκB2-
null mice following 2% DSS administration correlated with observations of reduced 
transcriptional expression of the pro-inflammatory cytokine TNF-α and increased 
transcriptional expression of the anti-inflammatory cytokine IL-4. Additionally, we 
have provided the first direct evidence for a crucial role of the alternative NFκB 
activation pathway in regulating inflammation associated carcinogenesis in the 
colon. We found a great reduction in the number and size of colonic tumours in 
NFκB2-null mice compared to their wild-type counterparts following administration 
of the AOM/DSS regimen. Data from a recently published study indirectly support 
our observation that activation of the alternative NFκB pathway promotes colonic 
inflammation and its associated colorectal carcinogenesis. This study showed that 
the increased colonic inflammation and tumour load that was observed in mice 
deficient in the anti-inflammatory protein Nlrp12 was associated with a marked 
increase in the activation of the alternative NFκB signalling pathway (353). Hence, 
we suggest that loss of the pro-inflammatory function of the alternative NFκB family 
protein NFκB2 is a plausible mechanism responsible for the reduced colonic 
250 
 
inflammation and protection against colitis associated colonic carcinogenesis that 
was observed in NFκB2-null mice.  
In addition to the influence of inflammation, impaired apoptosis is an important 
cellular mechanism that contributes to carcinogenesis (47, 357). Thus, the increased 
intestinal epithelial apoptosis that was observed at both 8 and 24 hours in NFκB2-
null mice following administration of the carcinogen AOM could be a second cellular 
mechanism that contributes to the reduced incidence of AOM/DSS induced colonic 
tumours. However, the molecular mechanisms responsible for this have not yet 
been fully identified. It has been shown that binding of membrane bound FAS-L to 
FAS (CD95) induces apoptosis (366, 367). A recent study (368) showed that the 
alternative NFκB activation pathway is a negative regulator of FAS expression and 
FAS-L induces apoptosis and inhibits the growth of various types of tumours 
specifically through the FAS receptor in vitro. Additionally, mice deficient in FAS 
have been shown to be more susceptible to developing 3-methylcholanthrene 
(MCA)-induced sarcoma and AOM/DSS-induced colorectal carcinoma (368). Our 
observations of marked increases in the relative mRNA expressions of FAS-L in the 
small intestine and colon of NFκB2-null mice following irradiation provide evidence 
that the alternative NFκB activation pathway is a negative regulator of the 
physiological ligand of FAS (FAS-L) in vivo. Hence, up-regulated intestinal expression 
of FAS-L may be one of the possible causes of the enhanced epithelial apoptosis and 
reduced tumour incidence that was seen in NFκB2-null mice following AOM/DSS 
administration. 
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6.2 Potential medical implications 
Current anti-inflammatory drugs that are used to manage IBD such as steroids have 
multiple endocrine and metabolic side effects. Indeed, there is a large body of 
evidence which supports the notion that inhibition of NFκB can be a therapeutic 
target for treating IBD (349). For example the anti-inflammatory effects of many 
available general anti-inflammatory drugs such as glucocorticoids (369), aspirin 
(370), gold salts (371) and mesalazine (372) have been at least in part attributed to 
their ability to inhibit NFκB activity. However, recent studies have also shown that 
NFκB is protective in intestinal inflammatory conditions and its inhibition may 
therefore exacerbate these diseases (252, 268). To provide a more rational 
approach, it is essential to dissect the roles of specific NFκB family members in 
regulating the development of inflammation and inflammation associated 
carcinogenesis in the colon. The data in this thesis have for the first time shown 
differential and unique functions of individual NFκB family members in murine 
models of colitis and colitis associated colon cancer. Our results suggest that 
specific inhibition of NFκB2 may be a promising novel strategy to manage IBD and 
reduce the risk of cancer development in these patients. Once specific NFκB2 
inhibitors have been developed, an ideal approach would be to target NFκB2 
inhibition selectively in intestinal cells where NFκB2 appears to exert its major role 
in promoting intestinal inflammation and inflammation associated colorectal 
carcinogenesis. Such specific cell type administration of NFκB2 inhibitors may be 
possible in the future using nanotechnology approaches.  
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6.3 Limitations of presented studies and potential future approaches 
to resolve them 
6.3.1 Limitations related to the animal models used 
Germline deletion of specific NFκB family proteins in mice is a viable method for 
studying the various functions of these proteins in the complete organism. 
However, the presence of these deletions in all cell types in the animal from 
embryonic development does not permit assessment of the functions of individual 
members of NFκB family in specific cell types or at selected times. It is therefore not 
currently clear whether the decreased susceptibility to colitis observed in NFκB2-
null mice or the increased susceptibility to colitis observed in c-Rel-null and NFκB1-
null mice following DSS administration are due to epithelial and/or immune cell 
effects. Assessing the expression of c-Rel, NFκB1 and NFκB2 in murine colonic 
epithelia or immune cells following DSS treatment could help in identifying the 
responsible cellular mechanisms. Due to a lack of specificity of all commercially 
available anti-NFκB2 antibodies tested to date using immunohistochemistry and 
Western blotting in mice (M. Burkitt, unpublished data), we suggest that the EMSA 
technique may be required for assessing NFκB family member activation in nuclear 
preparations from whole colonic tissue, purified colonic epithelial cells and 
lymphocytes (sorted by flow cytometry). As discussed in previous chapters, 
selective tissue deletion of NFκB proteins either in intestinal epithelial or immune 
cells using transgenic technology or bone marrow transplantation chimaeras could 
also be utilised to address these important research questions. Additionally, 
inducible gene knockouts (108) could be utilised to define the roles of individual 
members of the NFκB family in intestinal epithelia at selected times of adulthood 
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and under selected physiological and pathophysiological conditions. For example, 
inducing NFκB2 gene disruption in adult murine intestinal epithelia might help to 
determine whether the reduced colorectal carcinogenesis observed in NFκB2-null 
mice is due to effects of NFκB2 deletion during the prenatal or postnatal period. 
DSS-induced colitis in C57BL/6 mice has previously been validated as a relevant 
model to translate findings to human diseases and as such it is a useful model to 
identify and validate new therapies for treatment of IBD (109). The AOM/DSS model 
has also been shown to be a relevant model for colitis associated cancer in humans 
and has been described as a valuable and practical tool for investigating the 
pathogenesis of colitis associated colon cancer (194). However, the duration 
required for developing colitis and colitis associated cancer is relatively short in 
both these models. This appears to be a limiting factor for the relevance of these 
animal models to human disease. Development of colon cancer in IBD patients is 
thought to require a long period of chronic inflammation that results in 
accumulating epigenetic and genetic alterations to key proto-oncogenes and 
tumour suppressor genes (373). IL10-null mice which spontaneously develop colitis 
followed by cancer (374) could be a useful tool to study the consequences of a 
longer period colonic inflammation in a setting which may be closer to that 
observed in IBD patients. Thus, the current studies of colonic inflammation and its 
associated cancer could further extended by crossing our transgenic mice (c-Rel-
null, NFκB1-null and NFκB2-null mice) with IL10-null mice. Given the importance of 
micrbiota in the pathogenesis of DSS induced colitis, the differences in susceptibility 
to DSS observed between the transgenic mice used in this thesis might be (at least 
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partially) due to the effects of deletion of specific NFκB proteins on gut micrbiota. 
Hence, future work should also study the consequences of deleting various NFκB 
family members on gut micrbiota. 
6.3.2 Limitations related to the techniques employed 
Mitotic index is a cheap, simple and relatively consistent way to measure a 
proliferation rate. Mitosis represents the shortest phase of the cell cycle, but it may 
not be possible to detect the early and late stages of this process using a light 
microscope. As a result, the absolute numbers of mitotic figures are much less than 
the numbers of proliferating cells determined by other methods such as 
immunohistochemical staining for Ki67 which marks all stages of a cycling cell 
(active proliferating cell) (375). It has also been reported that the duration of the 
mitotic phase is variable and therefore the correlation between mitosis and 
proliferation rate may not be linear (341, 376). These considerations might 
potentially explain our inability to detect any significant increases in proliferation as 
determined by mitotic figure counts in the elongated intestinal crypts of c-Rel-null 
and NFκB1-null mice relative to wild-type mice. It would therefore be helpful to 
perform immunohistochemical staining for Ki67 to investigate this further. 
The HCT116 cell line originates from colonic epithelial cells and represents several 
biological aspects of normal colonic epithelial cells. In addition to the non-
physiological conditions of the culture media in which these cells were maintained, 
this in vitro model also has the disadvantage that these cells have undergone 
several mutations in order to permit unlimited growth in culture. This is likely to 
have changed the biology and biochemical characteristics of the cells. This may 
255 
 
therefore affect the interpretation of any analysis. Unfortunately however, it is not 
currently possible to maintain long term cultures of non-transformed human 
colonic epithelial cells. 
Assessing mRNA expression can give valuable information about possible molecular 
mechanisms that are involved in different processes. However, protein expression 
and ultimately protein function are also affected by post transcriptional and post 
translational modifications. Given that the proteins under investigation in this thesis 
belong to the transcriptional system, assessing mRNA can provide evidence for 
apparent functions of these transcriptional factors. However, it would also be 
interesting to further assess protein expression particularly of those genes which 
showed altered transcriptional expression in our studies. 
6.4 Future research plans 
Several potential future plans have already been discussed above and performing 
these experiments could help to answer several important research questions and 
elucidate the molecular mechanisms responsible for the different intestinal 
responses to injury that were observed between animals with specific deletions of 
individual NFκB proteins. Data in this thesis have demonstrated that NFκB signalling 
via NFκB2 is essential for the development of colitis and colitis associated cancer. 
Thus, it would be interesting to investigate the effect of administering antisense 
oligonucleotides for NFκB2 on the development of DSS induced colitis and 
AOM/DSS induced colon cancer using C57BL/6 mice.  
The ultimate aim of our studies was to improve understanding of pathogenesis of 
inflammatory bowel disease and its associated colon cancer in humans. Therefore, 
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it is now necessary to extend these studies into humans. Several antibodies have 
been established and can be used to detect specific NFκB proteins in human cells. 
Such antibodies could therefore be utilised to quantify the activity of individual 
NFκB family proteins in colonic mucosal biopsy samples taken from patients with 
IBD or colonic tumour biopsies obtained from patients with colitis associated cancer 
using techniques such as EMSA. Real time PCR could also be used to assess mRNA 
expression of individual members of the NFκB family in these biopsy samples. 
6.5 Conclusions 
Findings from this thesis have demonstrated that individual members of the NFκB 
family of proteins play specific roles in regulating intestinal homeostasis and 
intestinal responses to various types of injury. NFκB1-dependent classical NFκB 
signalling is involved in the regulation of epithelial susceptibility to DNA damage 
induced apoptosis, whereas c-Rel appears to be redundant in this process. In the 
setting of inflammation, deleting either c-Rel or NFκB1 exacerbated the severity of 
experimental acute and chronic colitis in mice. However, c-Rel but not NFκB1 
deletion resulted in increased inflammation associated colorectal carcinogenesis 
induced by AOM/DSS as summarised in Table 6.1. These findings suggest that 
classical NFκB pathway inhibitors may be paradoxically harmful in IBD. 
Data in this thesis also provide evidence that alternative pathway NFκB signalling via 
NFκB2 plays a major role in regulating intestinal epithelial apoptosis in vitro and in 
vivo. The increased susceptibility to irradiation induced intestinal epithelia 
apoptosis resulting from deletion of NFκB1 and NFκB2 may be mediated by 
modulating expression of a number of known NFκB dependent apoptosis regulating 
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Table 6.1: Summary of the main observations from transgenic mice following 
irradiation, irinotecan, DSS or AOM/DSS administration compared to wild-type 
mice. 
Response Tissue c-Rel-null  mice NFκB1-null mice NFκB2-null mice
Irradiation-induced 
apoptosis
Small 
intestine
↔ ↑ ↑
Colon ↔ ↑ ↑
mRNA expression of pro-
apoptotic genes following 
irradiation
Small 
intestine
↔ ↑ TRAIL, 
Caspase12
↑TRAIL, Caspase12,
BAK, P53 and FAS-L
Colon ↔ ↑ TRAIL ↑Caspase12, BAK and
FAS-L
Irinotecan-induced 
apoptosis 
(6 and 48 hours)
Small 
intestine
↔ ↑ ↑
Colon ↔ ↑ ↑
Severity of DSS-induced 
colitis
Colon ↑ ↑ ↓
mRNA expression of 
cytokines encoding genes 
in DSS-induced colitis
Colon ↓ TNF-α ↑ IL-1β, IL-6 ↓TNF-α , ↑ IL-4
Incidence and size of 
AOM/DSS induced 
tumours
Colon ↑ ↔ ↓
Proliferation index of 
AOM/DSS induced 
tumours
Colon ↑ ↔ ↔
Initial colonic epithelial 
responses to the 
carcinogen AOM
Colon ↑ mitosis
↓ apoptosis
↔ ↑ apoptosis
genes as well as the novel gene caspase12. Although deletion of NFκB2 sensitised 
mice to intestinal epithelial apoptosis, conversely and intriguingly, NFκB2 loss also 
protected mice from developing colitis and colitis associated colon cancer as 
summarised in Table 6.1. This suggests that the alternative NFκB2 activation 
pathway is essential for the development of colonic inflammation and its associated 
colorectal cancer. Pharmacological inhibition of NFκB2 signalling may therefore be a 
promising novel therapeutic strategy for treating IBD and preventing cancer 
development in such patients. Whether these specific roles of individual members 
of NFκB family are due to epithelial and/or immune cell mediated effects currently 
remains to be established.  
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